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The principal findings of this PhD research study have been compiled into an article format and presented 
as a thesis by manuscript.  
 
Chapter One: Provides background information with a brief review of selected topics relevant to the 
study. Study aims and objectives, hypotheses and potential benefits of this research are also highlighted.  
 
Chapter Two:  Forms part of the literature review and describes the ethnopharmacological benefits and 
screening of South African plants with antihypertensive properties through the inhibition of ACE. This 
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is currently under review (Manuscript number: 9687)   
 
Chapter Three: Reports on the phytochemical components and in vitro preliminary screening of 
Tulbaghia acutiloba for potential therapeutic effects.  This forms the first part of the PhD experimental 
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journal), Volume 19, Issue 3, 2019. 
 
Chapter Four:  Forms part of experimental research that evaluated the antihypertensive and 
cardioprotective effect of Tulbaghia acutiloba extracts in an L-NAME induced hypertensive rats. 
 
Chapter Five: Reports on the effect of Tulbaghia acutiloba on renal function and haematological 
parameters in an L-NAME induced hypertensive rats.  
 
Chapter Six: Provides general conclusions and synthesis of the research findings. It also highlights 
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ABSTRACT 
The increasing prevalence of hypertension over the years has been identified as a major contributor to 
high morbidity and mortality, globally and locally, in Africa, posing a serious global health threat. The 
demand for novel therapeutic strategies has become increasingly important, given that conventional 
options may be inaccessible and costly, and are often associated with side effects, hampering patient 
compliance. The scientific validation of alternative strategies, such as phytotherapy has, therefore, 
become a major focus in the treatment and management of hypertension, as it is perceived as being cheap, 
accessible, and possessing minimal side effects.  Hence the investigation of medicinal plants, within the 
field of novel drug discovery, is of interest as plants possess various phytochemicals displaying biological 
activities, which may be beneficial in hypertension, and it’s associated complications. Since there is no 
existing scientific data available to validate its medicinal usage, this study, therefore, evaluated the in 
vitro and in vivo antihypertensive effects of Tulbaghia acutiloba. The hydro-methanolic extracts of the 
plant parts (i.e. leaves, flowers, rhizomes and roots) were initially evaluated in vitro for their 
phytochemistry, antioxidant potential, angiotensin-converting enzyme (ACEI) inhibition activities, and 
heavy metal content. The phytochemical investigation of the various parts of the plants showed the 
presence of phenols, amino acids and alkaloids in all parts, with the leaves exhibiting a higher total 
phenolic content, in comparison to the other parts. Further analysis, using gas chromatography–mass 
spectrometry (GC-MS), revealed the presence of bioactive compounds, such as α-linolenic acid, which 
was found only in the leaves. Other compounds such as oleic acid and palmitic acid were found in all the 
parts of the plants. All parts of the plant showed antioxidant activity in vitro. Heavy metal toxicity 
analysis revealed the safety profile for all parts of the plants. All parts also showed a potential ACE 
inhibitory effect of greater than 50%, with the leaves showing the most significant effects, comparable to 
the conventional drug, Ramipril. We further investigated the effect of the hydro-methanolic leaf extract 
on oxidative stress, endothelial function, cardiovascular, renal and haematological parameters, associated 
with hypertension, in an L-NAME induced hypertensive rat model. The administration of the hydro-
methanolic leaf extract of Tulbaghia acutiloba at different concentrations of 40, 60 and 80mg/kg b.w., 
reduced systolic, diastolic and mean arterial pressure in the model, with a pronounced effect at the dosage 
of 80mg/kg b.w. Additionally, the leaves of T. acutiloba significantly enhanced bradykinin receptor levels 
(B1 and B2), nitric oxide (NO) availability, promoted antioxidant activities and significantly reduced 
ACE activity in  serum and cardiac tissues in hypertensive rats. Cardioprotection was significantly 
enhanced at 80mg/kg b.w. of T.acutiloba, as depicted by the cardiac function and morphology, and 
cardiac gene expression in experimental rats. There was no evidence of toxicity as depicted in the liver 
enzymatic activity after the administration of T.acutiloba in the hypertensive rats. Administration of T. 
acutiloba improved renal function as evidenced by the increased creatinine clearance (Ccr), improved 
xiv 
 
fractional excretion of sodium and decreased urine protein-creatinine ratio (UPr/UCr). Additionally, 
decreased levels of leucocyte infiltration, decrease in both, neutrophil to lymphocyte ratio (NLR) and 
lymphocyte to monocyte ratio (LMR), was found after administration of T.acutiloba, with a maximal 
effect occurring at a dose of 80mg/kg b.w. Together, these findings provide scientific validation for 
T.acutiloba as  a medicinal plant that has cardioprotective and antihypertensive properties, and is able to 
improve renal function and haematological parameters in an L-NAME induced hypertensive rat model. 
Overall, the data also provides substantive evidence for the possible usage of T.acutiloba as an alternate 
antihypertensive agent, in resource limited areas where conventional drugs are inaccessible.    
 
Key Words: Tulbaghia acutiloba, phytotherapy, cardioprotection, L-NAME, renal function, haematology 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1 Background 
Over the last decade, the prevalence of hypertension has risen at a faster rate than recorded previously in 
both developing and developed countries, with dire outcomes. There is consistent evidence of the growing 
health and economic repercussions of hypertension and its associated complications, specifically in Africa 
(1). Distinctive efforts intended to focus on preventing and managing hypertension remains less than 
optimum (2). Hypertension (HTN) is a major risk factor for many cardio-renal diseases and remains one 
of the major causes of mortality worldwide (3). Several conventional treatment options are available to 
manage HTN, but remain inaccessible and unaffordable to many who need them, specifically in low- and 
middle-income countries, where the prevalence of HTN is increasing at a faster rate compared to the 
high-income countries (3).  Current conventional regimens have a number of setbacks, as they present 
with severe side effects that may pose mild to severe discomfort to hypertensive patients when 
administered. There is therefore a focus to scale up access to affordable anti-hypertensive therapy that 
have minimal side effects in the global fight against the burden of hypertensive conditions and other non-
communicable diseases (4).  
 
According to the World Health Organization (WHO), there is a growing global interest and high demand 
for phytopharmaceutical products, with many pharmaceutical companies now focusing on producing 
phytotherapeutic products and herbs in the fight to reduce hypertensive cases (5). Reports from the WHO 
further suggests that the global non-communicable disease (NCD) goal for hypertension is a 25% relative 
reduction in prevalence by 2025 (5). Phytotherapy, which is scientifically proven to be of good quality, 
efficacy and safety, facilitates access to healthcare and has the added benefit of  minimal perceived side 
effects (5). In Africa, it is estimated that the ratio of traditional medicine healers to the population is 
approximately 1:500, while clinicians have a ratio of  1:40 000 (6). As many medicinal plants have 
numerous bioactive compounds that work synergistically to produce antihypertensive and antioxidant 
effects, investigating regional medicinal plants will enhance access to  affordable treatment (6). 
In South Africa, it is reported that over 27 million people (more than 50%) rely on indigenous medicinal 
plants for healing of various ailments, including HTN, (7) with the scientific validation of existing and 
novel medicinal plants being essential for managing and treating hypertension. 
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1.2 Definition and Classification of Hypertension  
Hypertension (HTN), or high blood pressure, has been defined as repeated elevated blood pressure of 
more than a systolic pressure of 140mm Hg and a diastolic pressure of 90mm Hg (>140/90mm Hg) (8). 
According to a report of the American College of Cardiology (ACC) and the American Heart Association 
(AHA) Task Force on Clinical Practice Guidelines on Prevention, Detection, Evaluation, and 
Management of High Blood Pressure in Adults, 2017, HTN is now defined as persistent rise in blood 
pressure of more than 130/90 mm Hg on at least three different occasions in a relaxed physiological state 
(9). This condition has been regarded as major risk for cardiovascular and renal diseases through its effect 
on target organs, such as the heart and kidneys (10). Based on repeated measurements of the systolic 
(SBP) and diastolic blood pressure (DPB), the ACC and AHA Task Force on Clinical Practice now 
classifies HTN as normal, elevated, stage 1 and stage 2 hypertension (Table 1.1) 
Table 1: Categories of hypertension as defined by the American College of Cardiology and the 
American Heart Association Task Force (10) 
 
 
 
 
 
 
 
 
 
*SBP = systolic blood pressure, DBP = diastolic blood pressure 
Source: the American College of Cardiology and the American Heart Association Task Force on Clinical 
Practice Guidelines on Prevention, Detection, Evaluation, and Management of High Blood Pressure in 
Adults, 2017 (10). 
 
 
Known as a ‘silent killer’, HTN may exist for an extended period as an asymptomatic condition, which 
may gradually affect the quality of life of a person before symptoms begin to manifest (11). These usually 
occurs after a mild or serious complication has been caused by the influence of the persistent 
asymptomatic elevated blood pressure (12). These manifestations can include persistent headaches, 
fatigue, chest pains, irregular heartbeats and poor vision (12). Untreated HTN in the midst of these 
symptoms may lead to serious complications, such as stroke, heart attack, renal failure and blindness (13). 
Hypertension is broadly grouped under two main types based on the cause and disease progression 
namely: primary or essential hypertension and secondary hypertension (14). 
BP Category  SBP  DPB 
Normal <120 mm Hg and <80mm Hg 
Elevated 120-129mm Hg and <80mm Hg 
Hypertension 
Stage 1 130-139mm Hg or 80-89mm Hg 
Stage 2 ≥140mm Hg or ≥90mm Hg 
Hypertensive crisis >180mm Hg and/or >120mm Hg 
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1.2.1 Primary or essential Hypertension 
This type of HTN accounts for approximately 95% of all hypertensive cases worldwide. Sometimes 
known as ‘idiopathic hypertension’, this form has previously been described as having an unknown 
underlying cause, although it is mainly attributed to hereditary and of a genetic origin (15). While many 
theories have tried to establish the specific cause of essential HTN, they have not been able to clearly 
define the pathway of the disease. Many researchers have therefore adopted a multifactorial approach to 
determining the cause of the disease (16). The elusive etiology of essential HTN makes it a critical factor 
for therapeutic intervention,  as most treatments are targeted at the symptoms rather than the main cause 
(16). Studies have supported a natural progression in the disease process, implying that the initial rise in 
cardiac output and blood volume may set off successive increases in systemic vascular resistance, thereby 
resulting in increased blood pressure (15). Moreover, certain predisposing factors are known to initiate 
multiple complex genetic and molecular mechanisms that could lead to the rise in arterial blood pressure. 
Such predisposing factors include obesity, insulin resistance, high alcohol and salt intake, ageing, 
sedentary lifestyle,  stress,  low potassium levels, and a lack of fruit and vegetables as sources of 
antioxidants (17). It has therefore become necessary to incorporate a multidisciplinary research approach 
to explain the mechanism, progression and management of this multifaceted disorder, and hence the focus 
of our present study.  
1.2.2 Secondary hypertension 
Secondary hypertension (HTN) is due to a known cause, enabling an easier and effective intervention 
(18), the condition accounting for approximately 5% or less of all cases. Some of the conditions that 
could cause secondary HTN include, but are not limited to, pregnancy, certain medications and 
supplements, tumours, thyroid and hormonal disorders, such as Cushing’s Syndrome (19). 
 
1.3 Epidemiology of Hypertension 
Despite concerted efforts by local and international agencies to reduce the prevalence of HTN globally, 
the rate remains unacceptably high at 22% (14), being estimated to cause 7.5 million deaths annually, 
representing 12.8% of the total deaths globally. It is estimated that one in every four men, and one in five 
women, globally has raised blood pressure, representing 22% of the adult population (20). This trends 
indicates that there was a rise in the number of adults with HTN from 594 million in 1975, to 1.13 billion 
in 2015, implying a growing rate of HTN with the increasing  ageing population (1). The prevalence of 
hypertensive cases are known to be highest in Africa, with 27% of the adult population having high blood 
pressure (20). The high-income countries, such as the United States of America, have declining HTN 
prevalence from 25% to 18% of the adult population over the past two decades.  These estimations are 
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predicted to decline with an increase in the availability of healthcare facilities, and more easily accessible 
and affordable therapeutic interventions (21).  
 
Hypertension (HTN) is currently under focus in Africa, and is regarded as the most common cause of 
cardiovascular and renal disease, being a key contributor to high mortality and morbidity in adults (22). A 
prevalence rate of 30-32% is reported in most rural and middle-income urban areas in Africa.  The studies 
show a 20.8% prevalence rate in Eastern and Southern Africa, and it is postulated that NCDs, such as 
HTN and its complications, may soon surpass  communicable diseases as a major cause of death if left 
untreated (22).  The greater risk of hypertensive cases among the Black African population should lead to 
a more intense investigation of HTN in Africa (23).  In South Africa, it has been reported that one in three 
adults live with elevated blood pressure;  accounting for one in every two strokes and two in every five 
heart attacks (24). In 2017, it was estimated that 42% to 54% of the adult population were living with 
HTN in South Africa, this figure being expected to rise if critical interventions are not implemented (25), 
necessitating the search for novel therapeutic interventions. 
 
1.4 Aetiology and Pathogenesis of Essential Hypertension  
The human body has several mechanisms to ensure that the blood pressure is maintained within a 
homeostatic range. Blood pressure is known to be a product of cardiac output (CO) and peripheral 
vascular resistance, and its control is therefore exerted by regulating one or two of these components (26). 
A rise in blood pressure develops as a result of disturbances of the components and mechanisms involved 
in its regulation, with an acute or chronic rise possibly involving the dysregulation of the cardiorenal, 
nervous and circulatory systems (27). Several contributing factors have been associated with interruptions 
in the functioning of the blood pressure regulation, leading to the pathogenesis of essential HTN. These 
factors include: the overproduction of reactive oxygen species (ROS); endothelial-derived constricting 
factors leading to endothelial dysfunction; genetic alterations, reduction in the bioavailability of nitric 
oxide (NO), dysregulation of the renin-angiotensin system (RAS) or renin- angiotensin aldosterone 
system (RAAS), increased activation of the sympathetic nervous system, renal sodium and water 
retention, variations in the kallikrein-kinin system expression, chloride and potassium homeostatic 
imbalance; haematological disorders and environmental factors, such as chronic stress, alcohol intake and 
physical inactivity (28) 
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1.5 The role of the Renin-Angiotensin System in the pathogenesis of Hypertension 
1.5.1 The Classical RAS 
The renin-angiotensin system (RAS) functions as a key modulator to regulate  blood pressure in both the 
physiological and pathological states (29). The production of renin from the juxtaglomerular apparatus 
(JGA) cells of the kidney is the initial step for regulating blood pressure. Renin, produced as a circulatory 
enzyme, is involved in  maintaining the extracellular volume and arterial integrity (30) in the hydrolytic 
catabolism of angiotensinogen, which is produced and secreted by the liver cells. The hydrolyses of 
angiotensinogen by renin leads to the formation of a decapeptide angiotensin I (Ang1), which is further 
cleaved by the angiotensin converting enzyme (ACE) and primarily situated in the pulmonary circulation 
that is bound to the endothelium (31). The cleavage of Ang I by ACE leads to the hydrolyses of Ang I to 
form the most vasoactive peptide, angiotensin II (Ang II), which activates the G-protein coupled 
angiotensin II receptor type 1 (AT1) and increases the peripheral vascular resistance, leading to 
vasoconstriction and a subsequent rise in blood pressure (32). The effects of angiotensin II are also 
mediated by another receptor, AT2, which has been demonstrated to be abundant in foetal tissues, 
although adult cardiac and renal tissues have recently been reported to be actively involved in its activities 
(33). 
Ang II also acts on the adrenal gland, activates the stimulation of aldosterone, which causes the epithelial 
lining of the kidneys to increase the re-absorption of sodium and water, thereby increasing blood volume  
(34). It is also known to increase vasopressin release through the activation of the pituitary gland (34). 
The local tissue production of Ang II in the heart, brain, kidneys, adrenals and blood vessels is regulated 
by ACE and other key enzymes. The activity of RAS at the local level plays a crucial role in 
cardiovascular and renal remodeling in HTN (35).  
1.5.2 The Novel RAS  
The classical view of the RAS presents a direct signalling pathway that begins with the conversion of 
angiotensinogen to Ang I by renin, as described earlier. For the past few decades, the classical RAS has  
been considered to be active in circulation, with the vasoactive Ang I exerting various mechanisms in the 
pathophysiology of HTN (35). However, the RAS has become much more complex, with the discovery of 
novel peptides that demonstrates several biological effects (36). As RAS is also locally produced in a 
number of tissues, such as the kidneys and heart, there are novel pathways of Ang II expression that are 
independent of angiotensin converting enzyme (ACE) (36). In 2000, ACE2 was discovered, with 
characteristics of an enzyme similar to ACE,  the description of a homologue for ACE called ACE2, 
building on the emerging premise of complexity (37). While the classical ACE converted Ang I to Ang II, 
ACE2 results in Ang (1-9) formation and Ang (1-9) can be converted to Ang (1-7), which acts as a 
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vasopressor agent. The ACE2 local expression correlates with Ang (1-7) concentration and leads to the 
antagonism of Ang II. Therefore, ACE inhibition may increase Ang (1-7) levels and reduce Ang II (38), 
with ACE2 being mainly expressed in the heart and kidney, and to some degree in the vascular 
endothelium (38).  
 
Almost all pathophysiologic and physiologic functions that are Ang II induced, such as vasoconstriction, 
tubular transport stimulation, aldosterone release, growth stimulatory actions and proinflammatory 
effects, are mediated by AT1, although information regarding the exact role of AT2 is not clear (39). It 
has been postulated that the AT1 blockade may result in Ang II formation and increased concentration, 
with free Ang II binding to AT2, AT3 and AT4. While there is little information regarding AT3 and AT4 
stimulation, they have been suggested to promote thrombosis (40). Unlike ACE, with ACE 2, there is no 
conversion of Ang I to Ang II, and the ACE inhibitors do not inhibit its enzymatic activity directly. Thus, 
ACE2 is an inhibitor in Ang II formation by stimulating alternate pathways for the degradation of Ang I, 
which may lead to a possible vasodilatory effect (40, 41).   
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Figure 1: Representation of the classical (RED) and alternative pathways (BLUE) of the renin-angiotensin 
system (RAS) and their interactions. ATI, angiotensin II type 1; AT2, angiotensin II type 2, NO, nitric oxide, 
CAGE, chymostatin sensitive AngII-generating enzyme. (Adapted from (42-44) 
 
1.6 The Role of the kallikrein-kinin system (KKS) in the pathogenesis of Hypertension 
An imbalance in the endogenous vasoconstrictor and vasodilator systems may lead to the development 
and maintenance of high blood pressure (41). Kinins (bradykinin, lys-bradykinin and bradykinin 
receptors) are classified as endogenous vasodilators, and are known for antagonising angiotensin II-
induced vasoconstriction and sodium retention (45). Bradykinin and lys-bradykinin are known to act 
mainly through the bradykinin type1 (B1) and type 2 (B2) receptors. Studies have suggested that the 
bradykinin type 2 receptor (B2) is the main inducer of changes in the cardiovascular and renal function 
(46). The beneficial effect of kinins in renal and cardiovascular diseases is mainly mediated through the 
bioavailability of nitric oxide and prostaglandins, extending their role to cardioprotection and 
nephroprotection (47). Importantly, the angiotensin-converting enzyme (ACE), which catalyses the 
conversion of angiotensin I to angiotensin II, is also known as kininase II, and is responsible for the 
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degradation of bradykinin into inactive metabolites (48). This implies that high serum ACE activity will 
result in the inactivation of bradykinin and a reduction in its receptor activity, hence leading to the 
vasoconstrictive and end organ damaging activities of uncontrolled Ang II (46). In the human body, 
therefore, ACE inhibitors are known to lower blood pressure and enhance the activity of the kallikrein-
kinin system (KKS), leading to the accumulation of kinin in circulation and target tissue organs (47). 
Therefore, development of novel therapeutic interventions to augment the kinin activity in the vasculature 
and specific compartments in the heart and kidney may be a highly effective approach to manage and 
treat HTN and its complications.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Renin-angiotensin system and kallikrein-kinin system in the regulation of blood pressure. 
Angiotensin I (Ang I), Angiotensin II (Ang II), Angiotensin converting enzyme (ACE), Angiotensin converting 
enzyme 2 (ACE 2), Angiotensin receptor 1 (AT1), Angiotensin receptor 2 (AT2), Bradykinin receptor 1 (B1), 
Bradykinin receptor 2 (B2), Nitric oxide (NO), Prostaglandins 2 (PgI2). (Adapted from Majumder and Wu, 
2015 (49). 
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1.7 Endothelial dysfunction in Hypertension 
Endothelial dysfunction, defined as the biological and physical alteration of the vascular endothelial 
lining, is characterized by the release of pro-constrictive, pro-inflammatory and pro-thrombotic agents 
(50). Essential HTN is associated with an imbalance between vasodilators and vasoconstrictors, which 
upsets the integrity of the endothelial cells, leading to a vicious cycle that may result in the maintenance 
of high blood pressure (51). Reports indicate that endothelial activation and injury could lead to the 
alteration in vascular reactivity and tone, fibrinolytic pathways, as well as coagulation. These alterations 
are reliable indicators in the prognosis of HTN and end-organ damage (51). 
 
Evidence from research over the past few decades has identified nitric oxide (NO) as a central modulator 
of vascular endothelial function, and while it is highly versatile, it is a structurally simple molecule that 
plays a key role in various activities in the vasculature (52). It is known to regulate vasodilation, the 
permeability of the vascular bed and platelet activity. Endothelial cell-derived NO, at an optimum level, is 
known to cause vasodilation and inhibition of platelet activity in the blood vessels through the activation 
of soluble guanylyl cyclase, which, coupled with a decrease in cytosolic Ca2+  concentration, facilitates 
the biosynthesis of 3,5-cyclic guanosine monophosphate (cGMP) (53). The decrease in cytosolic Ca2+ 
concentration is caused by the ability of NO to inhibit the voltage-gated Ca2+ channels and the activation 
of protein kinases that phosphorylates proteins in the sarcoplasmic reticulum. The release of cGMP, 
coupled with a decrease in cytosolic Ca2+  concentration, facilitates the inhibition of calcium-calmodulin 
myosin light chain kinase in vascular smooth muscle cells, which further promotes vasorelaxation and 
platelet inhibition (54). The biosynthesis of endothelial NO increases in response to external and internal 
stimuli, such as serotonin, bradykinin, acetylcholine, adenosine disphosphate (ADP) and shear stress. 
Reports indicate that acute or chronic inhibition of NO synthesis in the endothelial lining could lead to 
hypertension, myocardial ischaemia or stroke (54). Recent studies have also shown that the excessive 
elevation of NO may be associated with the general cytotoxicity, and its maintenance in its accepted 
cellular range is therefore crucial for therapeutic targets and endothelial function (55). 
 
Adequate NO production may not be able to meet the target of protecting the vascular integrity due to the 
presence of reactive oxygen species. Several reports from studies suggest that oxidative stress caused by 
reactive oxygen species (ROS) alters the biological functions of the endothelium through their 
inactivation of endothelial-derived NO (56). An increase in oxidative stress that is caused by superoxide 
(O2-), hydroxyl radical (OH-) and other reactive oxygen species (ROS) increases the NO destruction, 
hence reducing its physiological activities in the endothelium. There are further indications that Ang II 
promotes the formation of the oxidant, superoxide (O2-) at concentrations that affect blood pressure 
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minimally (57). Previous reports show that despite the presence of oxidative stress, the activities of NO 
could be enhanced by administering a potent antioxidant, such as superoxide dismutase (SOD) and 
reduced glutathione (GSH), which are known to effectively scavenge oxidants, i.e. superoxide and 
hydroxyl radical, to restore the endothelial function (58).   
 
There is, however, a controversial viewpoint on whether endothelial dysfunction remains a cause or an 
effect of HTN. Some studies have shown a bi-directional relationship, with the evidence indicating that 
endothelial dysfunction leads to HTN, while others suggest that this could be a risk factor for HTN (59). 
Despite this, there is a clear relationship between HTN and endothelial dysfunction, although the exact 
mechanism to establish  cause and effect needs to be ascertained through further investigations (59). 
Based on the possible therapeutic benefits of an enhanced endothelial function in hypertensive patients 
due to the bioavailability of NO, a reduction of blood pressure, antioxidant activity and other measures to 
improve the vasculature; the current studies focus on assessing the effective mechanism of novel 
antihypertensives, which promotes NO production, coupled with antioxidant activity (60). There is a 
growing interest in investigating the role of ACE inhibitors, which are known to lower blood pressure, 
increase NO production, and also have therapeutic and antioxidant effects on the endothelial function 
(61). 
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Figure 3: Pathways from endothelial dysfunction (ED) to hypertension. The link between ED and 
hypertension is clearly illustrated with oxidative stress and inflammation as the key role players. ROS  
indicates reactive oxygen species. (Adapted from Brandes, 2014(62). 
 
1.8 Haematological Indices in the Pathogenesis of Hypertension 
In recent years, there has been a growing interest in the role of haematological indices in the pathogenesis 
of HTN, with the exact mechanism and relationship between them being under investigation and the clear 
directives yet to be ascertained (63). It has been suggested that oxidative stress and decreased endogenous 
NO concentrations, associated with a dysfunctional endothelium, could lead to a number of functional and 
structural abnormalities of organs, that are involved in the hematopoietic process during HTN (64). The 
kidney is one of the major organs involved in the hematopoietic process, as the active hormone, 
erythropoietin, associated with the production of red cells, is produced in the kidneys. Reports indicate 
that renovascular HTN is accompanied by abnormalities of red blood cells that may adversely impact the 
microcirculation and exacerbate end-organ damage (65). Haematocrit levels have been identified as being 
generally higher in hypertensive patients, and the occurrence of HTN and stroke, are known to double 
with every 10% increase in the haematocrit level (65). The mechanism behind blood pressure and 
haematocrit is most likely related to the blood viscosity that is associated with peripheral resistance 
during HTN. Higher blood viscosity is known to affect the peripheral resistance to blood flow, and this 
increased resistance could lead to raised blood pressure (66). Although the specific pathways for this 
relationship are unclear, it is hypothesized that the reduction in red cell deformability, and an increase in 
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the aggregability, size and numbers of red blood cells, may cause a circulatory defect that could lead to 
target organ damage (67). It is also suggested that increased haemoglobin levels may lead to left 
ventricular hypertrophy, while low haemoglobin levels could cause anemia and heart failure,  therefore 
compounding the effect of HTN (65).  
 
As a chronic inflammatory condition, HTN is also known to be associated with elevated white blood cells 
(leucocytes) in vessels. Several studies have reported on the activation and infiltration of leucocytes in the 
vascular bed, as an indication of tissue ischaemia and vascular injury, in the pathogenesis of HTN (68). 
Leucocytes are also reported to play a major role in the initiation and progression of atherosclerosis and 
its deleterious effect on endothelial function. The infiltration of leucocytes in the blood vessels is known 
to be enhanced by the activation of inflammatory genes, such as NF-κB, Heme Oxygenase-1 (HO1), and 
increased activation of AT1and AT2 receptors (69). Current research has indicated that the ratio of 
specific white blood cells differentials may be a better marker in the progression of HTN than individual 
differentials. The ratios of differential white blood cell markers, such as neutrophils, basophils, 
lymphocytes and monocytes, have recently been identified as a novel yet inexpensive method of 
identifying the prognosis and pathogenesis of HTN. Such ratios include the neutrophil-lymphocyte ratio 
(NLR), lymphocyte-monocyte ratio (LMR) and the platelet-lymphocyte ratio (PLR) (70). 
 
Endothelial dysfunction during HTN may also lead to platelet activation due to vascular complications. 
During vascular injury, activation of platelet at the injured site leads to the over production of platelets, 
which could result in coronary thrombosis and myocardial infarction (71). Haematological findings 
during HTN are generally considered a strong indicator for the prognosis and the pathogenesis of HTN. 
The number of researchers, who aim to identify therapeutic agents that possess the potential of improving 
relative haematological functions during HTN, have risen recently. Their findings will lead to an 
improved understanding the role of haematological parameters to treat and manage essential HTN (72).  
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1.9 TREATING AND MANAGING HYPERTENSION 
A number of pharmacologically active compounds are conventionally used to treat and manage HTN,  
these drugs are generally being classified into three main groups, namely: (1) Direct vasodilators  (2) 
Adrenergic inhibitors  and (3) Diuretics (73). 
 
1.9.1 Direct Vasodilators 
This group of antihypertensive drugs acts directly by inhibiting the ACE, calcium channel blockade or 
angiotensin receptor blockade. 
1.9.2 Angiotensin Converting Enzyme Inhibitors  
Studies have established the crucial role that the ACE plays in the formation of Ang II, a potent 
vasoconstrictor (74), and their key role having been extensively investigated.  ACE inhibitors are known 
to be the first line of therapy in most hypertensive cases (75). The mechanism underlying the lowering of 
blood pressure by ACE inhibitors, is by reducing the circulating levels of Ang II (76). Simultaneously, the 
activity of ACE in the vessel walls and various tissues, including the kidney and heart, are known to be 
inhibited to varying degrees by diverse ACE inhibitors. They also inhibit the breakdown of bradykinin, 
and together with the kinin, stimulate NO production, leading to a direct vasodilatory effect and an 
improved endothelial function (77). In addition, ACE inhibitors lessen the anticipated rise in the 
sympathetic activity observed after vasodilation, and results in a decreasing heart rate and cardiac output 
(77). 
 
Additionally, studies show that the multiple effects of ACE inhibitors could lead to dampening the arterial 
wave reflection and increasing the aortic distensibility. The dynamics of blood flow in managing HTN 
with ACE inhibitors contributes to the reversal of hypertrophy in the heart (78). This action of ACE 
inhibitors surpasses that of other antihypertensive agents, therefore making it a drug of choice in 
preventing end-organ damage associated with HTN (78). A large clinical trial supports the use of ACE 
inhibitors for all patients who are at a higher risk of developing various heart diseases and renal 
abnormalities associated with hypertension. Apart from their haemodynamic effects, they are also able to 
prevent interstitial collagen deposition (79).  
Side effects associated with ACE inhibitors 
Despite its beneficial role in preventing end-organ damage, conventional ACE inhibitor, such as 
Captopril, Ramipril, Lisinopril and Enapril have a number of disadvantages, as they have various side-
effects  (80). A dry hacking and sometimes obstinate cough is the most common side-effect reported with 
ACE inhibitor therapy, which is suggested to be caused by the increase in kinin levels. Other reported 
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side effects include increased blood-potassium level (hyperkalemia), fatigue, dizziness, persistent 
headaches and a loss of taste. Studies have also linked conventional ACE inhibitors to loss of libido as a 
side-effect (81).While these side-effects, such as coughing, could be managed with inhaled sodium 
cromoglycate and aspirin, it would be desirable to replace ACE inhibitors with potent therapeutic agents 
that have minimal side effects. 
1.9.3 Calcium channel blockers 
 
The antihypertensive mechanism of calcium channel blockers is by binding to the L-type high voltage 
calcium channels, leading to an inhibited influx of calcium ions in vessels, causing vasodilation (82). 
Previous studies also indicate that calcium channel blockers may increase NO bioavailability and hence 
improve endothelial function (83). Drugs in this antihypertensive category include Nifedipine, which is 
known to exert an effect on blood vessels and a lesser action on cardiac output (84). Due to the important 
role of calcium in several cellular functions, studies have raised concerns over the potential adverse 
effects of blocking these channels (84). 
Side effects associated with calcium channel blockers  
Common side effects associated with calcium channel blockers include excessive hypotension, headache, 
tachycardia and oedema. Studies have also reported excessive bradycardia and a reduction in the 
electrical conduction (85).  
1.9.4  Angiotensin receptor blockade 
Angiotensin receptor blockers (ARBs) are known to displace ang II from its target receptor, angiotensin II 
receptors (AT1), in blood vessels, thereby antagonizing its effect (86). Reports indicate that ARBs cause a 
decrease in aldosterone production, leading to increased sodium excretion (87). Although both act on the 
renin-angiotensin system (RAS), the major disparity between ARBs and ACE inhibitors is that, unlike the 
latter, the former do not increase kinin levels (88), their increase possibly, a key factor accounting for 
some of the beneficial effects of ACE inhibitors over ARBs (88). 
Side effects associated with angiotension receptor blockade 
Current treatment guidelines for HTN recommends a combined use of ACEIs and ARBs, especially in 
cases where patients are intolerant to the persistent dry cough caused by ACEI (89, 90). This combination 
has been shown to offer additional benefits to managing HTN.  However, angioedema and ageusia have 
also been reported as a side-effect of ARBs (89).  
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1.9.5 Adrenergic inhibitors 
This group of antihypertensive drugs acts by several different mechanisms (91), including by inhibiting 
the sympathetic nervous system, thereby leading to a decreased force and rate of cardiac contractility 
(92), and a reduction in peripheral vascular resistance that decreases blood pressure (93). Beta-adrenergic 
blockers are known to act on the renin angiotensin system (RAS) by decreasing the renin production in 
the juxtaglomerular cells of the kidney (91). 
Side effects associated with adrenergic inhibitors 
Common side-effect reported in the usage of adrenergic inhibitors include orthostatic hypotension, 
ejaculatory disorders, and a severe hepatotoxicity that could be life threatening (94). In recent times, 
adrenergic inhibitors are rarely used to treat HTN due to its life threatening side-effects, which could 
increase mortality in hypertensive cases (94). It is therefore recommended that patients on adrenergic 
inhibitors be monitored closely for any lethal effect (95). 
1.9.6  Diuretics 
Diuretics form a common initial therapeutic strategy for most hypertensive cases, despite a decline in 
their use in the early 1990s. The short-term use of diuretics has been reported to induce natriuresis, with a 
simultaneous reduction in blood volume, hence reducing cardiac output (96). Moreover, the evidence 
suggests that chronic use of diuretics may also lead to a reduction of peripheral vascular resistance and 
therefore decreasing blood pressure (97). Most published works recommend thiazide-type diuretics as the 
first-line therapy, in cases where specific antihypertensive agents are not indicated, which act on the distal 
tubules of the kidney where they increase urinary excretion of sodium and potassium (98). 
Side effects associated with diuretics 
Common side effects reportedly associated with thiazide-duiretics include hyperlipidemia,  
hyperglycaemia,  hypokalaemia, glycosuria and  hyperuricaemia (99). The need for diuretics has been 
shown to be lessened with the use of ACE inhibitors and ARBs, which alters the renin-angiotensin-
aldosterone mechanism with a natriuretic effect (100).  
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1.10 ANIMAL MODELS USED IN EXPERIMENTAL HYPERTENSION 
A number of experimental animal models have been developed that mimic the pathophysiology and 
mechanism of HTN in humans, most of which share many features with HTN in humans (101). These 
models have suitable features to better understand the aetiology and progression of HTN, as well as to 
pharmacologically screen potential antihypertensive drugs for better treatment options. The aetiological 
factors that contribute to human HTN (102) include excessive salt intake, genetic predisposition, 
hyperactivation of the renin-angiotensin system (RAS) and nitric oxide bioavailability (102).  
 
Studies have shown that a single animal model may not have all the answers to the pathogenesis and 
treatment of HTN, as its aetiopathology is multifactorial (103, 106). However, each model explains a 
particular pathway for the progression and treatment of HTN, and the studied model is therefore 
associated with the aetiology and treatment of interest (103). The currently preferred animal model for 
HTN is the rat (104, 105). As essential HTN is the most common presentation of HTN in humans, and is 
generally associated with a genetic and pharmacological interest, most experimental models are 
developed for essential HTN (106). Examples of such models include the spontaneous hypertensive strain 
(SHR), Dahl-salt sensitive strain, and Milan, Lyon and Sabra strain. Among these rat models, the SHR 
has been generally used, although it explains only a specific type of HTN involving mainly the RAS  
(101).  
 
1.11 Chronic nitric oxide inhibition-induced Hypertension: The L-NAME model 
Studies have demonstrated several roles for NO in the development and treatment of HTN. As a 
vasodilator, NO has been demonstrated to be involved in several pathways involved in the 
pathophysiology of essential HTN (107). A deficiency of nitric oxide synthase (NOS) leads to a reduction 
of NO, causing reduced endothelium-dependent vasorelaxation, and eventually leading to HTN. As NO is 
involved in several pathways and mechanisms leading to essential HTN, it is a major focus area in 
hypertensive research (108). The chronic inhibition of NO synthesis with Nɷ-nitro-L-arginine methyl 
ester (L-NAME), has great potential for elucidating a number of mechanisms involved in the 
development and treatment of essential HTN (108).  
 
The L-NAME induced hypertensive rat model has been shown to involve more than the removal of the 
tonic vasodilatory action of NO, as there is also  evidence for contributions from the RAS, prostaglandins, 
sympathetic nervous system (SNS), superoxide anions, oxidative stress and the kallikrein-kinin system in 
the pathology of hypertension (109). It is therefore currently one of the main models for cardiovascular 
and renal studies associated with essential HTN (110), as NO has been implicated in a number of 
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pathological conditions that are associated with cardio-renal HTN, especially cardiac hypertrophy, end-
organ damage and inflammatory processes (111). Indeed, NO has been demonstrated to also inhibit 
monocyte adhesion, platelet function and vascular smooth muscle proliferation (112). Reports also show 
the involvement of NO in the haematological alterations during HTN (113). Given that drugs are more 
likely be highly efficient in the prevention and reversal of early, rather than late, vascular alterations in 
HTN; this model could be  most appropriate for testing  vascular protective effects and renal effects of 
antihypertensive drugs, in the context of NO deficiency (114). 
 
1.12 Medicinal and Nutritive Plants in Hypertension 
Medicinal plants generally refers to the whole or parts of plants or herbal materials that contain one or 
more active compounds, that are essential for therapeutic purposes, or that could serve as an essential 
ingredient in drug development (115).They possess various phytochemicals, and have unique nutritional 
value, that may show potential biological and therapeutic effects. Current research into the treatment of 
chronic diseases, such as HTN, has focused largely on the efficacy of medicinal plants, especially in 
Africa, due to the high cost and inaccessibility of the conventional pharmaceutical drugs. Additionally, 
conventional pharmaceutical drugs have a number of side effects and setbacks that make them difficult to 
adhere to (115, 116). The WHO, in its strategic goal to combat chronic diseases, such as HTN, supports 
the discovery of a novel therapeutic agent, that could effectively reduce systemic blood pressure with 
prolonged duration of action, to allow for once-daily dosing, as well as to reduce adverse reactions or 
untoward metabolic effects, to reduce end-organ damage (117, 118).  
 
Unlike medicinal plants, conventional drugs may contain a single active compound that works to produce 
a pharmacological effect, with its several side effects and contraindications with adverse reactions (119). 
Medicinal plants, on the other hand, are known to contain a number of bioactive compounds that work 
synergistically to produce a net therapeutic effect, with minimal side effects in most cases (120). Studies 
have shown that most plants produce a better therapeutic effect, when consumed in their crude form by 
indigenous populations, due to the presence of multiple bioactive compounds (119, 121). Moreover, these 
bioactive compounds could also be precursors to novel drug development, as 40% of conventional drugs 
are plants-derived (119). 
 
According to Van Wyk and Gericke (2000), local medicinal plants represent almost one eighth of the 
African plant population,  many of which can provide important leads for new drug discoveries that have 
not been investigated (122). Due to the renewed interest in medicinal plants, they are universally being 
recognized as beneficial to the economic, social and health needs of societies (123). Both local and 
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international initiatives are currently exploring South African botanical resources, with a focus on 
screening indigenous plants to identify the pharmacologically bioactive compounds (124). In the 
KwaZulu-Natal (KZN) Province, the Traditional Health Services are supported with more than $30  
million USD annually, due to medicinal plants. An estimated 700 000 tons of plant material is consumed 
annually in South Africa, amounting to almost  $150 million USD (125). The recognition and evaluation 
of medicinal plants in South Africa, and Africa, aims to improve the availability, efficacy, safety and 
affordability (126). In Africa, it is estimated that, approximately 90% of the population still rely 
exclusively on medicinal plants due to their efficacy, accessibility and affordability. South Africa has a 
strong history relating to traditional healing and hosts a variety of about 24 000 temperate and tropical 
flora, which also accounts for approximately 10% of the higher plant species, globally (127).  
1.12.1  Tulbaghia acutiloba Harv. 
Tulbaghia acutiloba Harv. (Alliaceae) is a small, cluster forming, bulbous perennial herb that is found 
mainly in the Southern African countries, such as Botswana, Lesotho, Swaziland, South Africa and 
Zimbabwe (128). The pointed petals of this plant species confer the name ‘acutiloba’, which in latin 
means ‘sharply pointed lobes’. It has sweet fragrant flowers with garlic scented edible leaves, and grows 
best in loamy soil, all year round (129). In South Africa, it is mainly located in the Eastern Cape, 
KwaZulu-Natal, Free State and Gauteng Provinces, where it is used by the indigenous populations for 
several purposes (130). It is also known as ‘wild garlic in English, ‘isihihi’ in Xhosa, ‘wildeknoffel’ in 
Afrikaans, ‘ishaladi lezinyoka’ in isiZulu, and ‘motsuntsunyane, sefothafotha’ in Sesotho (131). 
Tulbaghia acutiloba is one of the very few members of the family Alliaceae that has not been investigated 
biologically especially in an in vivo model, despite its various therapeutic uses. 
1.12.2 Traditional and Nutritive uses 
Tulbaghia acutiloba is mostly used therapeutically, as food, or as a protective ornament. In traditional 
medicine, it is used to treat diseases and conditions such as HTN, stroke, chest pains, diabetes, infectious 
diseases, flu, halitosis as well as an aphrodisiac (132). The leaves and the roots are used in the form of a 
decoction or extraction using alcohol, and in the case of some infectious diseases, may be used as a 
poultice (132). As a food, the leaves and flowers of Tulbaghia acutiloba are found in the diet of most 
indigenous people as a culinary herb.  It is believed that by eating the leaves as food, it prevents the 
development of chronic and infectious diseases (133). Tulbaghia acutiloba is also known to repel snakes 
and other poisonous reptiles, and they are therefore planted around houses as repellants. This practice is 
based on the belief that snakes and other poisonous reptiles, dislike the intense aromatic smell produced 
in the plant’s leaves and flowers (134). 
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1.12.3 Phytochemistry and biological activity  
In spite of a number of reports on the biological, pharmacological and phytochemical profiles of various 
plants of the Alliaceae family, there is a dearth of information on the scientific validation of the 
phytochemical profile, antihypertensive, cardioprotective, hematological and renal effects of Tulbaghia 
acutiloba. Generally, the presence of sulfur, flavonoids, phenols and saponins in the plants of the 
Alliaceae family, have been previously reported, although each plant may possess distinctive 
phytochemical components and biological activities that may augment its therapeutic effects (135, 136). 
Moreover, there is a dearth of information regarding the antioxidant and biological activities of Tulbaghia 
acutiloba, and hence the need to confirm its usage both in vitro and in vivo. 
 
1.13  Motivation and rationale of the study 
Natural product research is an exciting platform for novel drug discovery initiatives in the pharmaceutical 
industry. Hypertension, a growing public health threat, could have severe repercussions on the economy 
and the disease burden of South Africa and the region. Medicinal plants still constitute a considerable 
reservoir of new compounds and therapeutic options. As a treatment and preventive option, phytotherapy 
is readily accessible, localized and presents with minimal side effects. Amongst the 24 000 variety of 
species found in South Africa, less than 10%, have been subjected to thorough scientific and 
pharmacological investigations (123). Despite the lack of scientific evidence on the efficacy of medicinal 
plants, the general public uses herbal preparations to meet their primary health care needs. Reliance on 
herbal preparations without any scientific validation has potential health risks, as they may contain 
harmful substances. Biological testing for cytotoxity, chemical screening and functional studies are 
important to validate the use of the compounds. It is within this framework that this study was conducted, 
as there is little or no scientific validation of Tulbaghia acutiloba, a plant that has great potential, given 
that it is categorised within the well-known Alliaceae family 
 
1.14  Aim of the study 
This study aimed to investigate the chemical composition, and the in vitro and in vivo antihypertensive 
activities of the extracts of Tulbaghia acutiloba Harv. in a hypertensive experimental model, to 
understand the biological activity and therapeutic benefits of the plant extracts.   
 
1.15  Study objectives 
The objectives of the study (Chapters three, four and five) were: 
1. To identify the phytochemical constituents, in vitro antioxidant potential and analyse the heavy 
metal toxicity  of the crude extracts of Tulbaghia acutiloba  
20 
 
2. To evaluate the in vitro angiotensin-converting enzyme (ACE) inhibition potential of the crude 
extracts of Tulbaghia acutiloba  
3. To evaluate the antihypertensive and cardioprotective effect of Tulbaghia acutiloba extracts in an 
L-NAME model of hypertension 
4. To examine the effects of Tulbaghia acutiloba  extract on renal function in an L-NAME model of 
hypertension 
5. To determine the effects of Tulbaghia acutiloba extract on heamatological indices in an L-NAME 
model of hypertension 
 
1.16  Brief overview of methodology and study design 
To accomplish the objectives, standardized laboratory methods and treatment protocols were strictly 
adhered to, as illustrated in Chapters 3, 4 and 5. Animal experimental work was conducted as per the 
approval of the Animal Ethics Committee of UKZN (Ref: AREC/062/016PD) according to the guidelines 
of National Institutes of Health for the Care and Use of Laboratory Animals, South Africa. 
 
1.17  Potential benefit of this research  
This study is among the first to showcase the scientific validation of Tulbaghia acutiloba, and unravelling 
the pharmacological significance of this plant, offers new avenues in the search for improved therapeutic 
approaches for essential hypertension. Therefore, the outcomes from this study are novel and also 
contribute to the global understanding of the pathophysiology and treatment of essential hypertension and 
its associated complications, which will serve as a precursor for the possible development of drugs within 
WHO approved recommendations and guidelines.   
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Chapter 2: Manuscript One 
 
 
Ethnopharmacological Review of South African Indigenous Plants for Angiotensin 
Converting Enzyme (ACE) Inhibitory Activity 
(Submitted for peer review: Indian Journal of Traditional Knowledge, Manuscript 
Number: 9687) 
 
This chapter reviews South African Indigenous plants with ACE inhibitory activities within the context of 
their phytochemical profile and biological activities. This formed the background to evaluate Tulbaghia 
acutiloba for its therapeutic functions. 
 
Formats used in this chapter are according to the Journal specifications 
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Abstract  
South Africa has one of the highest prevalence of hypertension, with over 6 million people diagnosed as hypertensive. This being 
a major factor for cardiovascular diseases, needs to be critically managed to diminish the disease burden. Angiotensin converting 
enzyme (ACE) plays an imperative functional protagonist in regulating blood pressure by converting angiotensin I to 
angiotensin II, a robust vasoconstrictor. A review of traditional plants involved in ACE inhibition was conducted with evidence 
from published scientific journals, books and conference proceedings. Despite the availability of pharmaceutical drugs, 
underprivileged, predominantly rural sectors in South Africa facing socioeconomic challenges have opted for cost effective 
herbal concoctions with fewer perceived side effects. Whilst a number of plants and their formulations are used traditionally to 
treat hypertension, more scientific studies are needed to authenticate the efficacy and toxicity of these herbal remedies. 
Keywords: Hypertension, Cardiovascular disease, Indigenous medicine, Renin Angiotensin System. 
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Introduction 
Cardiovascular disease (CVD) is a rapidly growing multifactorial disease and major public health threat, 
despite the advancements in research made over the past few decades1. Hypertension is still the major 
leading risk factor of cardiovascular diseases, with serious and sometime fatal outcomes, accounting for 
16.5% of annual global deaths2.  Previously hypertension was defined as elevated blood pressure (BP) of 
more than 140/90 mm Hg. However according to the American Heart Association 20173, hypertension is 
now defined as elevated BP of more than 130/80 mm Hg. An estimated 23.5 million people will be die as 
a result of the condition by 2030 if the current interventions are not successful or new ones not 
established1. 
The renin angiotensin system (RAS) is considered to play an important role in the pathogenesis of 
cardiovascular diseases, including hypertension. Recent reports strongly support the use of RAS 
inhibiting agents, such as angiotensin receptor blockers, (ARB) as well as angiotensin converting enzyme 
(ACE) to clinically manage cardiovascular diseases. Angiotensin converting enzyme, is an enzyme 
responsible for the conversion of Angiotensin I to Angiotensin II. Angiotensin II is known to trigger a 
cascade of pathways that leads to vasoconstriction, which ultimately progresses to hypertension4.  
Conventional drugs are effective in treating hypertension, specifically those that acts as an ACE inhibitor 
(ACEI), including Captopril, Ramipril, Benazepril, Enalapril, Lisinopril and Perindopril5,6.  However, 
reports of uncontrolled BP in patients who adhere to the routine of these antihypertensive drugs, together 
with the adverse side effects, has been established5,6.  Furthermore, these chemical drugs are not easily 
available in developing countries, thereby contributing to non-adherence of therapeutic regimens6. These 
factors heightens the urgency to find cheaper, easily accessible and effective therapy7. According to the 
World Health Organisation (WHO), poverty and lack of modern medicine forces 65-80% of the world’s 
population to depend exclusively on plants for principle health care. Moreover, the isolation of natural 
compounds from medicinal plants, as rich sources of novel drugs with diverse potential therapeutic 
benefits, has gained considerable scientific attention7.  
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Etiopathogenisis of cardiovascular diseases and hypertension 
Blood pressure is defined as the pressure of the blood flow that is exerted against the blood vessel wall as 
it is pumped by the heart. Cardiac output and peripheral vascular resistance are regulated by the interface 
of several influences, such as genetic, environmental and demographic factors4. Arterial BP is the product 
of cardiac output (CO) and total peripheral resistance (TPR)8, with BP maintenance being dependent on 
the balance of both TPR and CO, as illustrated in  Figure 1. 
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Figure 1: Role cardiac output and total peripheral resistance in blood pressure regulation (Adapted from Kumar et al., 2005 9). 
 
Primary or idiopathic hypertension is well-defined as elevated BP, wherein secondary contributors, for 
example renovascular disease, renal failure, pheochromocytoma, aldosteronism, or other causes are not 
present10. Essential hypertension accounts for 90 – 95% of all hypertensive11. Key pathophysiological 
alterations associated with essential hypertension include: endothelial dysfunction; increased generation 
of reactive oxygen species (ROS); decreased bioavailability of the key vasodilator, nitric oxide (NO); 
increased sodium intake; altered expression of the kallikrein-kinin system that influences vascular tone 
and renal salt handling, as well as excessive activation of the renin angiotensin aldosterone system 
(RAS)12. 
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 The Classical Renin Angiotensin Aldosterone System (RAAS) 
The central role of the RAS in regulating BP is well recognized13, with Angiotensin II, the main effector 
octapeptide, being essential for its control. Angiotensin II (Ang II) directly activates the angiotensin II 
type 1 (AT1) receptor that leads to the stimulation of various tyrosine kinases, which in turn causes the 
phosphorylation of the tyrosine residues in a number of proteins, leading to vasoconstriction14. Abnormal 
RAS activity leads to an array of cardiovascular diseases, such as hypertension, atherosclerosis, 
myocardial infarction, congestive heart failure and renal disease14.  
 The Novel Renin Angiotensin System (RAS) 
According to the long-held classical theory, the RAS is viewed as an endocrine system, with circulating 
Ang II as the active metabolite15. Recent attention has focused on the tissue-specific paracrine and/or 
autocrine functions of Ang II16. Evidence strongly suggests that the essential components of the RAS are 
present in all organs and tissues of the body, and that the tissue/local RAS is regulated independently of 
the circulatory RAS, although they can interact15,17 which has important implications for therapeutic 
interventions.  
Local Ang II can be generated directly from angiotensinogen by the actions of the enzymes cathepsin G 
and chymostatin-sensitive-Ang II-generating (CAGE) enzyme, or from Ang I through the action of the 
enzyme chymase. Reports suggest that chymase is the major catalyst of tissue Ang II formation in the 
human heart (>80%) and the arteries (>60%)17,18. The alternative RAS pathway also identifies the enzyme 
ACE II, which is located in the heart, kidney, testes and the gastrointestinal tract. ACE II, a homologue of 
ACE, catalyses the conversion of Ang I to inactive angiotensin 1-9 [Ang (1-9)], and Ang II to angiotensin 
1-7 [Ang (1-7)]19. Ang I can also be converted to Ang (1-7) by the action of endopeptidases [18]. The 
‘classic’ ACE catalyses the conversion of Ang (1-9) to the vasodilator and anti-proliferative Ang (1-7) 
[19]. The Ang (1-7) G protein-coupled protein Mas receptor is a key component of the Ang 1-7/ACE 
II/Mas axis, which is believed to counter-balance the pressor effects of the ACE/Ang II /AT1 receptor 
pathway19.  
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Figure 2: Components of the classical and alternative pathways of the renin-angiotensin system (RAS) and their interactions 20 
 
ACE inhibition and its Implication on RAS and Hypertension 
ACE is a dipeptidyl-liberating expeptidase that catalyses the cleavage of histidyl-leucine from angiotensin 
I to produce the potent vasopressor octapeptide angiotensin II 21. Ang II is produced in various tissues, 
such as the blood vessels, heart, adrenals and brain, which are regulated by ACE as well as other 
enzymes, including rennin 13. Although the conversion of Ang I to Ang II by ACE is a normal regulatory 
process, unrestrained elevated ACE activity leads to increased levels of the latter, which leads to the 
development of hypertension 14. This occurrence is essential for the development of inhibitors that are 
involved in converting Ang I to Ang II to treat hypertension. Additionally, ACE is identical to kininase II, 
the enzyme that facilitates the degradation of bradykinin, a critical component of the kallikrein-kinin 
system (KKS). The increased levels of the potent vasodilator, bradykinin, due to kininase II inhibition, 
36 
 
stimulates the production of NO and prostaglandins, including prostacyclin and prostaglandin E2, 
resulting in increased local blood flow and the relaxation of smooth muscles18, 22.  
ACEIs have also been reported to prevent the progression of albuminuria to proteinuria, reduce 
proteinuria in patients with glomerular disease, and/or delay the progression of renal insufficiency to end-
stage renal disease 23. Moreover, ACEIs are reported to reduce total peripheral vascular resistance without 
significantly altering the heart rate23.   
Conventional prescription drug generally used as ACE inhibitor 
The most commonly used western drug for ACE inhibition is captopril, with studies having found that 
PCR analysis of rat renal tissue, following its use demonstrated down regulation of the AT1 gene, 
indicating that ACE inhibitors play an important role in AT1 receptor regulation 24, 25. Captopril 
bioavailability in adults is approximately 75%, with the majority of the drug being eliminated via the 
kidney together with inactive metabolites (50:50 ratio)26.  Captopril is usually well tolerated when 
administered orally, although occasional side effects have been reported. These adverse effects include 
metallic taste, rash, neutropenia, liver toxicity oliguria, acute renal failure, hypotension, hyperkalemia, 
anaemia and neurological complications 23, 27. Furthermore, hypotension, hyperkalemia and pregnancy 
related abnormalities have also been associated with ACEI therapy.  The most common side effects 
caused by an impaired metabolism of bradykinin due to ACE inhibitors is hypertensive patients 
manifesting a dry hacking cough and angioedema28.  
Novel drug therapy that mimics the hypotensive effects of captopril, but without the adverse side effects, 
is therefore essential to treat hypertension29. Additionally, in the plant world, active substances coexist 
with the other compounds that mitigate their negative side effects, with a recent return to phytotherapy 
having been observed. There has therefore been a renewed call by the WHO to screen plant material for 
the presence of biologically active compounds. It is firmly believed that a great, yet still not fully 
revealed, therapeutic potential exists in plants, because, thus far only a few percent out of  250,000 plant 
species have been investigated with regard to their usefulness in medicine30. 
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The Role of Herbal Medicines In Managing Cardiovascular Disease And Hypertension 
The use of medicinal plants to treat hypertension and other cardiovascular diseases has gained much 
attention by the scientific world over the last decade7. This is mainly due to medicinal plants being a 
cheaper alternative to manufactured formulations, with fewer, or no undesired side effects31. However, 
their use in primary health care is not a reflection of the economic status of a person, with 70% of the 
population in developed countries relying on complementary and alternative medicine (CAM) for 
treatment purposes, of which herbal medicines plays a significant role32.   
The chemical constituents of the plant cells that exert biological activities on human and animal cells fall 
into two distinct groups, depending on their relative concentration in the plant body, as well as their major 
function: (a) primary metabolites, the accumulation of which satisfies nutrition and structural needs, and 
(b) secondary metabolites, which act as hormones, pharmaceuticals and toxins33. 
Medicinal plants which are rich in a variety of secondary metabolites, such as flavonoids, alkaloids, 
polyphenols, tannins and terpenoids, have been explored for their cardio protective and antihypertensive 
properties34-37. The probability of plants secondary metabolites as a source of novel ACE inhibitors 
continues to be under investigated, whereby only a restricted amount of species have been examined33. 
Table 1 below shows common plant extracts and molecules isolated from them that have previously 
shown inhibitory effects on ACE. 
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Table 1:  Medicinal plants from around the world displaying ACE inhibition   
Plant name (family) 
Active 
Ingredients 
Medicinal 
uses 
Bioactivity 
tested 
Reference 
Crataegus spp (hawthorn) 
 
Glycosides, 
proanthocyanidins, 
flavonoids 
Stomach ailments, 
Chronic heart 
failures, 
Hypertension 
Antihypertensive, 
antiparasitic 
34 
 
Cassytha filiformis 
 
Alkaloids, phenols 
Male sexual 
dysfunction, 
Jaundice, 
Cardiovascular 
diseases, 
Aphrodisiac, 
antihypertensive 
       35 
Jatropha curcas 
 
Saponins, phytate, 
curcins 
 
Contraceptive, 
Laxative 
Antioxidant, 
anti constipative 
       36 
Moringa oleifera 
 
Amino acids, 
flavonoids, 
polyphenols 
Stomach 
ailments, 
Microbial 
infections 
anti-inflammatory, 
anti-parasitic, 
      37 
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Passiflora edulis 
 
 
Cardiac 
glycosides, 
terpenoids, 
alkaloids, 
steroids 
Jaundice, 
Sedative, 
Tranqulizer 
anti-depressant, 
antihypertensive 
39 
Psathura Borbonica 
 
Flavonoids, 
phenols 
 
Diuretic, 
Laxative, 
 
Anti-constipation, 
anti-hypertensive 
         40 
Apium graveolens 
 
Polynnes, apiin, 
apigenin, 
lunularin 
 
Arthritis, 
inflammatio
n, 
Antimicrobia
l  
Anti-
inflammatory, 
cardio protective, 
antibacterial 
          41 
Leea guineensis 
 
Phenylpropanoi
d, terpenoids, 
aldehydes 
Rheumatism, 
Oedema 
Anti-arthritic, anti-
inflammatory 
        42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
 
 
 
40 
 
Poupartia borbonica 
 
 
Cyclohexenone, 
phenols, 
flavonoids 
 
Malaria 
infection, 
Microbial 
infections 
 
Antiplasmodial, 
anti-bacteria, anti 
pesticidal  
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South African Indigenous Plants with ACE inhibition 
In South Africa, many people still use plants as medicines as an alternative or supplement to visiting a 
western health care practitioner 44. This is not surprising due to South Africa's cultural diversity as well as 
its large floral biodiversity. South Africa is home to over 30,000 species of higher plants and 3000 of 
these species have been found to be used in traditional medicine across the country 44. There are over 27 
million users of indigenous medicine 45 and an estimated 200,000 indigenous traditional healers, which up 
to 60% of the population consult with44. 
Within the wealth of plants in South Africa, scientists have reported on several with ACE inhibitory 
activities (≥50%), which may serve as a foundation for drug discovery to treat hypertension46,47.  
Moreover, they represent an untapped reservoir of potentially useful chemical compounds, unique 
templates that could serve as starting points to achieve a better understanding of biological processes 
involved in hypertension 47. The local plants of particular importance for ACE inhibition are stated below, 
these being found in various provinces of South Africa. 
Tulbaghia violacea Harv. 
A very popular garden plant, T. violacea belongs to the Alliacaea family, and is one of the fastest growing 
bulbous plants, which could grow to a height of 0.5m. It has long narrow leaves with a strong garlic smell 
and  pinkish mauve tubular flowers that are mainly seen from January to April48. It is a well distributed 
plant, stretching from the Eastern Cape, to KwaZulu-Natal and Limpopo, and extends as far north as 
Zimbabwe 48 (Figure 4).  
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Figure 4: T. violacea 48 
 
Ethnomedicinal uses and studies 
T. violacea is an edible plant that is usually prepared in salads and other dishes, with decoctions of 
the bulbs used to treat coughs and colds, as well as pulmonary tuberculosis. Findings on its antimicrobial 
and antifungal properties are well documented 49-51. It is also  used   traditionally to  treat  numerous  other 
ailments,  including  fits,  paralysis, headaches,  high  blood  pressure,  fevers,  rheumatism,  heart  
problems,  chest  complaints,  stomach cramps and constipation52. Several studies have confirmed the in 
vitro ACE inhibition activities of T. violacea, with both aqueous and methanolic extracts showing ACE 
inhibition activities4, 53, 54 . 
Phytochemicals in this genus 
Phytochemical analysis revealed the presence of flavonoids, glycosides, tannins, terpenoids saponins and 
steroids, these compounds being biologically active that may contribute to the antioxidant activities of the 
Tulbaghia species52.  T. violacea has been found to be rich in sulphur-containing compounds, which in 
most cases account for the characteristic odours and medicinal properties of both the Tulbaghia and 
Alluim species55.  
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Protorhus longifolia Bernh. 
P. longifolia is a medium to large, mostly dioecious class of tree belonging to the Anacardiaceae (Mango) 
family. It is commonly called red beech and is often distributed from the Eastern Cape to Limpopo. This 
species is an evergreen indigenous tall tree and mainly occurs in coastal, scarp and mist belt forests, rock 
ridges, cliffs, riparian frontiers, or in woodland56. P. longifolia is commonly known as uNhlangothi 
(isiZulu). It is one of the top 10 most important and frequently traded medicinal plants in the Eastern 
Cape Province57, and has patently yellow or red leaves, with flowers that are greenish-white (male) or 
pink to red (female) (Figure 5).   
 
Figure 5: P. Longifolia 58 
Ethnomedicinal uses and studies 
The bark has traditionally been used to treat numerous ailments, such as the bacterial infections of 
Ehrlichia ruminantium and diarrhea in cows 57, hemiplegic paralysis, heartburn and bleeding from the 
stomach. Some parts of the plants have also been used to fortify the heart59, while Suleiman et al. (2009)60 
claims that the leaf extracts possess antimicrobial activity. Mosa et al. (2011)61 showed that the stem bark 
has an anti-platelet aggregation. Mosa et al. (2016)62 examined the in vivo cardio protective effect of 
methyl-3b-hydroxylanosta-9, 24-dien-21-oate (RA-3) that was isolated from P. longifolia in ISO-induced 
myocardial injury in rats, while Duncan et al. (1999)54 reported a 77% in vitro ACE inhibition activity of 
P. longifolia extracts. 
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Phytochemicals in this genus 
Triterpenes isolated from the bark P. longifolia, have been linked to its cardio protective activity. 
Adenopodia spicata E. Mey. 
A. spicata belongs to the Fabaceae family, being frequently known as ‘spiny splinter bean’ (English), 
lugagane (siSwati), umlungumabele (isiXhosa) and umlungumabele (isiZulu).  It is a typical climbing 
shrub/tree found mainly in the coastal forests of KwaZulu-Natal as well as the Eastern Cape to 
Limpopo57. It is an evergreen shrub that grows up to 10m height comprising of small slender branches, 
with the leaf axis being mostly round or flattened, and often prickly. It contains bisexual flowers and 
gives rise to a glabrous pod fruit that breaks into segments57, (Figure 6). 
 
Figure 6: A. spicata 58  
 
Ethnomedicinal uses and studies 
The roots of A. spicata is traditionally used to treat chest pains and syphilis 63. In Zululand, a root infusion 
is used by traditional healers as an emetic to fatten goats, while Zulu sangomas use the crushed roots to 
increase their spiritual powers63. Duncan et al. (1999)54, found  in vitro ACE inhibitory activity in both the 
aqueous (97%) and methanolic (72%) extracts of the leaves of A. spicata. According to theses authors, A. 
spicata generated the highest in vitro ACE inhibition activity in South Africa to date. A detailed in vivo 
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study is necessary to establish the bioavailability of the active compounds in animal gut and hence an 
implication for drug discovery in man 
Phytochemicals in this genus 
The active compounds from A. spicata have not been isolated and identified.  
Catha edulis Vahl. 
C. edulis belongs to the Celastraceae family, and is commonly called Bushman's tea (Eng.), Boesmanstee 
(Afr.), umhlwazi (Zulu), iqgwaka (Xhosa) and khat (Arabic).  This is a small deciduous tree with bright 
green leaves that grows up to 10 m tall, has an upright crown, and somewhat drooping branches that 
resemble a eucalypt from a distance. It is dispersed in KwaZulu-Natal and Eastern Cape, mostly 
extending inland from the coastal belt, although it is also found in the Western Cape, Mpumalanga, 
Swaziland, Mozambique and through to tropical Africa and the Arab countries64 (Figure 7).  
 
 
Figure 7: C. Edulis 65 
 
Ethnomedicinal uses and studies 
C. edulis young buds and tender leaves are chewed to attain a state of euphoria and stimulation. 
Traditional use of this plant includes constipation, urine retention, acute cardiovascular and nervous 
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system effects, increased alertness, patience, dependence problems, as well as psychiatric symptoms 66. 
Duncan et al. (1999)54 established that the ethanolic extracts of the leaves of C. edulis produced an 82% 
ACE inhibition in vitro. 
Phytochemicals in this genus 
Many different compounds are found in C. edulis, including alkaloids, terpenoids, flavonoids, sterols, 
glycosides, tannins, amino acids, vitamins and minerals66. The phenylalkylamines and cathedulins are the 
major alkaloids, which are structurally related to amphetamines (chemical, nervous system stimuli), while 
cathinone has vasoconstrictor activity in isolated perfused hearts from guinea pig66. 
Justicia flava Vahl. 
  J. flava belongs to the Acanthaceae family, and usually grows in disturbed habitats, on a wide range of 
soil types, in full sun or semi shady areas. It is prevalent in tropical and Southern Africa, being a perpetual 
herb that grows up to 450 mm high. Is commonly called “ipela” in Zulu. The leaves are lanceolate or 
broadly ovate, with flowers that are subtended by large, leaf-like bracts, while the tubular flowers are pale 
to greenish with a bright yellow lower lip (Figure 8). 
 
 
Figure 8: J. flava 58 
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Ethnomedicinal uses and studies 
J. flava is used traditionally to treat coughs, paralysis, fever, epilepsy, convulsions, spasm, as well as skin 
disorders. A concoction of the roots are used for diarrhea and dysentery68. Agyare et al. (2013)69 reported 
that methanolic leaf extracts significantly increased the tensile strength and the rate of contraction of 
wounds, with intense granulation tissue formation.  Ramesar et al. (2008)70 reported that aqueous extracts 
of the leaves showed 53% ACE inhibition activity.  
Phytochemicals in this genus 
Steroids, including campesterol, stigmasterol, sitosterol, and sitosterol-D-glucoside, were isolated from its 
leaves and roots 71.  
Dietes iridioides L. 
D. iridioides is a part of the Iridaceae family, and is commonly called indawo-yehlathi, isiqiki-
sikatokoloshe or isishuphe somfula (isiZulu).  It is an evergreen herb that usually grows up to 600 mm in 
height, has green leaves that are arranged in a loose fan, with small flowers, each bloom lasting a single 
morning. This plant is very commonly used in South African landscapes and gardens59, being distributed 
throughout the country, specifically in the less dry provinces of KwaZulu-Natal, the Eastern Cape and 
Western Cape (Figure 9). 
 
Figure 9: D. Iridioides72 
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Ethnomedicinal uses and studies 
D. iridioides infusions made from of the rhizome are traditionally used as an enema, to treat dysentery 
and hypertension. The rhizomes also being used to facilitate childbirth73. Ground rhizomes are ingredients 
in tonics for goats74, while the roots are used to treat menstruation disorders. It is widely used in 
traditional medicine to treat flu, cold, toothache, malaria, and bruise75. Duncan et al. (1999)54, found that 
the aqueous leave extracts produced an in vitro ACE inhibition activity of 80%. 
Phytochemicals in this genus 
The main secondary metabolites isolated from extracts of Iridaceae include isoflavonoids, flavonoids, 
triterpenoids, naphthoquinones, anthraquinones, naphthalene derivatives, xanthones and phenolics76. 
Active compounds found in this family were reported by Lucena et al. (2007)77, to have an extensive 
variety of biological activities, including antibacterial, antiprotozoal, antiviral, antioxidant, 
antinociceptive, anti-inflammatory cytotoxic, and immunomodulatory benefits.  
 
Dombeya rotundifolia Hochst. 
 D. rotundifolia belongs to the Sterculiaceae family, often referred to as the chestnut family78, being 
frequently known as wild pear (English) or inhliziyonkhulu (isiZulu). The wild pear is a deciduous tree 
that grows approximately 1 - 1.5 m per year and can reach heights of up to 10 m. The bark is dark brown, 
bumpy and corky on fully developed trees. The leaves are almost round and are shielded with tiny spiky 
hairs, which is a distinguishing characteristics79. D. rotundifolia are distributed throughout KwaZulu-
Natal and Mpumalanga, where they grow in woodlands, grasslands or bushel as well as on rock-strewn 
slopes (Figure 10). 
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Figure 10: D. rotundifolia 58 
Ethnomedicinal uses and studies 
D. rotundifolia is traditionally used to treatment heart problems, vomiting in pregnant women, intestinal 
ulcers, headaches, stomach ailments, haemorrhoids, diarrhoea and dyspepsia, as well as to accelerate the 
onset of labour80. Duncan et al. (1999)54, established that the ethanolic leave extracts exhibited an 83% 
ACE inhibition activity.  
Phytochemicals in this genus 
Reid et al. (2001) 80, isolated two main types of tannins i.e. condensed and hydrolysable tannins. 
Condensed tannins have traditionally been used to assist in wound healing and scorches, and produce a 
waterproof layer when applied to the skin80. These tannins also have particular shielding significance 
against toxins when ingested, with hydrolysable tannins being thought to have antiviral and anti-tumour 
properties81.  
Searsia chirindensis Baker f.  
S. chirindensis (previously called Rhus chirindensis) belongs to the Anacardiaceae family, and is 
generally called red currant (English), umhlakothi (Xhosa), inhlokoshiyane enkulu (Xhosa) or 
muvhadela-phanga (Venda).  It is widely distributed in Limpopo, Mpumalanga, KwaZulu-Natal, Eastern 
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Cape, and Western Cape. S. chirindensis is a semi-deciduous shrub to small tree that grows up to 6-10 m 
in height (Figure 11). 
 
Figure 11: S. chirindensis 82 
 
Ethnomedicinal uses and studies 
Traditional healers usually use the sap of this plant to treat heart conditions, strengthen the body and 
encourage blood circulation, while the bark is used to treat rheumatism as well as mental disorders83. 
Ojewole (2008)84 showed that the aqueous extract of the stem-bark portentously postponed the 
commencement of seizures brought by pentylenetetrazole (PTZ), or antagonized picrotoxin (PCT)-
induced seizures, suggesting that S. chirindensis acts as an analgesic and anti-inflammatory. Other studies 
have reported that the stem bark is used ethno-medically as an agent to control type 2 diabetes. Duncan et 
al. (1999)54, established that the ethanolic leaf extracts of S. chirindensis could be used as an anti-
hypertensive drug, as it possessed an 85% ACE inhibitory activity.  
Phytochemicals in this genus 
The stem bark contains flavonoids, small quantities of saponins, tannins, triterpenoids, traces of alkaloids 
and cardiac glycosides, which are thought to act as an anticonvulsant.  
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Can South African Indigenous Plants be Harnessed Therapeutically for ACE inhibition?  
Despite centuries of traditional use of medicinal plants, several scientific based studies still remain poorly 
understood, debateable, or unrecognized. The human body may be regarded as multifaceted, with the 
ability to mend itself. However, in the modern world, the variables are almost infinite. It is well 
recognized that the existing global population face greater health concerns, particularly life-threatening 
diseases such as hypertension.  In light of this, scientists are currently reviewing the historical use of plant 
extracts to cure ailments in order to produce medicines85. 
During the last few eras, it has become evident that there exists a superfluity of plants with medicinal 
potential and it is increasingly being accepted that the African traditional medicinal plants offer probable 
prototype molecules in the search for novel antihypertensive drug agents.  Many of the plants presented in 
this review show boundless potential for ACE inhibition thus justifying supplementary clinical 
investigations. Nevertheless, very limited scientific and clinical evidence is available, thereby 
necessitating comprehensive screening and scientific investigations before exposure to the global 
market86. 
 
Conclusion 
Inhibition of ACE is a contemporary beneficial objective in the management of hypertension. Synthetic 
ACE inhibitors are understood to have numerous side effects. Consequently, the investigation for non-
toxic, innocuous, novel and cost-effective ACE inhibitors as substitutes to conventional treatment is 
needed. Medicinal plants are likely to play an increasingly important role in providing health care in 
South Africa. In this review, investigational as well as the traditional knowledge of South African plants 
used for ACE inhibitory activity were identified, each with their benefits and limitations. Ongoing studies 
are required to investigate their therapeutic potential in the management and treatment of hypertension.  
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Chapter 3: Manuscript Two 
Biochemical, Phytochemical Profile and Angiotensin-1 Converting Enzyme Inhibitory 
activity of the Hydro-methanolic extracts of Tulbaghia acutiloba Harv. 
(Accepted: Journal of Natural Remedies; Volume 19, Issue 3, 2019) 
 
Literature reviewed at the beginning of the study indicated the importance of assessing novel medicinal 
plants through preliminary screening and identification of phytochemical contents, and investigating 
antihypertensive effects and biochemical parameters as part of a holistic approach to finding accessible 
alternate remedies in the treatment of hypertension. Thus Chapter 3 presents a detailed in vitro study 
conducted to assess the phytochemical constituents, antioxidant activity, heavy metal toxicity and 
angiotensin-converting enzyme inhibition properties of the indigenous herb, Tulbaghia acutiloba.  
Formats used in this chapter are according to the Journal specifications. 
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ABSTRACT 
Phytotherapeutic treatments have been on the ascendancy over the years as the quest for alternate 
and easily accessible health care is on the rise. Tulbaghia acutiloba has been used by both 
traditional healers and the South African population for the management of chronic conditions, 
but lacks scientific authentication for usage. Hydro-methanolic extracts (roots, rhizomes, leaves 
and flowers) of the plant were evaluated for their antioxidant activities, biochemical and 
phytochemical profile. Additionally, the heavy metal content and antihypertensive effects 
including angiotensin 1-converting enzyme inhibitory activities (ACEI) were investigated. The 
antioxidant ability of the hydromethanolic extracts were determined by 2, 2-diphenyl-1-picryl 
hydrazyl (DPPH), hydrogen peroxide and nitric oxide scavenging activities. Phytochemical 
profile was assessed using qualitative and quantitative methods whereas the heavy metal toxicity 
was determined by using inductively-coupled plasma optical emission spectrometry (ICP-OES). 
In vitro ACEI activity was determined by the hydrolysis of the tripeptide, hippuryl –L-Histidyl-
L-leucine (Hip-His-Leu). All the extracts showed potent antioxidant activities which was 
concentration dependent. Phytochemical analysis showed the presence of phenols, amino acids 
and alkaloids in all the extracts. The leaves showed a relatively higher total phenolic content of 
43.26±1.15 mgGAE/g. Gas chromatography–mass spectrometry (GC-MS) analysis showed the 
presence of major compounds such as α-linolenic acid in the leaves as well as oleic acid and 
palmitic acid in other parts of the plants. Toxicity of heavy metal was undetected in all extracts 
of the plant. All the extracts of the plants showed a >50% ACE inhibition at different 
concentrations with the leaves showing a relatively higher inhibitory activity (76.66 ± 1.65, 
IC50;154.23μg/ml) compared with the other parts of the plants. It is therefore concluded in this 
study that the biological activities and phytochemical component of the hydro-methanolic 
extracts of T. acutiloba is indicative of its possible use for the treatment as well as prevention of 
hypertension and oxidative stress-related diseases. 
Key words: Tulbaghia acutiloba, Angiotensin 1-Converting Enzyme, Phytochemical, Heavy 
Metal Toxicity, Antioxidant.  
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1. Introduction 
Chronic lifestyle-related metabolic diseases such as hypertension (HTN)  cause double the 
number of deaths compared to infectious diseases1. Hypertension, as the major risk factor of 
cardiovascular diseases, continues to be on the ascendancy with increased  numbers of patients 
with high blood pressure seeking herbal and naturopathic treatments, especially in developing 
countries such as South Africa2. Phytotherapy is an integral part of the traditional healing system 
in developing countries, a trend that is rapidly rising in developed countries owing to the belief 
that herbal remedies and indigenous medicine are generally considered safer, affordable, easily 
accessible and with no or minimal side effect as compared to the drugs used in conventional 
medicine3. Moreover, several conventional drugs are derived from herbal medicines, but the 
major variation between the two is that herbal drugs mostly contain a number of bioactive 
compounds, whereas the conventional drugs mostly contain an isolated bioactive substance; 
therefore, the constituents of both herbal and conventional medicines may act on one another to 
augment or enhance an effect. In South Africa, it is estimated that between 12 and 15 million 
people still depend on traditional herbal medicine, from as many as 700 indigenous plant 
species4,5. New remedies discovered by traditional healers are increasingly being used (especially 
for cardiovascular diseases), increasing the need  for scientific validation  of mechanism of 
action and drug dosage formulations6.   
Bioactive compounds such as flavonoids, phenols, saponins, steroids and tannins obtained from 
medicinal plants, show high antioxidant activities that are key to the therapeutic management of 
chronic conditions such as hypertension, cancer and diabetes7. It is now widely reported that 
central to the pathology of these diseases is oxidative stress, caused by free radicals.  Free 
radicals are either generated in the human body, in situ or from the external environment through 
air pollutants8, however an increase in free radicals in the body could lead to oxidation of 
biomolecules 9,  and other pathological conditions10. Prolonged oxidative stress leads to heart 
diseases, and in particular  the risk factor,  hypertension11. Moreover, the reducing capacity or 
scavenging activity of an extract or compound against free radicals may serve as a significant 
indicator of its potential antioxidant activity12. 
 
It is important to note that a drawback of phototherapy may include heavy metal accumulation, 
absorbed from the environment by the plant. The continuous ingestion of toxic heavy metals 
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such as lead, chromium, barium, arsenic and cadmium, into the human body may have genetic 
and epigenetic effects leading to numerous disorders13. Therefore, there is the need to evaluate 
medicinal plants for toxic heavy metal content. 
 
The increasing use of plants therapeutically, with little scientific data to verify their safety profile 
and dosage could lead to side effects.  One such plant is Tulbaghia acutiloba. T. acutiloba is 
commonly known as ‘wild garlic”, “ishaladi lezinyoka” in Zululand, “sefothafotha” in South 
Sotho and lisela in Swaziland. It is indigenous to the Eastern Cape, KwaZulu-Natal, Gauteng, 
Free State and Mpumalanga regions of South Africa14. Generally, It is used as a herbal treatment 
for a number of  health conditions such as fungal infections, bruised skin, sores and also forms 
part of many delicacies in the Eastern Cape region15. Traditionally, the Basotho’s, cook the 
leaves, bulb and roots of T. acutiloba to make a lotion. This lotion is used to wash incisions to 
avoid bacterial contamination and aid in wound healing. A concoction of this plant is made and 
drunk for the treatment of high blood pressure as well as diabetes16,17. They are also grown 
domestically by the Zulu’s and Xhosa’s around their homes as a protective charm to repel snakes 
and other harmful reptiles 17.  
We have previously investigated Tulbaghia violacea or ‘wild garlic’ which is closely related to 
the Tulbaghi acutiloba. We were able to show antidiabetic, antihypertensive and renoprotective 
effects which could be attributed to its organosulfur compounds18.   
In spite of the therapeutic herbal properties and the wide use of T. acutiloba, there is a lack of 
scientific information concerning the pharmacological and biological activities of its extracts. 
This study investigated the antihypertensive properties, antioxidant activities, toxic heavy metal 
content and phytochemical profile of T. acutiloba. 
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2. Material and Methods 
 
2.1 Preparation of Plant Material and Extract 
Fresh rhizomes, roots, leaves and flowers of T. acutiloba were collected from Durban, KwaZulu-
Natal and authenticated by Prof Himansu Baijnath (Botanist) from the University of KwaZulu-
Natal (UKZN). The parts collected were washed thoroughly under tap water and allowed to air 
dry at room temperature over a period of 72 hours. Each part of the plant was crushed in a 
Waring blender. The powdered form (50g) of each part was immersed in separate 500ml hydro-
methanolic solution (80% methanol; 20% water) and shaken at 80rpm for 48 hours. The crude 
extract for each part was filtered and concentrated in a rotary evaporator, thereafter air dried to 
form a sludge. The remaining extracts were weighed and the percentage yield determined for 
each part of the plant. 
 
2.2 Antioxidant activity 
 
2.2.1 2, 2-Diphenyl-1-Picryl Hydrazyl (DPPH) Radical Scavenging Activity 
The scavenging activity of each part of the plant on the stable radical DPPH was determined 
according to the method by Murthy et al., (2002) with some modifications19. A volume of 150 μl 
of the hydro-methanolic solution of each extract at different concentrations (1000, 500, 250, 125, 
62.5, 31.3 and 15.6 μg/ml) were mixed with 2.85 ml of a methanolic solution of DPPH (0.1 
mM).  Equal amount of MeOH and DPPH with no extract was used as control. The reaction was 
kept at room temperature for 30 minutes in the dark and thereafter the absorbance measured at 
517 nm against methanol as a blank using a UV spectrophotometer (SPECTROstarnano BMG 
LABTECH, Germany). The positive control used in the study was Ascorbic acid. A triplicate run 
of all tests was performed.  The free radical scavenging activity was expressed as percentage in 
accordance with the equation as follows:  
% scavenging activity (DPPH) = Ac-As/Ac × 100. 
Where As = absorbance of sample and Ac = absorbance of control  
 
2.2.2  Hydrogen Peroxide Scavenging Activity 
The potential of the T. acutiloba extracts in the scavenging of hydrogen peroxide was evaluated 
using a method according to Ruch et al., (1989) with some modifications20. Hydrogen peroxide 
solution of 40 mM was made in a phosphate buffer of pH 7.4. Briefly, 0.2 ml of the various 
concentrations of the extracts (1000, 500, 250, 125, 62.5, 31.3 and 15.6 μg/ml) were added to a 
hydrogen peroxide solution (0.6 ml, 40mM) for 10 minutes.  The absorbance of hydrogen 
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peroxide was determined at a wavelength of 560 nm after 10 minutes. A solution of phosphate 
buffer without hydrogen peroxide was used as a blank before each reading. The positive control 
used in the study was Ascorbic acid. The hydrogen peroxide scavenging activity of the extracts 
was expressed as percentage as follows: 
% scavenging activity (H2O2) = Ac-As/Ac × 100. 
Where As = absorbance of sample and Ac = absorbance of control 
 
2.2.3  Nitric Oxide Scavenging Activity 
The scavenging activity of T. acutiloba against Nitric oxide was measured in accordance with 
the method developed by Govindarajan et al., (2003) with some revisions21.  A mixture of 0.5ml 
of a 10 mM sodium nitroprusside solution in a phosphate buffered saline was added to 1ml of 
different concentrations of the extracts (1000, 500, 250, 125, 62.5, 31.3,15.6 μg/ml) and 
incubated at 25°C for 180 min. Control samples without the extracts but with an equal volume of 
buffer were prepared in a similar manner to test samples. After 180 min, the incubated mixture 
(1.5ml) was taken out. A solution of 1.5 ml Griess reagent made up of 1% sulphanilamide, 0.1% 
N-1-naphthylethylenediamine dihydrochloride and 2% phosphoric acid was used to dilute the 
incubated solution. The absorbance of the resulting chromophore formed after the addition of the 
Griess reagent to the incubated solution was measured at 546 nm. The positive control used in 
the study was Ascorbic acid.  The radical scavenging activity of the extracts was expressed as a 
percentage using the formula as follows:  
% scavenging activity (NO2) = Ac-As/Ac × 100. 
Where As = absorbance of sample and Ac = absorbance of control  
2.3  Determination of In-vitro Angiotensin-1 Converting Enzyme (ACE) Inhibition Activity  
Stock Substrate Solution:  A 100ml stock substrate solution of  25mM hippuryl –L-Histidyl-L-
leucine (Hip-His-Leu) was freshly made by the dissolution of 1.12g of Hip-His-Leu (sigma 
Aldrich, schnelldorf, Germany) in 25mM sodium hydroxide (NaOH). 
Sodium Borate Buffer:  Sodium borate buffer was freshly made up by the dissolution of 30.5g of 
boric acid (H3BO4) and 65.7g of sodium chloride (NaCl) in distilled water. The final volume 
prepared was 1L and this preparation gave a 1.25 –fold concentration (0.5M). The pH of the 
solution was adjusted to 8.3 using 13N NaOH. 
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ortho-phthaldialdehyde (o- phthaldialdehyde):  ortho-phthaldialdehyde (OPA) (sigma Aldrich) 
solution was prepared by dissolving 200mg of OPA in 10ml of methanol. 
 Assay Buffer: An assay buffer used in the study was made by mixing one volume of stock 
substrate solution to four volumes of 0.5M sodium borate buffer 
The activity of ACE was determined on the principle that the tripeptide hydrolysis is blocked at 
the amino terminal. The tripeptide (Hip-His-Leu) has a sequential terminus of Angiotensin I 
(Ang I) and its subsequent chemical breakdown due to the reaction with water, could be 
identified by the resultant hippuric acid formation. The ACE inhibition activity of each plant 
extract was performed in accordance with the method developed by Santos et al (1985) with 
amendments22. Briefly, 10μl of ACE from rabbit lung (Sigma Aldrich) was incubated in 480μl of 
assay buffer and 10μl of different concentrations of plant extracts (1000μg/ml, 500μg/ml, 
250μg/ml and 125μg/ml) in a test tube for 15 mins at 37ºC. The reaction was terminated by 
adjusting the pH with 1.2ml of 3.4N NaOH. Ortho-phthaldialdehyde (100μl) was then added to 
the reaction mixture and left for 10mins. In order to acidify the solution thereafter, 200μl of 3N 
hydrochloric acid was mixed to the solution. The measurement of the resulting chemical 
Histidine-Leucine (His- Leu) was made fluorometrically at 365nm excitation and 495nm 
emission wavelengths using a fluorescence spectrophotometer (F-2500/F-4500 FLsolutions).  A 
blank solution prepared by the addition of the ACE from rabbit lung after 3.4N NaOH without 
the test compounds was used. Ramipril, a conventional ACE inhibitor drug was used as control. 
Percentage Inhibition was expressed as % Inhibition: = Ab-As/Ab x 100;  
Where As = absorbance of sample and Ab = absorbance of blank 
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2.4  Phytochemical anlaysis  
2.4.1 Alkaloids 
The presence of alkaloids was determined by mixing 0.5g of the crude extract in 5 ml of 1% 
hydrochloric acid solution. The solution was stirred and thereafter, positioned in a water bath for 
10 minutes. The solution was then filtered and three drops of the Mayer’s reagent (1.36g of 
mercuric chloride; 5.0g potassium iodide in 100ml of water) were added to the filtrate. A 
yellowish brown colour indicated the presence of alkaloids23. 
 
2.4.2 Tannins 
The ferric chloride test24 was performed to determine the presence of tannins. Ten milliliter 
(10ml) of water was used to dissolve the plant extracts (0.25 g) and thereafter, three drops of 1% 
ferric chloride solution was added in a test tube. The reaction was observed for colour changes. 
A greenish black or a black color formation showed that tannins were present. 
 
2.4.3 Terpenoids 
The Salkowski test25 was performed to determine the presence of terpenoids. Five milliliter (5ml) 
of the extract was mixed with 2 ml of chloroform in a test tube. Thereafter, 3ml of concentrated 
sulphuric acid was carefully added. The development of a colour change was observed. The 
formation of a reddish brown colour confirmed the presence of terpenoids.  
 
2.4.4 Steroids 
Test for steroids was determined by dissolving 1mg of each plant extract in 10 ml of chloroform 
in a test tube. Afterwards, 10ml of concentrated sulphuric acid was added and the colour change 
was noted. Red ring formation indicated the presence of steroids26. 
 
2.4.5 Flavonoids 
The extracts (1g) were dissolved in 5ml of distilled water in a test tube. Three drops of a diluted 
lead acetate solution were added and the development of colour was noted and recorded. The 
formation of a yellow coloration confirmed the presence of flavonoids27. 
2.4.6 Saponins                                                                                                                                                     
Determination of saponins was evaluated using the foam test28. Each extract (0.5 g) was 
dissolved in 2 ml of distilled water and shaken for 15 minutes. The formation of a foam layer 
point to the presence of saponins.  
67 
 
2.4.7 Phenols                                                                                                                                                   
The ferric chloride test was used to determine the presence of phenolic compounds24. One (1) 
gram of each extract was placed to dissolve in 2 ml of distilled water. Thereafter, three drops of a 
10% ferric chloride solution was added. A black colour formation specified the presence of 
phenols. 
2.4.8 Glycosides                                                                                                                                               
The Borntrager test was used to determine the presence of glycosides29. Fifty (50) mg of each 
extract was put in a 5 ml of hydrochloric acid to dissolve. The solution was immersed in a warm 
water bath for 2 hours. After 2 hours the samples were filtered, 3 ml of chloroform was added to 
the filtrate and shaken. The chloroform layer was then separated and 5 drops of 10% ammonia 
solution was added to this layer to observe the resulting colour change. A pinkish red colour 
indicated the presence of glycosides. 
2.4.9 Cardiac Glycosides                                                                                                                                  
The legal’s test was used to determine the presence of cardiac glycosides30. One (1) ml of each 
extract was placed in 1 ml of water to dissolve. Thereafter, three drops of 10% sodium 
hydroxide, 1 ml of 0.3% nitroprusside sodium and 1 ml of pyridine reagent. A blood red colour 
disclosed the presence of cardiac glycosides. 
 
2.4.10 Amino Acid  
The ninhydrin test for the determination of amino acid was used in this study31. Briefly, 1g of 
each extract was added to 0.25% w/v of the ninhydrin reagent and boiled for 5 minutes. The 
development of a dark blue coloration indicated the presence of amino acid. 
2.4.11 Reducing Sugar                                                                                                                                                          
Reducing sugars were determined using the Benedict’s test32.  Three to four drops of Benedicts 
reagent was added to 0.5g of each extract and heated gently for 5 minutes to observe for any 
possible colour change. The formation of an orange red precipitate verified the presence of 
reducing sugars. 
 
 
68 
 
2.4.12 Total Phenolic Content 
The method developed and standardized by Singleton and Rossi (1965)33 with minor 
modifications was used in the determination of the total phenolic content of each extract of the 
plant. The Folin and Ciocalteu reagent was used in the study. Each plant extract (0.2 ml) was 
dissolved in a 0.6 ml of distilled water and 0.2 ml of Folin-Ciocalteu's phenol reagent. The 
reaction was timed for 5minutes and thereafter, 1 ml of sodium carbonate solution saturated 
(8% w/v in water) was placed into the mixture and the resulting  mixture volume was topped up 
to 3 ml with distilled water and kept in the dark for 40 min for the development of a colour. After 
incubation the absorbance of the resulting colour was determined at 750 nm wavelength. The 
phenolic content was expressed as Gallic acid equivalents (GAE/g) of dry plant material with 
reference to a Gallic acid standard curve with concentrations 25 - 200μg/l. All experimental 
procedures were conducted in triplicates. Readings for the various extracts and standards were 
carried out using a spectrophotometer (Cary 50 Bio UV-Vis Spectrophotometer, Varian) at 
725 nm with a reagent blank. 
2.5  Gas Chromatography-Mass Spectrometry (GC-MS) Analysis of Plant Extracts 
The gas chromatography-mass spectrometry analysis of each part of T. acutiloba extract was 
performed using the Perkin-Elmer Gas Chromatography (Clarus 580) which has an MSD 
spectrometer (Clarus SQ8S) instrument with in-built auto sampler.  Samples were analyzed on 
Elite 5MS columns (30m × 0.25mm id × 0.25μm).  The temperature of the oven was 
programmed from 37ºC to 320ºC at an 18-25ºC/min rate and held for 0.5; 1.85min and 18 at 
320ºC, respectively. The temperature of the injector was 250ºC with an MS Ion source 
temperature of 280ºC with a full scan and a solvent delay of 0 – 2.3min. The scan range of the 
MS scan was m/z 35-500 in 0.10s. Each sample (1μl) was introduced into a helium carrier gas 
with a split flow of 20ml/min. 
2.6  Heavy Metal Toxicity Testing 
Heavy metal toxicity analysis was performed using the inductively-coupled plasma optical 
emission spectrometry (ICP-OES). The test is based on the principle that when energy from a 
plasma source is transferred to a sample, there is an excitation of the component elements 
(atoms) and they move to a higher energy state. Once these stimulated atoms come back to a low 
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energy state, there are rays of emission that are released. There is therefore the measurement of 
the released emitted rays that characterises the wavelength of the photons. The constituent 
elements are identified by their characteristics emission lines and quantified by the intensity of 
the same lines34.The following heavy metals were analysed; Arsenic (As), Cadmium (Cd), 
Chromium (Cr), Mercury (Hg), Lead (Pb), and Nickel (Ni). Each extract (0.5g) was weighed out. 
The digestion was carried out on a hot plate (60-70 ° C) using 10 ml of Aqua Regia. The mixture 
was then filtered into a 10ml volumetric flask. The solution was made up to the mark with 
double distilled water. The solution was then filtered into ICP vials with a 0.45 micro-filter and 
analysis was performed using ICP-OES. Analysis was performed in triplicate. 
 
2.7  Data Analysis  
All experimental observations were performed in triplicate and were expressed as an average of 
three analyses ± standard error of the mean (SEM). One sample t-test was used in the statistical 
analyses for comparing two observations and one way ANOVA for multiple comparisons. The p-
value<0.05 were regarded as significant. 
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3. RESULTS  
3.1  Plant Extraction and Physicochemical properties 
The percentage yield and the physicochemical properties of the parts of T. acutiloba are shown 
in Table 1. The plant is well known for its sweet-scented nature that is inherent in the flowers 
and leaves.  
Table 1.  Physicochemical properties and Percentage yield of extracts of Tulbaghia acutiloba 
Plant Part  Percentage yield (%) Physical appearance  odour 
Roots  2.62  
   
 
 
Pale brown 
Garlic-like odour 
(alliaceous odour) 
Rhizomes 8.00 
Brown 
Garlic-like odour 
(alliaceous odour) 
Flowers 3.62 
 
Green with fleshy orange to 
reddish brown ring 
Sweet scented 
Leaves 12.8 
Dark green 
Sweet scented 
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3.2  Antioxidant Activities 
3.2.1  2, 2-diphenyl-1-picryl hydrazyl (DPPH) radical scavenging activity 
It is observed from the results that there is a concentration dependent activity for the DPPH 
radical scavenging activity for the various parts (roots, rhizomes, leaves, flowers) of T. 
acultiloba. Interestingly, the rhizomes showed a relatively higher antioxidant activity at the 
various concentrations than all the other parts of the plants with an IC50 value of 201.99μg/l and 
a peak scavenging activity of 95.18± 0.20.  However, there was no significant difference in the 
activities of the various parts of the plants as compared to the positive control, ascorbic acid 
(p>0.05) as shown in figure 1.  
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3.2.2  Hydrogen peroxide scavenging activity 
Figure 2 shows the hydrogen peroxide scavenging activities of each part of the plant and the 
positive control. The result indicated a dose dependent inhibition of hydrogen peroxide with the 
rhizomes once again showing a relatively higher scavenging activity than the other parts of the 
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plants with a peak value of 72.42±0.35 occurring at the concentration of 1000μg/l and an IC50 
value of 518.16μg/l. Interestingly, there was no scavenging activity at 15.6μg/l for all the parts 
Moreover, all the parts of the plants showed a significantly lower scavenging activities (Leaves 
(p<0.001), flowers (p<0.001), roots (p<0.01), rhizomes (p<0.05) when compared with the 
scavenging activities of  Ascorbic acid.  
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*significantly different (p<0.05) from the value of standard compound;  ** significantly different(p<0.01) from the  
value of  standard compound;   ***  significantly different  (p<0.001) from the value of  standard compound 
 
 
3.2.3  Nitric oxide scavenging activity of T. acutiloba 
 
The outcome of the free radical scavenging potential of each extract tested is presented in figure 3. There 
was a generally good scavenging activity for all the extracts though the results did not show a strong 
dose-dependent activity. Interestingly, the lowest concentration of 15.6μg/l, produced an effective 
antioxidant activity. The leaves, rhizomes, and roots did not show any significant difference (p>0.05) 
from the activity of Ascorbic acid with the exception of the flowers that showed a significantly lower 
activity (p<0.01). 
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*significantly different (p<0.05) from the value of standard compound 
 
 
3.3  In vitro Angiotensin-1 Converting Enzyme (ACE) Inhibitor activity 
Figure 4 shows the percentage ACE inhibition of the hydro-methanolic extract of the various 
parts of the plants. All extracts showed a percentage inhibition of >50% within a concentration 
range of 125 - 1000μg/ml. The conventional ACEI drug used as a positive control in the study, 
showed a mean percentage inhibition of 80.67% with an IC50 value of 112.91μg/ml. There were 
no significant difference from the activity of the leaves (76.6% ± 1.65; IC50:154.23) as 
compared to the value of the conventional drug, Ramipril.  Moreover, the roots and flowers 
showed a significantly lower activity when compared to both the conventional drug and the 
leaves. Conversely, the rhizomes showed a significantly lower activity as compared to Ramipril 
but no significant difference when compared to the activity of the leaves. This observation from 
the study indicates a comparable activity of the leaves to the activity of the conventional drug, 
Ramipril. 
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*Significantly different (P<0.05) from the value of Ramipril; ** Significantly different (p <0.05) 
from the value of both Ramipril and Leaves.  
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3.4  Phytochemical analysis and total phenolic content of T. acutiloba 
 
The phytochemical analysis of the extracts of the plants is shown in table 2. Our findings 
indicate the presence of tannins, phenols, alkaloids and amino acids in all parts of the extract of 
the plant used in the study. Moreover, saponins were found only in the roots of the plants. The 
rhizomes and leaves showed the presence of terpenoids. However, there was an absence of 
glycosides, cardiac glycosides, flavonoids and reducing sugars in all parts of the plant. The 
presence of steroids was identified in the rhizomes only. 
 
Table 2: Phytochemical analysis of T. acutiloba 
 
Phytochemical  Rhizomes Roots Flowers Leaves 
Tannins + + + + 
Saponins - + - - 
Terpenoids + - - + 
Phenols + + + + 
Glycosides - - - - 
Cardiac 
Glycosides - - - - 
Steroids + - - - 
Alkaloids + + + + 
Flavonoids - - - - 
Amino Acids + + +           + 
Reducing 
sugars - - - - 
‘+’ indicates the presence of the compound; ‘-’ Indicates the absence of the compound  
 
3.5  Total Phenolic Content of T. acutiloba 
The total phenolic content was expressed as mgGAE/g extract as y =0.0072x + 0.0819 (R2 = 
0.9981). The total phenolic content of the various extract is represented in table 3. The leaves 
showed a relatively higher phenolic content of 43.26 ± 1.15 mg/g as shown in table 3. 
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Table 3: Total phenolic content of parts of T. acutiloba 
 
Sample  Total Phenolic content (mg/g) 
Rhizomes 28.04 ± 0.36 
Roots 31.54 ± 8.28 
 
Flowers 20.80 ± 1.22 
 
Leaves 43.26  ± 1.15 
 
 
 
3.6  GC/MS analysis of hydro-methanolic extracts of T. acutiloba 
Gas chromatography–mass spectrometry (GC-MS) was performed to determine the individual 
constituents in each extract. The various chemical components were detected by corresponding 
their retention time and mass spectra with that of an inherent citations library. The outcome of 
the analysis is shown in Table 4. A total of 14 compounds were isolated in the extracts. Major 
compounds identified included acetic acid, α-linolenic acid, palmitic acid, oleic acid, 9,12- 
octadecadienoic acid and decanoic acid among others. 
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Table 4: Compounds Identified in the Gas Chromatographic analysis of T.acutiloba  
 
Sample / 
 compound name 
Chemical 
formula  
Retention 
time (mins) 
Relative 
abundance                
height (%) 
4a. Leaves    
Acetic Acid CH3COOH 9.89 10.07 
α-linolenic acid  C18H30O2 21.87 4.24 
Palmitic acid C16H32O2 22.61 5.92 
Oleic Acid C18H34O2 24.22 54.56 
    
4b. Roots    
Acetic Acid CH3COOH 9.73 5.75 
Decanoic acid C10H20O2 20.16 3.12 
1-Tetradecyne  C14H26 21.80 3.22 
9,12-octadecadienoic acid C18H32O2 21.81 3.22 
Hexanamide C6H13NO 22.61 8.37 
Oleic Acid C18H34O2 24.22 61.54 
    
4c. Rhizomes    
1-methylcyclopropanemethanol C5H10O 10.14 3.10 
Dodecanamide C14H29NO2 22.60 7.86 
Lauramide C12H25NO 22.61 8.78 
9-octadecanamide C18H37NO 24.21 69.44 
Oleamide C18H35NO 24.22 71.50 
    
4d Flowers    
Acetic acid CH3COOH 9.76 8.32 
myristimide C14H29NO 22.60 8.15 
Palmitic acid C16H32O2 22.61 6.41 
Oleic acid C18H34O2 24.21 65.79 
 
 
3.7  Heavy metal toxicity analysis  
Table 5 shows the analysis of heavy metals that are of great concern to public health. From the 
results, it is evident that there were no toxic heavy metals detected in T. acutiloba. Moreover, the 
levels of barium, chromium and nickel were not significant.  
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Table 5: Toxic heavy metal analysis of T. acutiloba  
 
Metal  Root Leaves Rhizomes Flowers Minimum 
toxicity levels 
Arsenic Not Detected Not Detected Not Detected Not detected 5-10ng/ml 
Barium 0.25ng/ml* 0.29ng/ml* 0.131ng/ml* 0.20ng/ml* 8-14ng/ml 
Cadmium Not Detected Not Detected Not Detected Not detected   3-5 ng/ml 
Chromium 0.12ng/ml* Not Detected Not Detected Not detected 3.26- 7ng/ml 
Lead Not Detected Not Detected Not Detected Not detected 10-15 ng/ml 
Mercury Not Detected Not Detected Not Detected Not detected 20-32 ng/ml 
Nickel 2.06ng/ml* 0.22ng/ml* 0.424ng/ml* 0.15ng/ml* 4-8.6ng/ml 
*values are far below the minimum toxicity levels   
 
3.8  Correlation between the Antioxidant activites, Total phenolic content and ACE 
inhibition activities of T. acutiloba. 
Table 6 indicates the correlation between the antioxidant activities, Total phenolic content and 
ACE inhibition activities of T. acutiloba using the Pearson correlation coefficient analysis. From 
the results obtained, there was generally a weak positive correlation between the antioxidant 
activities and ACE inhibition activities. However, a moderate positive correlation was observed 
between the Total Phenolic content and ACE inhibition activities (r=0.464). 
Table 6. Pearson correlation coefficient between Antioxidant activities, Total Phenolic 
content and ACE Inhibition activities of Tulbaghia acutiloba 
 
 ACE Inhibition Activity Total Phenolic Content 
DPPH scavenging activity 0.092 0.168 
Nitric Oxide scavenging 
activity 
0.035 0.033 
Hydrogen peroxide 
scavenging activity 
0.077 0.226 
ACE Inhibition activity  0.464 
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4. Discussion 
The prevention and treatment of hypertension involves several mechanisms in the body that 
contributes significantly to the regulation of blood pressure35. These mechanisms include the 
reduction of oxidative stress in the body, inhibition of Angiotension-I converting enzyme (ACE), 
the presence of bioactive compounds as well as the regulation of nitric oxide in the human 
body36.  
Since most diseases are related to increased free radicals or reactive oxygen species, the potential 
scavenging activity will reduce excess free radicals which may otherwise lead to disease37. Our 
current findings indicate an active scavenging activity of the various parts of T. acutiloba, as 
seen in the DPPH assay. Our findings in the scavenging activities of the DPPH is in 
corroboration with other studies done on similar plant species of the same family of Tulbaghia 
where effective scavenging activity was observed38,39. 
Additionally, though our findings indicate a significantly lower scavenging activity as compared 
to Ascorbic acid, there was generally a good scavenging activity of hydrogen peroxide especially 
at the highest concentration of 1000μg/L of each part of the plant. This finding is in line with 
other studies performed on similar species of plants within the family of Tulbaghia38,40.   
Hydrogen peroxide is known to be a weak oxidizing agent that incapacitates some enzymes in 
the body directly, usually through the oxidation of essential thiol (-SH) groups. It is permeable to 
cells and can cross cell membranes rapidly and once inside the cell, it could form a bond with 
Fe²+ and possibly Cu²+ ions to form hydroxyl radicals and this could account for the basis of 
many of its toxic effects41,42. Therefore, the reducing capacity of an extract or compound may 
serve as a significant indicator of its potential antioxidant activity12.  
With respect to Nitric Oxide scavenging activities, it was generally observed that there were no 
significant differences between the activities of the parts of the plants and Ascorbic acid with the 
exception of the flowers. This findings seems to be in agreement with other studies conducted on 
Tulbaghia violacea which was observed to have a good scavenging activity against Nitric 
oxide43,44. There is a substantial evidence that Nitric oxide (NO) is a potent pleiotropic mediator 
of physiological processes such as neuronal signaling, smooth muscle relaxation, regulation of 
cell mediated toxicity and inhibition of platelet aggregation45. It is known to have a biphasic 
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action at the cellular level; optimal concentrations of NO are known to safeguard the tissues 
against oxidative killing whereas higher doses promotes cell death, and these dual effects occur 
through distinct mechanisms46-48. At higher doses, it is a permeable free radical which has been 
proven to have a crucial role in the pathogenesis of inflammation and pain. Nitric oxide 
inhibitors that could reduce excessively high dose of nitric oxide to optimal levels, have been 
shown to have anti inflammatory effects on inflammatory tissues and tissue changes seen in 
models of inflammatory bowel disease49,50. This may be one of several reasons for its usage by 
traditional healers in the hypertensive and wound healing process; as anti-inflammatory agents 
are very crucial in wound healing and the management of high blood pressure. 
The phytochemical analysis showed the presence of phenols in all parts of the plant. Phenolic 
compounds are well known for their antimicrobial and antioxidant protection against cancer and 
heart diseases. Phenolic compounds are known to exert their antioxidants effect by chelating ions 
and scavenging free radicals particularly, superoxide (O2
●-), peroxyl and hydroxyl radicals 
(OH●). This process inhibits both DNA damage and lipid peroxidation, which can cause 
membrane damage hence maintaining cellular integrity and body function53. The high 
concentrations of phenolic compounds may account for the medicinal value of T. acutiloba in the 
management and treatment of oxidative stress induced disorders.  Moreover, tannins are water 
soluble polyphenols that bind and precipitate proteins and other organic compounds51,52. There 
are controversial views of the role of tannins in the human body. In the past years, tannins were 
known to be anti-nutritional because it was suggested that they bind to proteins and amino acids, 
hence reducing their absorption in the body53,54. However recent studies have supported their 
potential benefit in inhibiting the ACE and hence reducing blood pressure in the vessels55-57. 
Studies have also suggested that low doses of tannins in the human body may be very 
beneficial58.  
T. acutlioba also has alkaloids. The presence of alkaloids in plants is known for their numerous 
health benefits and therapeutic functions. Various studies has confirmed the effective role of 
alkaloids as antiinfectious, antipyretic, aphrodisiac, vasodilator, antihypertensive and 
anticarcinogenic59,60. The vasodilatory mechanism of alkaloids is not well established, however, 
it is known to lower intracellular calcium concentration which contributes to smooth muscle cell 
relaxation leading to vasodilation and a subsequent decrease in blood pressure60-61. Other studies 
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conducted on similar species of the plants indicates an active role of such plants in the 
management of hypertension and infectious diseases61,62. 
Heavy Metal analysis of T. acutiloba also revealed that all metals analysed were either 
undetected or were within the safe limit, therefore, we can deduce that different parts of the plant 
are safe for human consumption provided it is sampled from a non-contaminated geographical 
location. Heavy metals are naturally occurring elements with a high atomic weight and density63 
and are considered toxic based on their dose and route of exposure in the human body8. 
Persistent exposure to heavy metals could lead to heart attacks, lung damage, chronic kidney 
diseases and tremors8, 45. Due to the irreversible effects that heavy metals could pose on the  
health of human beings, this study confirms the validity of the safe usage of T. acutiloba45. 
 
In this study we also found that all parts of the plants at different concentrations produced more 
than 50% ACE inhibition. Additionally, the activities of the leaves were comparable to the 
conventional ACEI.  Similar studies conducted on the parts of plants in the same family of 
Tulbaghia and related species, also exhibited more than 50% inhibition of ACE64-66. Importantly, 
unlike other studies conducted on other species of Tulbaghia and related families, T. acutiloba 
showed very promising ACE inhibition that is comparable to the conventional ACEI, Ramipril. 
The significance of this is multifold; including the possible modification of these plants derived 
novel compounds to avoid the debilitating side effects of conventional ACEIs. 
Furthermore, it was observed that the correlation between the antioxidants and ACE inhibitory 
effect was positively associated, although a weak correlation was recorded. However, since a 
moderately strong positive correlation was observed between the total phenolic content of the 
plant and ACE inhibitory effect, it suggests that the ability of the plant to inhibit ACE could be 
due to the synergistic effect of the antioxidant potential, total phenolic content and the presence 
of other bioactive compounds indentified in the GCMS analysis. Key among these bioactive 
compounds is the presence of α-linolenic acid (ALA), which was found mainly in the leave 
extract and absent in the other parts of the plant extracts. Palmitic acid and oleic acid were also 
identified as bioactive compounds which have supporting literature confirming their therapeutic 
effect especially in regards to cardiovascular diseases67,68.  Interestingly, the higher concentration 
of total phenolic content, antioxidant potential and the presence of ALA and other bioactive 
compounds in the leaves may account for the comparable ACE inhibition activity of the leaves to 
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the conventional drug, Ramipril. This is worth noting since none of the parts of the plants 
exhibited a comparable activity to Ramipril. Several studies conducted on ALA (also known as 
omega-3-fatty acids) has proven to be an effective therapeutic agent especially in relation to 
cardiovascular diseases such as hypertension 69-71. Studies conducted on other species of plants 
of Tulbaghia and similar plants revealed compounds such as palmitic acids, oleic acids, 
octadecanoic acids among others which were also identified in our studies72-74.   
Though there are several studies to suggest that isolated compounds may produce therapeutic 
effects, current studies has also confirmed that bioactive compounds in certain plants may 
produce superior therapeutic effects when they act synergistically with other bioactive 
compounds75-78.  
5. Conclusion 
The current study has so far shown that T. acutiloba contains bioactive compounds that are 
essential for therapeutic effects. It further shows that T. acutiloba may have an antihypertensive 
effect since it showed a comparable ACE inhibition activity to Ramipril. This finding therefore, 
support the ethnopharmacological use of T. acutiloba Harv.(Alliaceae) in the management and 
regulation of essential hypertension particularly in areas of the world where access to 
conventional ACEI drugs are limited for several reasons. T. acutiloba is a nutraceutical that can 
easily be harvested and obtained for its therapeutic effects. However, further studies are needed 
to explicate its effect on body organs, biochemical profile and relevant gene expressions in vivo 
in order to ascertain its comprehensive effect on hypertension. 
6. Study Limitations 
The study evaluated the in vitro activities of Tulbaghia acutiloba and therefore its effect in vitro  
may not be an indication of its activities in vivo. Therefore further studies are needed to assess its 
effect in an in vivo experimental model of hypertension. 
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Chapter 4: Manuscript Three 
 
Cardioprotective effects of Tulbaghia acutiloba hydro-methanolic leaf extract and Ramipril 
in an L-NAME induced hypertensive rat model  
 
The phytochemical content, antihypertensive potential, antioxidant effect and heavy metal toxicological 
safety exhibited by Tulbaghia acutiloba in the in vitro study identified in chapter 3, raises an important 
concern for its effect in a long term in vivo administration of the plant on antioxidant activities, systolic 
and diastolic blood pressure as well as its effect on cadioprotection. The leave extract showed a better 
therapeutic potential as evident in the ACE inhibition effect which was higher than all the other parts of 
the plants and comparable to Ramipril. In addition, the leaves showed the presence of essential bioactive 
compounds such as α-linolenic acid as well as high phenolic content and  antioxidant activity as observed 
in the study conducted in chapter 3 and hence the need to investigate further in an in vivo model of 
hypertension. Since hypertension is closely associated with oxidative stress, cardiovascular diseases, 
cardiovascular end-organ damages and NO bioavailability, there was the need to evaluate the 
antihypertensive and cardioprotective effect of Tulbaghia acutiloba hydro-methanolic leaf extract in an L-
NAME induced hypertensive rats. Thus chapter 4 presents a detailed in vivo study and analysis of 
Tulbaghia acutiloba hydro-methanolic leaf extract on hypertension and its associated cardiovascular 
function and protection.  
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ABSTRACT 
The indigenous herb, Tulbaghia acutiloba, has been used traditionally in the management of 
hypertension, but to date there is no scientific validation of its cardiovascular effects. We evaluated the 
effect of T. acutiloba (TA) on Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME)-induced 
hypertension and its effect on cardioprotection. Experimental hypertension was induced by orally 
administering L-NAME (50mg/kg b.w.) in rats for 5 weeks. Rats were treated with varying doses of 
hydro-methanolic leaf extracts of TA (40, 60 and 80mg/kg b.w.) and Ramipril (10mg/kg b.w.) in separate 
groups for 5 weeks. Systolic (SBP) and diastolic blood pressure (DBP) were measured weekly using the 
tail-cuff method. The rats were sacrificed on Day 36 by halothane overdose. Blood and heart tissues were 
collected for biochemical and molecular assays, as well as histological examinations. Treatment of TA in 
the hypertensive rats significantly reduced SBP and DBP. Rats with hypertension showed cardiac 
hypertrophy and this condition was attenuated with the administration of TA and Ramipril. TA and 
Ramipril administration further reduced cardiac troponin I (cTnI) levels, creatine phosphokinase (CK),  
CK-MB(creatine phosphokinase- muscle/brain), and angiotensin-converting enzyme (ACE) activity in the 
L-NAME induced rats. Concentrations of hepatic enzymes including alanine transaminase (ALT), 
aspartate transaminase (AST) and alkaline phosphatase (ALP) were also reduced significantly with the 
treatment of TA and Ramipril. There was a significant increase in plasma and tissue nitric oxide (NO) 
concentrations as well as increased superoxide dismutase(SOD), catalase(CAT) and glutathione (GSH) 
concentrations with the treatment of TA. Lipid peroxidation, measured in TBARS, was significantly 
reduced in the TA treated groups. TA significantly decreased cardiac tissue mRNA expressions of ACE, 
AT1 and AT2 while increasing tissue expressions of B1 and B2 significantly. Additionally, 
histopathological examination confirmed the biochemical findings of the protective effect of TA on 
cardiac tissues. In all investigations, the TA dose of 80mg/kg showed a maximum effect as compared to 
the other dosages. These results suggest that TA dose of 80mg/kg, may have beneficial role in the 
treatment of hypertension and act as a protective agent against a long term cardiovascular abnormalities 
associated with hypertension.  
 
Key words:  Tulbaghia acutiloba, Cardioprotection, Hypertension, L-NAME, Antioxidant enzymes. 
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Introduction 
Cardiovascular disease and its associated complications remain a leading cause of morbidity and 
mortality in both developed and developing countries (1). Hypertension is a leading risk factor for 
cardiovascular disease, accounting for 7.6 million deaths globally. Recent studies indicate that 54% of 
stroke and 47% of coronary heart disease are attributed to hypertension (1, 2). 
 
The renin–angiotensin aldosterone system (RAAS) plays a key physiological role in the maintenance and 
regulation of blood pressure and body fluid homeostasis (3). The octapeptide angiotensin II (Ang II) is the 
main effector in RAAS. Classically, by binding to type I angiotensin II receptor (AT1), Ang II activates a 
cascade of actions and reactions that results in vasoconstriction and increased sodium (Na) reabsorption 
leading to high blood pressure. Ang II is produced when angiotensin-converting enzyme (ACE), a zinc 
containing metalloprotease hydrolyses peptides by removing a dipeptide from the C-terminus from 
inactive decapeptide angiotensin I (4). RAAS, therefore, provides crucial targets for the treatment of 
hypertension and its related end-organ diseases. Angiotensin-converting enzyme is well recognized 
therapeutic target, whose levels are known to increase in myocardial infarction and atherosclerosis (3). 
Reports indicate that chronic administration of nitric oxide synthase inhibitor, Nω-nitro-L-arginine methyl 
ester hydrochloride (L-NAME) activates the RAAS (5-7). Furthermore, blockade of  the RAAS with a 
potent ACEI  has been shown to avert increased blood pressure in L-NAME-treated animals (8). 
The L-NAME model is widely used to show the therapeutic efficacy of putative antihypertensive agents. 
This model is based on the chronic inhibition of nitric oxide synthase (NOS) by, an L-Arginine analogue, 
L-NAME leading to a cascade of reactions that elevates blood pressure and its pathophysiological process 
has been closely linked to essential hypertension (9). Nitric oxide (NO) is a well-known biological 
mediator involved in several physiologic and pathological processes, notably in the regulation of vascular 
function, blood pressure and body fluid homeostasis (10). In view of this, the reduction in the 
biosynthesis of NO basal levels due to its chronic inhibition with an orally active nitric oxide synthase 
(NOS) inhibitor, L-NAME, makes it a suitable hypertensive model for experimental studies (11).  ACE 
inhibitors, such as Ramipril and Captopril, have been extensively used in the treatment and management 
of hypertension.  In addition to ACE inhibition, Ramipril and Captopril are also known to decrease blood 
pressure by preventing the breakdown of bradykinin, a potent endothelium-dependent vasodilator (12). 
Importantly, several studies have suggested that an increase in bradykinin levels with ACE inhibitors, is 
accompanied by a potential augmentation of NO levels leading to a vasodilatory effect (13)., 
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Although Ramipril and Captopril are conventional ACE inhibitors in the treatment of hypertension,  there 
are still setbacks, such as high cost and side effects including persistent dry cough, nephropathies and 
targeted organ dysfunctions (14). Hence there has been a focus on ‘herbal alternatives’ with minimal 
perceived side effects (15) such as Tulbaghia acutiloba. 
 
Tulbaghia acutiloba, belonging to the family, Amaryllidaceae,  is traditionally used as a culinary herb,   
infusion for chest and gastric ailments, bacteria and fungi infections as well as management of 
hypertension (16). Despite its classification in the well-studied Alliaceae family (17, 18) this plant’s 
biological and therapeutic activities have not been investigated. Previous studies in our laboratory showed 
a very potent in vitro antioxidant activity of the plant.  We showed that all parts of the plants (leaves, 
flowers, rhizomes, roots) showed a >50% in vitro ACE inhibition activity, with the leaves showing a 
significantly higher inhibitory activity, comparable to Ramipril (19). Therefore, this study was undertaken 
to examine the in vivo antihypertensive and cardioprotective effect of T. acutiloba (TA) hydro-methanolic 
leaf extracts in an L-NAME hypertensive model.  
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MATERIALS AND METHODS 
Plant material and preparation 
The leaves of T. acutiloba were freshly harvested and collected after being authenticated by a botanist, 
Prof. Himansu Baijnath, at the School of Life Sciences, University of KwaZulu-Natal (UKZN), Durban, 
South Africa. They were thoroughly washed under running water and dried at room temperature for 72 
hours. Subsequently, the leaves were crushed in a Waring blender. The powder (300g) obtained after 
crushing was immersed in 3L hydro-methanolic solution (80% methanol and 20% water). The mixture 
was agitated at 80rpm for 48 hours and thereafter filtered. The filtrate was concentrated in a rotary 
evaporator and freeze-dried at -40ºC to yield an extract for experimental use. The hydro-methanolic 
extract of the leaves showed a yield of 12.8%.  
Animal Study 
Animals 
Forty-two, healthy, male albino Wistar rats (155-210g) were acquired from the Biomedical Resource Unit 
(BRU) of the University of KwaZulu-Natal (UKZN), South Africa. The animals were housed in a 
propylene cage at a temperature range of 19-23ºC with a 12h light/12h dark cycle. Water and standard rat 
chow were provided ad libitum to all animals. Ethical approval was obtained from the UKZN Animal 
Ethics Committee (Reference number: AREC/062/016PD).  
Chemicals 
Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) and Ramipril were procured from Sigma-
Aldrich (St. Louis, Missouri, USA).  
L-NAME –induced arterial hypertensive model and Experimental protocol. 
The experimental rats were given L-NAME orally at a dosage of 50mg/kg body weight (b.w) daily for 5 
weeks (20, 21). Ramipril and T. acutiloba were dissolved in distilled water and all doses were dispensed, 
orally, daily (at the same time every morning) via an intragastric tube, for 5 weeks. The animals were 
randomly grouped into 6 groups of 7 animals each, as outlined below; 
Group 1: Control (distilled water only) 
Group 2: L-NAME control (50mg/kg b.w.) 
Group 3: L-NAME + Ramipril (10mg/kg b.w.) 
Group 4: L-NAME + T. acutiloba leaves (40mg/kg b.w.) 
Group 5: L-NAME + T. acutiloba leaves (60mg/kg b.w.) 
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Group 6: L-NAME + T. acutiloba leaves (80mg/kg b.w.) 
 
Blood pressure, heart rate and body weights measurements 
Systolic and diastolic blood pressure measurements as well as heart rates were evaluated using the non-
invasive tail-cuff method (IITC, Life Sciences Inc. Model 31, Woodland Hills, CA, USA). Prior to the 
initiation of the procedure, the animals were pre-conditioned for 7 days in order to acclimatize the 
animals to the conditions of the experiment. They were placed in restrainers in heating chambers and 
exposed to a temperature of 31-34 ºC for 15-20 minutes. The blood pressure measurements and heart rate 
were recorded every week during the experimental period. Values reported are the mean value of three 
consecutive readings. Body weights were determined weekly for the duration of study using a pre-
calibrated electronic scale. 
 
Animal Sacrifice 
The duration of the animal study was 35 days (5 weeks). On day 36, the rats were sacrificed by the 
administration of halothane overdose and blood was collected via cardiac puncture. Plasma and serum 
samples were obtained through centrifugation at 224 x g for 10minutes prior to biochemical analysis. The 
heart, liver and kidneys of each rat was harvested, washed to remove blood and weighed. Thereafter they 
were snap-frozen in liquid nitrogen. All samples were stored temporarily at -70ºC before use. The heart 
was further divided into two; the left heart was used for molecular assays while the right heart was fixed 
in a neutral buffered formalin (10%) for 72 hours and used for histological assessment 
 
NOx estimation 
Plasma and heart tissue nitric oxide (NO) estimation was determined based on the principle of the Griess 
reaction (22, 23). The reaction of nitrate with a mixture of sulfanilamide and naphthlethylenediamine, 
leads to the formation of a chromophore which is measured at an absorbance of 550nm. There is a 
reduction of nitrate to nitrite after incubating the mixture for 30 minutes in the presence of NADPH with 
nitrate reductase. A standard curve was used to estimate the amount of nitrite/nitrate in the plasma and 
heart tissue homogenates. Units were expressed as μmol/L. 
 
Antioxidant Assay in heart tissues 
Enzymatic antioxidant activities of catalase (CAT) and superoxide dismutase (SOD) in heart tissues were 
determined using a method adapted from those developed by Sinha (1972) and Kakkar et al., (1984) 
respectively. Non-enzymatic antioxidant determination of reduced glutathione (GSH) in heart tissues was 
95 
 
estimated by the method of Ellman (1959) with modifications. Thiobarbituric acid-reactive substances 
(TBARS) concentration was estimated using the method developed by Niehaus & Samuelsson (1968). 
 
Serum ACE activity and cardiac function  
Serum angiotensin-converting enzyme (ACE) activity was measured by an enzymatic rate method using 
available commercial kit purchased from Trinity Biotech, USA and experimental procedures performed 
according to manufacturer’s instructions. Cardiac markers including creatine phospokinase (CK), 
creatinine phosphokinase-muscle-brain (CK-MB- the bound combination of the isoenzymes CKM and 
CKB of the enzyme phosphocreatine kinase) and Troponin I (cTnI) were measured in the serum using an 
automated chemistry analyser (Beckman Coulter Synchron, DXC 600, Access Clinical System, USA). 
 
Estimation of Serum Lipids and hepatic function markers 
Serum Triglyceride (TG), HDL-Cholesterol and Total Cholesterol concentration were measured using an 
automated chemistry analyser (Beckman Coulter Synchron, DXC 600, Access Clinical System, USA). 
Low-density Lipoprotein (LDL-C) was calculated according to the formula developed by de Cordova and 
de Cordova, 2013 (24) as follows: LDL-C = ¾(TC-HDL-C). Very Low-density Lipoproteins (VLDL) 
were estimated using the formula developed by Friedwald et al, 1972 (25) as follows VLDL= TG/2.2 (in 
mmol/l). Hepatic function markers including alanine transaminase (ALT), aspartate transaminase (AST) 
and alkaline phosphatase (ALP) were measured in the serum using an automated chemistry analyser 
(Beckman Coulter Synchron, DXC 600, Access Clinical System, USA).  
 
Analysis of mRNA Expression  
Total mRNA was extracted from left cardiac tissues using the Zymo Research Quick-RNA Miniprep kit 
(ZymoResearch, Irvine, USA) according to the protocol of the manufacturer. The purity and 
concentration of RNA were determined by a nanodrop spectrophotometer (Thermoscientific Nanodrop 
1000 Spectrophotometer). Thereafter a total RNA of 1μg was reverse transcribed to cDNA using the 
iScript cDNA synthesis kit (Bio-Rad Laboratory (Pty) Ltd. USA) according to the manufacturer’s 
protocol.  
Real time-Polymerase chain reaction (RT-PCR) was carried out using the Lightcycler 96® (Roche 
Diagnostics, Germany). Conditions used for the RT-PCR analysis were as follows:  95ºC initial 
denaturation cycle for 10minutes thereafter a PCR run consisting of 40 cycles at 95ºC for 15s, 60ºC for 
30s and 72ºC for 30s with a single fluorescent measurement. The housekeeping gene used in the analysis 
was Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and the fluorescent dye utilized in the 
analysis was SYBR Green 1 (SSO Advanced Univers SYBR GR. SUPRMIX, Bio-Rad Laboratory (Pty) 
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Ltd. USA). The oligonucleotide primer sequences for the various genes investigated in the RT-PCR 
analysis were as follows:  
 
 
Histological Examination of cardiac tissues 
Sections of 5μm thickness was prepared from the heart tissues of each animal from processed paraffin-
embedded samples. The tissue sections of the heart were stained with Haematoxylin and Eosin (H&E) 
and examined under a light microscope for indications of tissue changes. Micrographs of the cross-
sectional area of tissue samples were taken at 40x magnification and analyzed using the Leica SCN 400 
scanner (Leica SCN 400, Germany). 
 
Statistical Analysis 
All values are presented as means ± SEM for seven rats in each group. Data analysis was computed using 
analysis of variance (ANOVA), followed by post-hoc tests for multiple comparisons using either the 
Bonferroni and Dunnett’s test (as appropriate), on GraphPad Prism Version 6. A p-value of <0.05 was 
considered significant. 
 
 
 
 
Gene Forward Primer Reverse Primer 
ACE 5'-TCGGCCATGTTGAGCTACTTC-3' 
 
5'-TCCCCATGCAGCTCGTTC-3' 
AT1a 5'-TATCACAGTGTGCGCGTTTCA-3' 5'-TGGTAAGGCCCAGCCCTAT-3' 
 
AT2 5'-CCTTCCTGTATTGTTTCGTTGGA-3 
 
5'-CGGCAAGACATAGTCTCTCTCTTG-3' 
 
B1 5' - AGG GTT CGT CAT CAC TAT -3' 5'- AGG TAG ATT TCC GCT ATG -3' 
 
B2 5'-TGA GGAACAACGAGATGAAGAAG -3' 
 
5'- GGAAACCAACACAGCACAAAG AC-3' 
GAPDH 5’-TGACAACTCCCTCAAGATTGTCA-3’ 
 
5’-GGCATGGACTGTGGTCATGA-3’ 
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RESULTS 
Effect of TA on body weight, heart weight and heart rate 
The effect of T. acutiloba (TA) at three different concentrations (40, 60 and 80mg/kg) on the body 
weight, heart weight and heart rate is shown in Table 1. There were no significant differences in body 
weights (g) in the 6 experimental groups at baseline and at week 5 (P>0.05). The L-NAME untreated rats 
(group 2) showed a significantly increased heart weight and heart weight-to-body weight ratio (P>0.05), 
while treatment with TA or Ramipril showed a significant decrease (P <0.05). Moreover, there were no 
significant differences in the heart weight and heart weight-to-body weight ratio between the control 
group, Ramipril group and the three different concentrations of TA. The baseline heart rate (bpm) of the 6 
experimental groups were not significantly different (P>0.05), however, the L-NAME untreated group 
showed a significant increased heart rate (bpm) at week 5 as compared to the other experimental groups. 
This increase was attenuated by the treatment of Ramipril and TA at the three different doses (40,60, 
80mg/kg). 
Table 1: Body weight(b.w.), Heart weight(HW) and Heart Rate(HR) of the various experimental 
groups (1-6) 
Group 1- Control; Group 2-L-NAME(50mg.kg); Group 3- L-NAME + Ramipril(10mg.kg); Group 4- L-NAME + TA(40mg/kg); 
Group 5- L-NAME + TA(60mg/kg); Group 6- LNAME + TA(80mg/kg). Values are expressed as mean ± SEM for seven rats per 
group. a P <0.05 vs. control; b P <0.05 vs. L-NAME. 
 
Effect of TA on blood pressure  
The effect of TA at concentrations of 40, 60 and 80mg/kg on systolic and diastolic blood pressure in L-
NAME induced hypertensive rats are shown in Figures 1 and 2. It was observed that there was a 
significant (P<0.05) increase in systolic and diastolic blood pressure in the L-NAME induced rats from 
week 2 to week 5 and this increase was attenuated by the treatment of TA and Ramipril. The effect of TA 
Parameter 
Samples 
                                                    Groups  
1 2 3 4 5 6 
 
B.W.(g) (baseline)  170.14 ± 9.15 170.57 ±7.20 176.43 ± 5.20 173.57 ± 1.80 173.86 ± 6.01 172.83 ± 12.62 
B.W.(g) (Week 5) 316.86 ± 9.85 295.43 ±8.08 305.57 ± 12.39 292.14 ± 7.38 315.14 ± 8.62 308.00 ±  2.97 
HW(g)  1.02  ±  0.05 1.56 ±  0.08 a 1.02 ±  0.04 b 1.00 ± 0.04 b 1.11  ± 0.03 b 1.01 ± 0.09 b 
HW/b.w. (%) 0.34 ± 0.02 0.56 ± 0.02 a 0.35 ± 0.02 b 0.37 ±  0.02 b 0.38 ±  0.02 b 0.36 ± 0.03 b 
HR(bpm)(baseline) 368.71 ± 9.21 373.43 ±7.07 373.71 ± 11.05 381.29 ± 7.46 382.57 ± 8.54 381.83 ± 4.81 
HR(bpm) (Week 5) 396.86 ± 0.91 456.71 ±4.84a 386.00 ± 2.32b 400.00 ±2.45b 392.00 ±1.18b 392.83 ± 1.56b 
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on systolic and diastolic blood pressure was more pronounced at doses of 60 and 80mg/kg. There was no 
significant difference in systolic and diastolic blood pressure between the TA treated rats at 60 and 
80mg/kg, Ramipril and the control group throughout the study. 
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Figure 1: Effect of TA on systolic blood pressure (SBP) in L-NAME induced hypertensive rats, Values are 
expressed as mean ± SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME; ∇ P<0.05 vs. 
Ramipril 
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Figure 2: Effect of TA on diastolic blood pressure (DBP) in L-NAME induced hypertensive rats, Values are 
expressed as mean ± SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME; ∇ P<0.05 vs. 
Ramipril 
 
Effect of TA on plasma NOx concentration 
The effect of TA on plasma nitric oxide metabolites (NOx) concentration in L-NAME induced 
hypertensive rats are shown in figure 3. It was observed that the L-NAME administration significantly 
(P<0.05) decreased the plasma NOx concentration when compared to the control, whereas the treatment 
with TA and Ramipril significantly restored the plasma NOx concentration. There was no significant 
difference in the plasma NOx concentration of the TA treated rats, Ramipril and the control groups. 
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Figure 3: The effect of TA on plasma NOx concentration in L-NAME induced hypertensive rats. Values are 
expressed as mean ± SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME. 
 
Effect of TA on enzymatic and non-enzymatic antioxidant activity in heart tissue 
The effect of TA on enzymatic and non-enzymatic antioxidants in heart tissue samples is shown in Table 
2. The L-NAME untreated rats showed a significant (P<0.05) reduction in the activities of SOD and CAT 
when compared to the control whiles the administration of TA and Ramipril significantly increased the 
activities of these enzymatic antioxidants. It was also observed that GSH levels were significantly 
(P<0.05) reduced in the L-NAME untreated group and the treatment with TA and Ramipril significantly 
increased the levels with maximum effect at 80mg/kg of TA. Moreover, the levels of TBARS were 
significantly increased in the L-NAME untreated group and the administration of TA and Ramipril 
significantly (P<0.05) reduced the levels of TBARS with a more pronounced effect at 80mg/kg of TA. 
However, the levels of TBARS at 40mg/kg of TA was significantly increased when compared to the 
Ramipril treated group and the control group. Similar to plasma NO levels, NOx concentration at the 
heart tissue level of the L-NAME untreated group significantly decreased (P<0.05) when compared to the 
control. There was also a reduction in all the treated groups (Ramipril, 80, 40 and 60mg/kg). However, 
none were significantly different compared to the control. 
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Table 2: Effect of TA on superoxide dismutase (SOD), catalase (CAT), reduced Glutathione(GSH), 
Thiobarbutiric acid reactive substances(TBARS) and NOx activities in heart tissue 
Parameter Samples                                                     Groups  
1 2 3 4 5 6 
 
SOD(Ua/mg 
protein) 
13.17 ± 1.10 7.75 ± 0.99a 12.64 ± 0.72b 10.77 ± 0.74 12.11 ± 0.56b 16.68 ± 0.79b,c,d,e 
CAT(Ub/mg 
protein) 
63.54 ± 2.07 38.10 ± 0.28a 61.63 ± 1.11b 60.75 ± 1.64b 49.93 ± 0.31b 44.97 ± 1.12b 
GSH (μg/mg 
protein) 
0.023 ± 0.00 0.016 ± 0.00a 0.023 ± 0.00 0.03 ± 0.01b 0.02 ± 0.00 0.04 ± 0.01a,b 
TBARS        
(mmol/100g wet 
tissue) 
0.49 ± 0.04 1.28 ± 0.12a 0.63 ± 0.02b 0.95 ± 0.03a,b,c 0.79 ± 0.02a,b 0.61 ± 0.03b 
NOx(μmol/l) 92.73 ± 1.02  74.59 ± 4.94a 79.07 ± 0.93a 82.09 ± 1.10 76.47 ± 5.08a 91.47 ± 1.10b 
Group 1- Control; Group 2-L-NAME(50mg.kg); Group 3- L-NAME + Ramipril(10mg.kg); Group 4- L-NAME + TA(40mg/kg); 
Group 5- L-NAME + TA(60mg/kg); Group 6- LNAME + TA(80mg/kg). Values are expressed as mean ± SEM for seven rats per 
group. a P <0.05 vs. control; b P <0.05 vs. L-NAME; c P<0.05 vs. Ramipril; d P<0.05 vs. TA(40mg/kg); e P<0.05 vs. 
TA(60mg/kg) 
 
Effect of TA on serum ACE activity and cardiac function markers 
The effect of TA on serum ACE activity and cardiac function markers is shown in Table 3. Serum ACE 
activity increased significantly (P<0.05) in the L-NAME untreated group when compared to the control 
group and this increase was attenuated by the administration of TA and Ramipril with maximum effect at 
80mg/kg of TA. There was no significant difference between the control, Ramipril and TA treated groups. 
Serum cardiac markers CKMB and Troponin I (cTnI) were significantly increased (P<0.05) in the L-
NAME group whiles the treatment with TA and Ramipril led to a significant decrease with maximal 
effect at 60 and 80mg/kg of TA. However, the 40mg/kg dose of TA showed a significant increase in 
serum CKMB levels when compared to the control, Ramipril group and TA treated group at dose 
80mg/kg. There was no significant difference in the serum CKMB and cTnI in the control, Ramipril and 
TA dose of 80mg/kg. There was no significant difference in the serum creatine phosphokinase (CK) in all 
the experimental groups, although there was a tendency for decreased levels in the Ramipril and TA 
treated groups of 60 and 80mg/kg dose. 
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Table 3: Effect of TA on serum ACE activity and cardiac function markers. 
Parameter 
Samples 
                                                    Groups  
1 2 3 4 5 6 
 
ACE (U/L) 158.00 ± 15.18 261.50 ±23.64a 222.7 ± 22.59 216.10 ±9.34 244.60 ±23.43 206.50 ± 15.57 
CKMB (IU/L) 58.81 ±  3.38 99.60 ± 4.09a 70.69 ± 3.77b 98.84 ±3.84a,c 60.10 ± 4.98b,d  58.33 ± 4.47b,d 
CK (IU/L) 906.4 ± 72.04 1064 ± 149.9 949.1 ± 90.76 1094 ± 131.2 869.5 ± 103.9 705.8 ± 66.70 
cTnI (ng/ml) 0.37 ± 0.03 0.88 ± 0.13a 0.51 ± 0.05b 0.77 ± 0.04a 0.53 ± 0.02b 0.55 ± 0.05b 
Group 1- Control; Group 2-L-NAME(50mg.kg); Group 3- L-NAME + Ramipril(10mg.kg); Group 4- L-NAME + TA(40mg/kg); 
Group 5- L-NAME + TA(60mg/kg); Group 6- LNAME + TA(80mg/kg). Values are expressed as mean ± SEM for seven rats per 
group. a P <0.05 vs. control; b P <0.05 vs. L-NAME; c P<0.05 vs. Ramipril; d P<0.05 vs. TA(40mg/kg). 
 
Effect of TA on lipid profile and hepatic function 
The effect of TA on the lipid profile and hepatic function is presented in Table 4. There was no significant 
difference in the lipid profile in all the experimental groups in the study, although total cholesterol, LDL- 
C and VLDL-C were slightly elevated in the L-NAME group as compared to the control and the TA 
treated groups. The Ramipril treated group showed a slightly increased triglyceride and HDL-C levels 
when compared to the control, L-NAME group and the TA treated groups. Hepatic function markers were 
represented by a significant (P<0.05) increase in ALT levels in the L-NAME untreated group but this 
increase was attenuated by the administration of Ramipril and TA with a more pronounced effect at the 
80mg/kg dose. However, the TA treatment at 40mg/kg was significantly (P<0.05) increased, when 
compared to the control and Ramipril group. There was no significant difference in ALT levels between 
the Ramipril and the TA dosages of 60 and 80mg/kg, respectively, although Ramipril showed a greater 
effect (P<0.05). There were no significant differences in AST and ALP levels in all experimental groups, 
although the L-NAME untreated group showed a slightly increased concentration. 
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Table 4: The effect of TA on lipid profile and hepatic function markers 
Parameter 
Samples 
                                                    Groups  
1 2 3 4 5 6 
 
Total Cholesterol 
(mmol/l)   
0.86 ± 0.05  1.00 ± 0.04 0.90 ± 0.06 0.94 ± 0.05 0.95 ± 0.05  0.85 ± 0.06 
Triglycerides 
(mmol/l) 
1.331 ±  0.09 1.37 ± 0.16 1.87 ± 0.23 1.43 ± 0.31 1.69 ± 0.13 1.45 ± 0.33 
HDL-C (mmol/l) 0.69 ± 0.03 0.74 ± 0.04 0.75 ± 0.04 0.67 ± 0.03 0.70 ± 0.02 0.69 ± 0.02 
LDL-C (mmol/l) 0.15 ± 0.03 0.19 ± 0.02 0.11 ± 0.02 0.21 ± 0.02 0.18 ± 0.02 0.14 ± 0.04 
VLDL-C(mmol/l) 0.61 ± 0.04  0.66 ± 0.06 0.85 ± 0.11 0.65 ± 0.14 0.66 ± 0.13 0.57 ± 0.16 
AST (IU/L) 128.9 ± 4.93 130.6 ± 6.90 120.0 ± 7.16 147.4 ± 13.72 120.5 ± 2.60 116.0 ± 2.98 
ALT (IU/L) 59.14 ± 4.17 98.40 ± 8.51a 49.43 ± 3.44b 84.29±5.45a,c 78.33 ± 4.49c 70.00 ± 3.49b 
ALP (IU/L) 152.4 ± 7.37 186.8 ± 13.92 176.4 ± 10.98 175.3 ± 7.35 163.2 ± 7.24  178.7 ± 8.01 
Group 1- Control; Group 2-L-NAME(50mg.kg); Group 3- L-NAME + Ramipril(10mg.kg); Group 4- L-NAME + TA(40mg/kg); 
Group 5- L-NAME + TA(60mg/kg); Group 6- LNAME + TA(80mg/kg). Values are expressed as mean ± SEM for seven rats per 
group. a P <0.05 vs. control; b P <0.05 vs. L-NAME; c P<0.05 vs. Ramipril.  
 
Expression of mRNAs in heart tissue 
ACE mRNA expression 
Figure 4 presents the levels of ACE mRNA expression in the heart tissues of the six experimental groups. 
The L-NAME rats showed a significant (P<0.05) elevated mRNA ACE expression (10 folds) when 
compared to the control. However, treatment with Ramipril and TA suppressed the elevated expression 
with the maximum effect at 80mg/kg of TA (5.8 folds). There was no significant difference in mRNA 
ACE expression between the Ramipril and TA treated rats (P>0.05). 
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Figure 4: The mRNA levels of ACE in L-NAME induced hypertensive rats. Values are expressed as mean ± 
SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME. 
 
Expression of Bradykinin receptors B1 and B2 mRNA  
The effect of TA on the mRNA expression of bradykinin receptors B1 and B2 in heart tissues are 
represented in Figure 5. The L-NAME group showed a decreased bradykinin receptor 1 (B1) mRNA 
expression (downregulation of 0.4 fold) when compared to the control. Ramipril and TA treatment 
significantly increased the mRNA expression of B1 with a pronounced effect at 80mg/kg of TA (4.4 fold 
increase). The TA dose of 80mg/kg had a greater effect as compared to the Ramipril treated group. 
Interestingly, all experimental groups showed a significant increase of bradykinin receptor 2 (B2) 
expression when compared to the control, with greater effect in the TA 80mg/kg dose group (6.8 fold 
increase). There was no significant difference between the Ramipril group and the TA treated groups. 
However, the TA dose of 80mg/kg was significantly increased when compared to the L-NAME group. 
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Figure 5: The mRNA levels of bradykinin receptors B1 and B2 in L-NAME induced hypertensive rats. Values 
are expressed as mean ± SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME. 
 
Expressions of AT1a and AT2 mRNA  
The expressions of AT1a and AT2 receptors in the heart tissue of the experimental and control groups are 
presented in Figure 6. The L-NAME untreated group showed a significant (P<0.05) 3.8 fold increase in 
AT1a receptor expression when compared to the control. Interestingly, treatment with Ramipril and TA 
showed a significant down regulation of AT1a receptor expression, with more pronounced effect at 
80mg/kg of TA (0.3 fold decrease). There was no significant difference in AT1a receptor expression 
between the Ramipril and TA treated groups. 
Similarly, the L-NAME group showed a significant 3 fold increase in AT2 receptor expression when 
compared to the control. Treatment with Ramipril and TA showed a significant down regulation of AT2 
receptor expression. There were no significant difference in the AT2 receptor expression between the 
Ramipril and the TA treated groups (P>0.05). 
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Figure 6: The mRNA levels of AT1a and AT2 receptors in L-NAME induced hypertensive rats. Values are 
expressed as mean ± SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME. 
 
Histopathological examination of cardiac tissues 
The histology of myocardial tissues of all groups is represented in Figure 7(A-F). There were clearly 
defined, well-organised normal, cardiac fibers with nucleated cells of similar sizes observed in the normal 
untreated group (figure 7A). The L-NAME group showed a gross disorganization of cardiac fibers and 
inflammatory cells (7B). Interestingly, there was a marked change in the histological appearance in the 
Ramipril and TA treated groups (7C-E). The Ramipril and TA doses of 60mg/kg and 80mg/kg produced 
profound vascular changes as compared to the L-NAME untreated group. Cardiac fibers in the Ramipril 
and TA doses of 60mg/kg and 80mg/kg looked normal with mild indications of vascular degeneration (7 
D, E). These effects were much pronounced in the TA dose of 80mg/kg (7E) which was similar to the 
control untreated group. However, there was a level of cardiac fiber disorganization with remarkable 
inflammatory cells in the TA dose of 40mg/kg, indicating a possible poor regeneration of cells following 
inflammation and vascular degeneration. 
 
 
 
107 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Photomicrographs representing histological changes in myocardial tissue sections (H & E, x40) 
(A)Control showing normal cardiac fibers; (B) L-NAME treated group showing gross myocardial fiber 
degeneration and thickened cardiac fibers with inflammatory cells; (C) Ramipril + L-NAME group similar to 
control showing attenuated degeneration of cardiac cells with normal cardiac fibers. (D) TA (40mg/kg) + L-NAME 
showing remarkable degeneration of cardiac cells with mild attenuated degeneration. (E) TA (60mg/kg) + L- 
NAME similar to control showing marked attenuated degeneration; (F) TA(80mg/kg) + L-NAME similar to 
control showing attenuated degeneration with normal cardiac fibers(N- Normal; CHI- Cardiac 
hypertrophy/inflammation;AHI-AttenuatedHypertrophy/inflammation). 
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DISCUSSION  
Chronic inhibition of NO synthase (eNOS) by L-NAME is known to produce systemic vasoconstriction 
and increase blood pressure. Additionally, reports indicate that NO deficiency in rats causes 
cardiovascular remodeling, endothelial dysfunction, increased production of ROS and decreased 
antioxidant enzyme systems (28).  
The successful induction of hypertension in L-NAME model was confirmed by the observed significant 
progressive rise in systolic and diastolic blood pressure as well as heart rate. This was further confirmed 
by the reduced plasma and tissue NO levels and accompanied by significant increase in oxidative stress, 
cardiac biomarkers and progressive long term cardiac hypertrophy. The treatments by Ramipril and the 
plant extracts of TA attenuated the rise of blood pressure and alleviated key pathological manifestations  
 
Cardiac hypertrophy is an adaptive response to both physiological and pathological stimuli. The 
pathological hypertrophy, caused by nitric oxide  deficiency,  may be attributed to the increase in cardiac 
muscle mass as a result of the increase in myocyte size, in order to adapt to the overload caused by the  
NO deficient hypertension (26). Our findings show that this condition was attenuated by the treatment of 
TA and Ramipril, hence the absence of cardiac hypertrophy in the treated groups (27). We also 
demonstrated that the five week L-NAME treatment caused  significantly decreased plasma NOx level, in 
keeping with others (28) while treatment with TA and Ramipril restored NOx levels to levels comparable 
to the control group.  
 
Furthermore, the development of oxidative stress caused by the excessive production of reactive oxygen 
species is a major contributor to the progression of cardiovascular disorders coupled with hypertension 
(29). In this study, we observed a significant reduction in the SOD, CAT and GSH levels in the L-NAME 
untreated groups, which is in keeping with Berenyiova et al, (2018). This   depletion is attributable to 
increased ROS such as superoxide anion (O2-) and hydroxyl radical (OH-), due to L-NAME 
administration (30). Moreover, TA and Ramipril significantly increased antioxidants levels, with maximal 
effects at 60 and 80mg/kg. These antioxidants, in L NAME group, may have a short duration in 
scavenging ROS,  hence prolonged oxidation exposure in the absence of antioxidant activity, could lead 
to deterioration in tissue antioxidant levels (30). Our study suggests that treatment with Ramipril and TA 
(60 and 80mg/kg) may have an active role in promoting the bioavailability of these antioxidants, hence 
maintaining steady state physiologic conditions. Additionally, lipid peroxidation, is known to alter the 
cellular integrity of tissues and organs, especially in the heart (31). The end product of lipid peroxidation, 
measured as Thiobarbutiric Acid Reactive Substances (TBARS) (32), was seen to increase significantly in 
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the heart in the L-NAME untreated rats, a clear sign of oxidative stress in these tissues. This was 
attenuated by the administration of Ramipril and TA treatment, with maximum effect at 80mg/kg. From 
these observations, it is evident that the protective role and antihypertensive effect of TA, would be 
partially due to its antioxidant potential. 
We also found increased levels of cardiac biomarkers such as CKMB, CK and cTnI in the L-NAME 
group, which is consistent with previous findings by others (33, 34). High concentrations of cTnI and 
cardiac markers indicate the presence of myocardial cell injury, which could lead to infarction (34).  The 
early rise in cTnI and cardiac enzymes CKMB and CK after myocardial injury is known to occur about 
the same time (35). Cardiac troponin I is currently known as one of the most sensitive cardiac markers, 
and together with a rise in CK and CKMB levels, provides evidence of myocardial injury in the L-NAME 
group (36). However, this was alleviated by the administration of TA and Ramipril.  
The process involved in the L NAME hypertensive induction involves multiple pathways. The processes 
involved in the induction of hypertension by L-NAME, entails more than the reduction or elimination of a 
tonic vasodilator action of NO through NO synthase inhibition (37). We observed increased cardiac and 
serum ACE activity, as well as ACE mRNA gene expression in heart tissues in the L-NAME untreated 
group. In contrast, treatment with TA and Ramipril decreased these parameters. Our findings are similar 
to other studies, that have demonstrated that increased NO bioavailability are effective in inhibiting the 
activity of ACE in a dose-dependent manner (38, 39). Though the exact mechanism of NO-stimulated-
ACE inhibition remains unclear, it is well known that there is an inverse relationship between ACE 
activity and the NO system, suggesting that the RAS is activated by inhibition of NO (40). Notably, our 
studies also indicated a significant upregulation in cardiac AT1 and AT2 receptor gene expression in the 
L-NAME untreated group. This was followed by a significant down regulation when treated with 
Ramipril and TA. This finding concurs with similar studies in L-NAME hypertensive rats (41, 42). 
Evidence from several reports also show that NO has an antagonistic effect on the biological function of 
Ang II (42, 43). Therefore the upregulation of AT1 and AT2 in the L-NAME model, with its subsequent 
downregulation in the treated groups, may be due to the multiple feedback mechanisms involved in the 
NO release and the ACE/Ang II/AT1 association (44).  
We further examined the effect of TA and Ramipril on the kinin-kallikrein system (KKS), through the 
expression of the bradykinin receptors B1 and B2. It was observed that bradykinin receptor B1 gene was 
significantly decreased in the L-NAME hypertensive rats, and significantly increased with the treatment 
of TA and Ramipril, with a profound effect in the 80mg/kg dose of TA. These findings are in line with 
other similar studies, that seems to suggest that ACE inhibitors promote the expression of bradykinin 
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receptors B1 and B2, through the bioavailability of NO production (45). Studies have shown that ACE 
inhibitors directly or indirectly affect bradykinin B1 and B2 receptor signaling, which may be the basis of 
some of their therapeutic effectiveness (45). There is also a strong evidence that B1 and B2 enhancement 
through ACE inhibition may activate endothelial NO synthase, and hence promoting the bioavailability of 
NO in the vascular system (46). Indeed, our studies confirmed the above-mentioned phenomenon, with an 
upregulation of B1 and B2 receptors in TA and Ramipril treated groups, coupled with an increase NO 
levels, and a significant reduction of B1 coupled with low levels of NO. Hence, TA (80mg/kg) and 
Ramipril may mediate their therapeutic role via the KKS.  
We further evaluated liver function to ascertain the toxicological effect of therapeutic agents (47). Our 
study showed that the liver enzymes ALT, AST and ALP in the Ramipril and TA (60mg/kg and 80mg/kg) 
treated groups were not significantly different from the control group, an indication of the absence of 
toxicity, although there was a tendency towards an increase in the TA dose of 40mg/kg and the L-NAME 
untreated rats. We examined the lipid parameters and found no significant difference in lipid profiles 
amongst the experimental groups, although triglycerides level  were increased slightly  in the Ramipril 
group. Our findings corroborates with other findings, where NO deficient induced hypertension may have 
led to progression of cardiovascular diseases independent of lipid profile (48)(49).                                                                                                                                                  
 Histopathological examination of cardiac tissue showed vascular degeneration and marked inflammation 
the L-NAME group. This is in keeping with other studies, which suggests that activation of RAS coupled 
with oxidative stress and decreased NO availability may cause inflammation and cardiovascular injury 
(50).  On the contrary, TA (80 mg/kg b.w.) and Ramipril treated hypertensive rats revealed a near normal 
morphology of cardiac fibres. The TA and Ramipril treated group showed no evidence of degeneration or 
cell death. Therefore, these observations demonstrate the protective role of TA at a dose of 80mg/kg and 
Ramipril on cardiovascular integrity. 
Conclusion 
To the best of our knowledge, this is the first study to examine the cardiovascular effects of TA. In 
conclusion, it is observed that the dose of 80mg/kg TA possesses a strong cardioprotective role, 
comparable to Ramipril, which may be attributed to its strong antioxidant and antihypertensive properties 
through the inhibition of ACE in an L-NAME induced hypertensive rats. TA shows promise as a possible 
therapeutic agent in the treatment and management of essential hypertension. However, further studies are 
needed to elucidate the precise underlying mechanisms of action of Tulbaghia acutiloba. 
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Chapter 5: Manuscript Four 
Haematological and Renal function markers as indicators of antihypertensive efficacy of 
the leaf hydro-methanolic extract of Tulbaghia acutiloba Harv. in an L-NAME induced 
hypertensive rats  
 
Chapter 4 demonstrated the antihypertensive and cardioprotective effect of Tulbaghia acutiloba in an L-
NAME induced hypertensive rats and the reduction of oxidative stress. Chapter 5 was therefore intended 
to assess the antihypertensive efficacy of T. acutiloba (TA) on renal function and haematological 
parameters. Since renal function and haemtological parameters are indicated as prognostic markers in 
pathophysiology of hypertension, it was therefore necessary to understand the effect of TA on these 
crucial parameters and functions to better appreciate the antihypertensive efficacy of TA in an L-NAME 
induced hypertensive rats. 
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ABSTRACT 
Haematological assessment and renal function are essential tools in assessing the antihypertensive 
efficacy of therapeutic agents including medicinal plants.  The effect of the indigenous plant, Tulbaghia 
acutiloba (TA) on renal and haematological parameters has not been investigated. Therefore, we 
evaluated the effect of TA on these parameters as indicators of its antihypertensive efficacy in L-NAME 
induced hypertensive rats. Male albino Wistar rats were treated, orally, with L-NAME (50mg/kg b.w.), 
hydro-methanolic leaf extracts of TA at different doses (40, 60 and 80mg/kg b.w.), Ramipril (10mg/kg 
b.w.) and water (control) in separate groups for 5 weeks. Mean arterial blood pressure was measured 
weekly using the tail-cuff method. A 24-hour urine sample was collected for each rat weekly. On day 36, 
the rats were sacrificed, and blood samples collected for the determination of renal function and 
haematological analysis.  Kidney mRNA gene expression was performed for NF-kB, HO-1 and eNOS. 
The treatment of the hypertensive rats with TA and Ramipril resulted in a significant reduction in the 
mean arterial blood pressure, with a pronounced effect observed in the 80mg/kg dose of TA. The TA 
treated group showed increased creatinine clearance (Ccr), urine volume and a reduction in serum 
creatinine, proteinuria and Urine protein-creatinine ratio (UPr/UCr). TA treatment also decreased lipid 
peroxidation in renal tissues and erythrocytes whiles increasing SOD, CAT, GSH and NO levels. 
Moreover, red cell distribution width (RDW), white blood cells (WBC), neutrophil to lymphocyte ratio 
(NLR), lymphocyte to monocyte ratio (LMR), platelet and Mean Platelet volume (MPV) were 
significantly reduced in the TA and Ramipril treated groups with maximum effect occurring at the dose of 
80mg/kg of TA. No significant difference was observed in the haemoglobin levels in all experimental 
groups. 
TA administration resulted in a significant decrease in renal NF-kB gene expression, while increasing 
HO-1 and NO gene expression in renal tissues. Generally, our results indicate improved renal function 
and haematological profile as markers of the antihypertensive efficacy of Tulbaghia acutiloba.  
 
Key words: Tulbaghia acutiloba, renal function, haematological parameters, hypertension, antioxidant 
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Introduction 
The aetiology and pathophysiology of systemic arterial hypertension, of which 95% is essential, is 
currently under investigation, as it poses a major health concern, globally (1). By 2030, it is estimated that 
the global annual death toll, due to hypertension, is predicted to reach 23.5 million (2, 3). Notably, 
hypertension is associated with oxidative stress and increased inflammatory responses, and is a major risk 
factor for renal and cardiovascular disorders (4). Moreover, endothelial dysfunction is a major role player 
in the pathogenesis of hypertension, together with these markers (5). Several animal models of 
hypertension, displaying these key pathological features have been developed. In this regards the chronic 
administration of N(ω)-nitro-L-arginine methyl ester (L-NAME), in a rat model, is known to block the 
endothelial nitric oxide synthase (NOS), leading to the reduction in the biosynthesis of NO, with 
downstream effects on endothelial function (6). In turn, impaired endothelial function increases oxidative 
stress, which may lead to chronic inflammation, and subsequently lead to severe, end-organ damage (7). 
The kidney, a major target organ of hypertension, is associated with changes in biochemical and 
haematological parameters, which are emerging as suitable prognostic indicators of the disease (8). In 
recent years, the primary focus of antihypertensive treatment has been to decrease the risk of organ 
damage associated with elevated blood pressure, in order to decrease morbidity and mortality (9). The 
study of inflammatory status, oxidative stress and biochemical changes associated with organ function, 
will increase functional understanding, and enable better prediction of the prognosis of hypertension (10).  
Recently, there has been an increased interest in the investigation of haematological parameters in chronic 
diseases, such as hypertension, as they may adversely affect blood cells in the body (11). Haematological 
indices such as neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), red cell 
distribution width (RDW), white blood cells (WBC), mean platelet volume (MPV) and mean cell volume 
(MCV) have emerged as a novel, yet inexpensive, means of determining the systemic inflammatory-
immunological markers for the prognosis of hypertension and the determination of vascular and renal 
integrity (12). The prognostic value of these indices has been demonstrated in stroke, coronary heart 
diseases and nephropathies (13). 
Haematological indices, used as indicators of the prognosis of hypertension, in conjunction with renal 
markers, are of great interest since most of the enzymes and biochemical elements necessary for  
haematological function are produced in the kidney (13). For instance, erythropoietin, a hormone required 
for the synthesis of red blood cells, is produced in the juxtaglomerular apparatus of the kidney (14). 
Moreover, the formation of  other lineages of blood cells, including white blood cell differentials, as well 
as platelets, are known to be directly or indirectly linked to the normal functioning of the renal organ.  
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Hence, these factors, together with biochemical parameters and relevant inflammatory gene expression 
such as NF-KB, eNOS, and Haem Oxygenase 1 (HO-1) in the kidney, can be used to determine the 
prognosis of hypertension (15, 16). 
Natural product research is key to finding novel therapeutic applications, to lower risk of mortality and 
morbidity in hypertension (17). Despite the progress made in the use of orthodox medicine, phytotherapy 
still remains as an important contributor to health care systems  because of cost, access and reported 
minimal side effects (17).  
Tulbaghia acutiloba is used traditionally in Southern Africa for the management of various ailments, 
including hypertension, as well as, infectious diseases (18). It is also used as a culinary herb in the Eastern 
Cape and KwaZulu-Natal of South Africa (18). Despite its widespread usage, there is a lack of reports on 
the effect of the plant on hypertension, in particular, pertaining to the renal system and haematological 
parameters.  Earlier studies in our laboratory reported (unpublished data) on the cardiovascular effects of 
Tulbaghia acutiloba. Therefore, the present study was conducted to examine the efficacy of the hydro-
methanolic leaf extract of Tulbaghia acutiloba on renal function, oxidative stress and haematological 
parameters in an L-NAME induced hypertensive rats. 
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MATERIAL AND METHODS 
Plant sampling and preparation 
Tulbaghia acutiloba (TA) leaves were identified, collected and authenticated by Professor Himansu 
Baijnath, a botanist at the University of KwaZulu-Natal (UKZN), Durban, South Africa. The leaves of 
TA were washed thoroughly under running water and allowed to air dry for 72 hours at room temperature, 
under sterile conditions. The air-dried leaf material was crushed into a powder using a Waring blender. 
Thereafter the air-dried powdered material was extracted using a hydro-methanolic solution (80% 
methanol, 20% water) on a shaker, at 80rpm for 48 hours. The supernatant solution was filtered and 
placed in a rotary evaporator. Thereafter the concentrate was freeze dried at -40ºC. The leaves were then 
ready for use in this study. There was a 12.8% yield of the leaf extract. 
 Animal Experimental protocol 
Male albino rats (n=42) in good health were obtained from the Biomedical Resource Unit (BRU) of the 
University of KwaZulu-Natal (UKZN). Standard housing conditions of 23±2˚C room temperature, 50-
60% humidity, and a 12h light/12h dark cycle were maintained throughout the study period. The animals 
had unrestricted access to standard rat food and water. Ethical consent was sought from the Animal Ethics 
Committee of UKZN (Ref: AREC/062/016PD), according to the guidelines of National Institutes of 
Health for the Care and Use of Laboratory Animals. 
Chemicals 
Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) and Ramipril were purchased from Sigma-
Aldrich (St. Louis, Missouri, USA).  
Animal Model of L-NAME induced hypertension and TA and Ramipril treatment 
Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) was administered to the animals orally at a 
dosage of 50mg/kg body weight(b.w.) for 5 weeks. Each dose of Ramipril and TA leaves in powdered 
form were mixed and completely dissolved in distilled water, and the various doses were administered to 
the rats orally, on a daily basis, using an intragastric tube for the entire study period. There were 6 groups, 
into which, each of the animals were randomly assigned. There were 7 animals in each group designated 
as follows: 
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Group 1: Control (distilled water only) 
Group 2: Rats were treated with L-NAME only (50mg/kg b.w.) 
Group 3: Rats were co-administered with L-NAME (50mg/kg) and Ramipril (10mg/kg b.w.) 
Group 4: Rats were co-administered with L-NAME (50mg/kg) and TA leaves (40mg/kg b.w.) 
Group 5: Rats were co-administered with L-NAME (50mg/kg) and TA leaves (60mg/kg b.w.) 
Group 6: Rats were co-administered with L-NAME (50mg/kg) and TA leaves (80mg/kg b.w.) 
 
Measurement of Mean arterial pressure  
Animals were subjected to the measurement of mean arterial blood pressure using the non-invasive tail-
cuff method (IITC, life Sciences Inc. Model 31, Woodland Hills, CA, USA), as previously reported. Prior 
to the measurement, the rats were given a pre-conditioning treatment for a week to ensure that the rats are 
exposed and adapted to the experimental conditions to avoid interference. The mean arterial blood 
pressure was measured weekly during the experimental period. Results reported represent the mean value 
of three consecutive readings.  
 
Animal Sacrifice and specimen collection 
On the next the day following the 5 week period, the animals were sacrificed using halothane overdose, 
thereafter cardiac puncture was performed in order to remove blood from rats. The kidney tissues were 
quickly collected, washed, weighed, and frozen in liquid nitrogen. Whole blood samples were collected 
into an EDTA tubes for haematological analysis. Plasma and serum samples were obtained after blood 
collection through centrifugation at 224 x g for 10 minutes for biochemical analysis. 
 
Lipid peroxidation and Antioxidant assay  
Lipid peroxidation in kidney and erythrocytes was assessed through the estimation of Thiobarbutirc acid-
reactive substances (TBARS) according to the method by Niehaus & Samuelsson (1968). 
Kidney tissue and erythrocyte catalase and superoxide dismutase (SOD) activities were determined by the 
method developed by Sinha (1972) and Kakkar et al., (1984) respectively, with slight modifications. 
Reduced glutathione (GSH) in erythrocytes and kidney tissues estimation was estimated by the method of 
Ellman (1959) with modifications. The NOx concentration estimation in the kidney tissues and 
erythrocytes was based on the Griess reaction (Green et al., 1982; Foresi et al., 2016).  
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Haematological analysis 
A full blood count was carried out on whole blood samples using an automated haematology analyser 
(Beckman Coulter Ac.T diff., Coulter Electronics, USA) as per manufacturer’s instruction. The NLR was 
calculated by dividing the neutrophil count by the lymphocyte count (Neutrophil count ÷ lymphocyte 
count). Similar ratios used in the study such as the LMR, were calculated in a similar manner. 
 
Renal function markers 
The urine volume for each animal was determined weekly, by placing the animals in metabolic cages for 
a 24-hour urine volume collection and measurement.  Urinary and serum/plasma electrolytes and protein 
concentration were analysed using an electrolyte and chemistry analyzer (Beckman Coulter Synchron, 
DXC 600, Access Clinical System, USA). Creatinine clearance was evaluated as a measure of Glomerular 
filtration rate based on the formula:  
Creatinine clearance rate (ml/min) = (Urine volume x urine creatinine concentration) ̸ plasma creatinine 
concentration ̸ time. 
Fractional excretions of sodium (FeNa) and potassium (FeK+) were measured to evaluate the urine 
sodium and potassium excretions, and were  expressed as percentages of sodium and potassium absorbed 
by the kidney using the standard equation according to the method of Steiner(1984) and Hare (1950), 
respectively, as follows:  
FeNa (%) = (Urinary sodium x Plasma creatinine) / (Plasma sodium x Urinary creatinine) X 100 
FeK+ (%) =  (Urine Potassium x Plasma creatinine) / (Plasma potassium x Urine creatinine) X 100 
             
Relative mRNA expression in the kidney 
Total mRNA was extracted from kidney tissues using the Zymo Research Quick-RNA Miniprep kit 
(Zymo Research, Irvine, USA) according to manufacturer’s instruction. A nanodrop spectrophotometer 
(Thermoscientific Nanodrop 1000) was used to assess the purity and concentration of RNA extracted. 
Thereafter, a total RNA of 1μg was reverse transcribed into cDNA according to the manufacturer’s 
protocol using the iScript cDNA synthesis kit (Bio-Rad Laboratory Pty, Ltd. USA).  
Realtime polymerase chain reaction (RT-PCR) was carried out using the Lightcycler 96 (Roche 
Diagnostics, Germany). Conditions used for RT-PCR analysis were as follows:  95ºC initial denaturation 
cycle for 10minutes, thereafter a PCR run consisting of 40 cycles at 95ºC for 15s, 60ºC for 30s and 72ºC 
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for 30s with a single fluorescent measurement. The house keeping gene used in the analysis was 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and the fluorescent dye utilized in the analysis 
was SYBR Green 1 [SSO Advanced Univers SYBR GR. SUPRMIX, Bio-Rad Laboratory (Pty) Ltd. 
USA]. The oligonucleotide primer sequences for the various genes investigated in the RT-PCR analysis 
were as follows:  
 
 
Statistical Analysis 
Values reported are means ± SEM for seven rats per group. Analysis of data was done by analysis of 
variance (ANOVA) followed by post hoc tests for multiple comparisons using Bonferroni and Dunnett’s 
test were appropriate on GraphPad Prism Version 6. Data values were considered significant at P<0.05. 
 
 
 
 
 
 
 
 
 
 
Gene Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) 
NF-κB 
 
GCGGCCAAGCTTAAGATCTGCCGCCGAGT
AAAC 
CGCTGCTCTAGAGAACACAATGGCCACT
TG 
HO-1 
 
ACTTTCAGAAGGGTCAGGTGTCC 
 
 
TTGAGCAGGAAGGCGGTCTTAG 
eNOS CTCGTCCCTGTGGAAAGACAA 
             
TGACTTTGGCTAGCTAGCTGGTAACTGT 
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RESULTS 
Effect of TA on Mean Arterial Pressure (MAP). 
Figure 1 shows the effect of TA on mean arterial pressure at three different doses (40, 60 and 80mg/kg 
b.w.) in L-NAME induced hypertensive rats. A significant (P<0.05) increase in the mean arterial pressure 
was observed in the untreated L-NAME group from week 1 to week 5, while treatment with TA and 
Ramipril significantly reduced the mean arterial pressure, with a more pronounced effect at 80 mg/kg b.w. 
of TA (vs. untreated L-NAME). No significant difference was observed between the effect of TA 
(80mg/kg b.w.) and Ramipril for mean arterial pressure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Effect of TA on Mean Arterial Pressure (MAP) in L-NAME induced hypertensive rats, Values are 
expressed as mean ± SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME; ∇ P<0.05 vs. 
Ramipril 
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Effect of TA on antioxidant activities in Kidney tissues and Erythrocytes 
The effect of TA on the antioxidant activities in the kidney tissues and erythrocytes are shown in table 1. 
The activities of superoxide dismutase (SOD) and catalase (CAT) were significantly (P<0.05) reduced in 
the L-NAME group of rats as compared to the control, while the treatment with TA and Ramipril 
significantly (P<0.05) increased these enzymatic antioxidants, with a maximum effect at 80mg/kg of TA.  
Furthermore, the levels of reduced glutathione (GSH) and nitric oxide (NOx) were decreased significantly 
in the L-NAME untreated rats, whiles it was increased significantly with the administration of TA and 
Ramipril, with a maximum effect occurring at the dose of 80mg/kg of TA. Lipid peroxidation, measured 
using Thiobarbutric acid reactive substances (TBARS), was also increased significantly (P<0.05) in the 
L-NAME untreated rats when compared with the control. This effect was significantly reduced with the 
treatment of TA and Ramipril, with a pronounced effect at 80mg/kg of TA. 
Table 1: Effect of TA on superoxide dismutase (SOD), catalase (CAT), reduced Glutathione 
(GSH), Thiobarbutric acid reactive substances (TBARS) and NOx activities in kidney 
tissues and erythrocytes 
Group 1- Control; Group 2-L-NAME(50mg.kg); Group 3- L-NAME + Ramipril(10mg.kg); Group 4- L-NAME + TA(40mg/kg); 
Group 5- L-NAME + TA(60mg/kg); Group 6- LNAME + TA(80mg/kg). Values are expressed as mean ± SEM for seven rats per 
group. a P <0.05 vs. control; b P <0.05 vs. L-NAME; c P<0.05 vs. Ramipril; d P<0.05 vs. TA(40mg/kg); e P<0.05 vs. 
TA(60mg/kg) 
 
 
Parameter Samples                                                     Groups  
1 2 3 4 5 6 
 
SOD        Erythrocytes (U/mg Hb) 
 
                Kidney (U/mg protein)   
17.95±1.18 
 
17.35±0.21 
7.53±0.69a 
 
12.24±0.08a 
17.31±0.18b 
 
16.12±0.10b 
15.60±0.20b 
 
13.53±0.05a,b.c 
15.36±0.11b 
 
14.60±0.13b.c 
16.22±0.08b 
 
15.89±0.06b 
 
CAT       Erythrocytes(U/mgHb)  
 
                Kidney (Ub/mgprotein) 
 
 
176.9±2.90 
 
91.63±1.04 
 
115.3±6.38a 
 
56.12±.0.59a 
 
144.7±2.14a,b 
 
128.0±0.52a,b 
 
120.5±6.83a.c 
 
109.0±1.51a,b,c 
 
159.9±0.95b.d 
 
117.6±6.29a,b 
 
166.1±6.38b,c,d 
 
179.1±1.60a,b,c,d,e 
GSH        Erythrocytes (μmol/g Hb) 
 
                Kidney (μg/mg protein) 
 
0.07±0.01 
 
0.03±0.00 
0.06±0.00a 
 
0.02±0.00a 
0.07±0.00b 
 
0.03±0.00b 
0.05±0.00a,b,c 
 
0.03±0.00b 
0.06±0.00a,d 
 
0.03±0.00b 
0.06±0.01a,d 
 
0.03±0.00b 
TBARS   Erythrocytes(nmol/g Hb) 8.19±0.06 19.47±0.43a 9.12±0.16b 11.32±0.06a.b,c 8.65±0.11b,d 8.25±0.14b,d 
                 Kidney(mmol/100g wet  
tissue) 
 
1.61±0.05 3.77±0.10a 2.17±0.06a,b 3.22±0.05a,b.c 2.29±0.05a.b,d 1.95±0.05b.d 
NOx         Erythrocytes(μmol/g Hb) 92.72±1.03 
 
74.59±4.94a 79.07±0.93a 82.09±1.10 76.47±5.08a 91.47±1.09b,e 
                 Kidney (μmol/l) 103.9±2.44 80.84±1.81a 92.09±1.09 100.7±2.10b 102.4±2.03b 137.1±5.78a,b,c.d.e 
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Effect of TA on red blood cell and platelet parameters 
Table 2 presents the effect of TA on red cell and platelet parameters. No significant differences were 
observed in the Haemoglobin concentration (Hb), red blood cell counts (RBC) and the haematocrit (HCT) 
values in all the experimental groups. However, the red cell distribution width (RDW) significantly 
increased in the L-NAME untreated group when compared to the control. This was significantly (P<0.05) 
decreased in the TA and Ramipril treated groups, with a pronounced effect at the 80mg/kg dose of TA. 
No significant difference was observed in the RDW between the TA treated groups, the control and 
Ramipril groups. Furthermore, a significant (P<0.05) increase in the platelet levels were observed in the 
L-NAME untreated group as compared to the control, whiles the administration of TA and Ramipril 
decreased the platelet levels. This decrease was significant (P<0.05) at concentrations of 40mg/kg and 
80mg/kg doses of TA. Again, the mean platelet volume (MPV) increased significantly (P<0.05) in the L-
NAME untreated group when compared to the control, and this was significantly alleviated with the 
treatment of TA and Ramipril, with maximum effect at 80mg/kg of TA. No significant difference was 
observed in MPV values between the TA treated groups, Ramipril treated and control groups (Table 2). 
Table 2: Effect of TA on Red cell and platelet parameters  
Parameter 
Samples 
                                                    Groups  
1 2 3 4 5 6 
 
Hb (g/dl)  15.26±0.38 15.73±0.77 15.20±0.53 15.89±0.41 15.63±0.58 15.87±0.28 
RBC (x 106/μL) 8.570 ±0.14 8.89±0.35 8.36±0.25 9.06±0.15 8.66±0.17 8.68±0.24 
HCT (%) 45.73±0.69 47.79±2.15 45.21±0.72 47.63±0.31 46.24±1.09 47.35±0.83 
RDW (SD)(fl) 10.14±0.31 13.64±0.56a 10.49±0.20b 10.39±0.25b 9.92±0.15b 9.88±0.14b 
 
PLT (x103/Μl) 
 
875.9±34.68 
 
952.9±9.45 
 
859.4±39.34 
 
827.4±29.05b 
 
849.9±12.70 
 
823.0±19.24b 
 
MPV(fl) 
 
6.23±0.13 
 
8.09±0.23a 
 
6.30±0.04b 
 
6.14±0.06b 
 
6.06±0.06b 
 
6.15±0.05b 
Group 1- Control; Group 2-L-NAME(50mg/kg); Group 3- L-NAME + Ramipril(10mg/kg); Group 4- L-NAME + TA(40mg/kg); 
Group 5- L-NAME + TA(60mg/kg); Group 6- LNAME + TA(80mg/kg). Values are expressed as mean ± SEM for seven rats per 
group. a P <0.05 vs. control; b P <0.05 vs. L-NAME;  
 
Effect of TA on white blood cell counts 
Figure 2 shows the effect of TA on white cell counts. There was a significant (P<0.05) increase in the 
white cell count in the L-NAME untreated group when compared to the control group, while the 
administration of TA and Ramipril significantly (P<0.05) reduced the white cell count. No significant 
difference was observed in the TA treated groups and the Ramipril groups. 
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Figure 2: Effect of TA on white cell count in L-NAME induced hypertensive rats, Values are expressed as 
mean ± SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME. 
 
Effect of TA on Neutrophil-lymphocyte ratio (NLR) and Lymphocyte-monocyte ratio 
(LMR)  
The effect of TA on neutrophil-lymphocyte ratio (NLR) and lymphocyte-monocyte ratio (LMR) is shown 
in figures 3 and 4 respectively. A significant (P<0.05) increase in the NLR and LMR was seen in the L-
NAME group as compared to the control group, and this was significantly attenuated with the 
administration of TA and Ramipril. No significant difference was seen in the NLR and LMR between the 
TA treated groups, Ramipril and the control group. 
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Figure 3: Effect of TA on neutrophil - lymphocyte ratio (NLR) in L-NAME induced hypertensive rats, Values 
are expressed as mean ± SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Effect of TA on lymphocyte-monocyte ratio (LMR) in L-NAME induced hypertensive rats, values 
are expressed as mean ± SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME 
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Effect of TA on renal function  
Tables 3, 4 and 5 shows the effect of TA on renal function markers 
Effect of TA on Urine electrolytes 
It was observed that urine sodium and potassium levels were decreased significantly (P<0.05) in the L-
NAME untreated group when compared to the control group, whiles the administration of TA increased 
the levels of sodium and potassium levels, with maximum levels at 80mg/kg of TA, though this increase 
was not significant as compared to the L-NAME untreated group (Table 2). Notably, the Ramipril group 
showed decreased levels of sodium and potassium levels, as compared to the L-NAME untreated group, 
and the TA treated groups (Table 2). Moreover, a similar pattern was observed in chloride levels in all the 
groups, with maximum level occurring at the 40mg/kg dose of TA (Table 2).  
Effect of TA on Urine creatinine, protein and urea levels 
Creatinine and urea levels decreased in the L-NAME untreated group as compared to the control group, 
while the treatment with TA increased in the creatinine and urea levels, although it was not significant 
(Table 3). However, the Ramipril group showed a decrease in creatinine and urea levels, as compared to 
the control group and the TA treated groups (Table 3). Protein levels increased in the L-NAME untreated 
group as compared to the control, and this was decreased in the Ramipril and TA treated groups when 
compared with the L-NAME. Interestingly, the Ramipril group showed the lowest levels of protein as 
compared to the other treated groups (Table 3). 
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Table 3: Effect of TA on renal parameters measured in Urine 
Parameter 
Samples 
                                                    Groups  
1 2 3 4 5 6 
 
Sodium Urine  
(mmol/l)   
164.7±12.38 98.00±4.84a 90.0±13.91a 109.0±14.87a 107.4±7.74a 120.4±4.26 
Potassium(mmol/l) 451.5±12.39 280.0±22.93a 207.3±26.94a 325.3±30.99a,c 308.9±18.24a 311.2±40.91a 
Chloride (mmol/l) 329.2±12.11 234.4±17.32 155.3±27.39a 216.0±21.72a 209.4±12.60a 207.8±25.41a 
Creatinine(mmol/l) 9.75±0.57 7.24±0.71 4.73±0.59a 7.21±0.52 7.31±0.42c 7.87±0.91c 
Protein(g/l) 
 
Urea(mmol/l) 
2.42±0.21 
 
955.3±89.19 
3.89±0.50 
 
702.6±52.65 
1.40±0.07b 
 
529.6±73.57a 
2.57±0.46 
 
769.1±74.80 
2.35±0.11b 
 
715.7±36.65 
2.69±0.44 
 
792.8±78.84 
 
Volume(baseline) 
(ml/24h) 
 
 
8.243±0.46 
 
8.46±0.15 
 
8.50±0.91 
 
7.64±0.82 
 
7.71±0.68 
 
8.20±0.46 
Volume(week 5) 
(ml/24hr) 
14.29±0.38 21.21±1.93a 23.00±0.82a 19.29±1.66 24.24±1.08a 24.00±1.60a 
Group 1- Control; Group 2-L-NAME(50mg.kg); Group 3- L-NAME + Ramipril(10mg.kg); Group 4- L-NAME + TA(40mg/kg); 
Group 5- L-NAME + TA(60mg/kg); Group 6- LNAME + TA(80mg/kg). Values are expressed as mean ± SEM for seven rats per 
group. a P <0.05 vs. control; b P <0.05 vs. L-NAME; c P<0.05 vs. Ramipril;  
 
Effect of TA on urine volumes 
Urine volume at baseline levels showed no significant difference amongst all the experimental groups. 
However, at week 5, there was a significant (P<0.05) increase in urine volume in the Ramipril and TA 
treated groups, as compared to the control, with a maximum level recorded at 80mg/kg of TA (Table 3). 
Furthermore, there was an increase in urine volume in the Ramipril and TA treated groups, as compared 
to the L-NAME untreated group, though this was not significant (Table 3). 
Effect of TA on Plasma/Serum electrolytes 
Plasma/serum sodium levels showed no significant difference (P>0.05) in all the experimental groups. 
Moreover, there were no significant difference in potassium levels between the TA and Ramipril treated 
groups and the control (Table 4). No significant difference was also observed potassium levels between 
the TA treated group and the L-NAME untreated group. Interestingly, there was a significant increase 
(P<0.05) in potassium levels in TA (40mg/kg) as compared to TA doses of 60 and 80 mg/kg (Table 4). 
Additionally, there was an increase in chloride levels in the TA and Ramipril treated groups, as compared 
to the L-NAME group, but this did not differ significantly; with the exception of TA dose of 80mg/kg 
which increased significantly as compared to the L-NAME treated group (Table 4). 
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Effect of TA on serum/plasma creatinine, protein and blood urea nitrogen (BUN) levels 
Serum creatinine levels in the Ramipril and TA treated groups were generally decreased, as compared to 
the L-NAME untreated group, although this was not significant (Table 4). However, a significant 
reduction was seen in TA dose of 40mg/kg when compared to the control, L-NAME group and Ramipril 
treated groups (Table 4). No significant difference was also seen in protein levels in all the experimental 
groups, although there was a slight increase (P<0.05) in the L-NAME untreated group (Table 4). Blood 
urea nitrogen levels was increased in the Ramipril group, as compared to the other experimental groups, 
however, no significant difference was observed between the TA treated group vs. L-NAME and the 
control groups (Table 4). 
Table 4: Effect of TA on Renal parameters measured in Plasma/serum 
Parameter                                                      Groups  
1 2 3 4 5 6 
 
Sodium (mmol/l)   142.4±0.65 142.6±1.16 142.7±0.72 140.7±0.64 142.7±0.62 143.7±1.06 
Potassium(mmol/l) 5.33±0.14 5.48±0.20 5.26±0.14 5.99±0.32 5.02±0.07d 4.93±0.17d 
Chloride (mmol/l) 97.86±0.77 95.60±0.68 97.43±0.81 97.75±0.59 98.33±0.76 99.67±1.12b 
Creatinine(mmol/l) 35.29±2.47 37.80±2.29 31.71±1.36 23.00±1.31a,b,c 30.00±1.69 29.00±1.93b 
Protein(g/l) 
 
BUN (mmol/l) 
60.86±1.46 
 
6.77±0.25 
65.80±2.97 
 
7.22±0.61 
63.43±0.78 
 
8.51±0.21a 
63.43±1.36 
 
7.76±0.14 
65.50±0.67 
 
7.48±0.22 
64.83±1.01 
 
7.70±0.33 
Group 1- Control; Group 2-L-NAME(50mg.kg); Group 3- L-NAME + Ramipril(10mg.kg); Group 4- L-NAME + TA(40mg/kg); 
Group 5- L-NAME + TA(60mg/kg); Group 6- L-NAME + TA(80mg/kg). Values expressed as mean ± SEM for seven rats per 
group. a P <0.05 vs. control; b P <0.05 vs. L-NAME; c P<0.05 vs. Ramipril; d P<0.05 vs. TA(40mg/kg). 
 
Effect of TA on Creatinine Clearance, fractional excretion of sodium, fractional excretion 
of potassium, Urine protein-creatinine ratio and kidney weight 
Creatinine clearance increased in the TA treated groups as compared to the L-NAME induced group, and 
the Ramipril group, with a maximum effect at 80mg/kg of TA (Table 5). There was no significant 
difference between the TA treated groups and the control group. Additionally, there was no significant 
difference in the fractional excretions of sodium and potassium between the TA treated groups and the L-
NAME group, although there was a slight increase in the L-NAME group (Table 5). Furthermore, there 
was an increase in the Urine protein-creatinine ratio (UPr/UCr) in the L-NAME group as compared to the 
control. This was decreased with the treatment of TA and Ramipril although it was not significant (Table 
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5). No significant difference was observed in UPr/UCr between the TA treated groups, the Ramipril and 
control group (Table 5). Left Kidney weight per body weight (LKW/BW) did not differ significantly in 
all the experimental groups (Table 5). 
Table 5: Effect of TA on Creatinine Clearance (Ccr), fractional excretion of sodium 
(FeNa), fractional excretion of potassium (FeK+), Urine Protein-Creatinine ratio 
(UPr/UCr) and left kidney weight-body weight ratio (LKW/BW) 
Parameter                                                      Groups  
1 2 3 4 5 6 
 
Ccr (ml/min) 0.31±0.03 0.26±0.03 0.24±0.04 0.42±0.03c 0.42±0.04c 0.46±0.09b,c 
FeNa (%) 4.00±0.19 3.49±0.30 4.14±0.47 2.44±0.27a,c 3.04±0.11 3.35±0.61 
FeK+ (%) 301.1±33.03 263.5±16.45 266.2±21.69 175.3±14.88a 249.9±13.78 237.7±29.45 
UPr/UCr  0.26±0.03 0.54±0.11a 0.33±0.05 0.38±0.07 0.32±0.02 0.34±0.04 
LKW/BW (%) 0.42±0.01 0.44±0.02 0.42±0.02 0.43±0.03 0.43±0.02 0.44±0.02 
Group 1- Control; Group 2-L-NAME(50mg.kg); Group 3- L-NAME + Ramipril(10mg.kg); Group 4- L-NAME + TA(40mg/kg); 
Group 5- L-NAME + TA(60mg/kg); Group 6- LNAME + TA(80mg/kg). Values are expressed as mean ± SEM for seven rats per 
group. a P <0.05 vs. control; b P <0.05 vs. L-NAME; c P<0.05 vs. Ramipril;  
 
Relative fold changes in the mRNA expressions in the Kidney  
 
HO-1 mRNA expressions 
 
Figure 5 shows the levels of HO-1 gene expressions in the kidney tissues of the experimental groups. The 
L-NAME group showed a 0.5 fold decrease in HO-1 gene expression, when compared to the control. 
Interestingly, treatment with Ramipril and TA showed a significant (p<0.05) upregulation of HO-1 gene 
expression, with more pronounced effect at 80mg/kg of TA (5.4 fold increase). However, the upregulated 
gene expression of HO-1 in the Ramipril and TA doses of 60mg/kg and 80mg/kg were significantly 
higher than that of the 40mg/kg. No significant difference was observed in the HO-1 gene expression in 
the TA treated groups (60mg/kg and 80mg/kg) and the Ramipril group (Figure 5). 
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Figure 5: Graph showing the renal mRNA levels of  HO-1 in L-NAME induced hypertensive rats. Values are 
expressed as mean ± SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME, *** P <0.001 
vs. TA (60mg/kg and 80mg/kg), ∇ P<0.05 vs. Ramipril 
 
 
NF-κB mRNA gene expression 
The mRNA gene expression of NF-κB in kidney tissues is represented in figure 6.  There was a 
significant (P<0.05) 3 fold increase in the gene expression of NF-κB in the L-NAME induced 
hypertensive group, when compared to the control. This increased expression was attenuated with the 
administration of TA and Ramipril, where there was a significant (P<0.05) downregulation with a 
maximum effect occurring at TA doses of 60 (0.4 fold decrease) and 80mg/kg (0.5 fold decrease). No 
significant difference was seen in the NF-κB gene expressions between the TA treated groups and the 
Ramipril treated group. 
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Figure 6: Graph showing the renal mRNA  levels of  NF-κB in L-NAME induced hypertensive rats. Values 
are expressed as mean ± SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME. 
 
 
eNOS mRNA gene expression 
The eNOS mRNA gene expression in the kidney is represented in figure 7.  There was a significant 
(P<0.05) 2-fold increase in the gene expression of eNOS in the L-NAME induced hypertensive group, 
when compared to the control. Interestingly, this increased expression was significantly (P<0.05) 
upregulated with the treatment of TA and Ramipril with the maximum effect occurring at the dose of 
80mg/kg of TA (5.8 fold increase). No significant difference was seen in the eNOS gene expressions 
between the TA treated groups (60 and 80mg/kg) and the Ramipril treated group. 
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Figure 7: Graph showing the renal mRNA levels of  eNOS in L-NAME induced hypertensive rats. Values are 
expressed as mean ± SEM for seven rats per group. * P< 0.05 vs. Control; # P <0.05 vs. L-NAME, *** P <0.001 
vs. TA (60mg/kg and 80mg/kg), ∇ P<0.05 vs. Ramipril 
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Discussion 
 
We have previously demonstrated a long term lowering of the systolic and diastolic blood pressure in an 
L-NAME hypertensive model and its subsequent effect on the maintenance of the cardiac function 
(unpublished data). In this study, we examined the long-term effects of TA and Ramipril on haematology 
and renal function, associated with hypertension, in an L-NAME induced hypertensive rat model. The L-
NAME rat model showed a significant progressive increase in the mean arterial pressure (MAP) over the  
period of the study, as compared to the experimental groups, thereby affirming the expected L-NAME 
induced chronic inhibition of NO, resulting in arterial hypertension (19). The alleviation of this rise in 
MAP with the treatment of TA and Ramipril confirms their antihypertensive effect, with a pronounced 
effect at a TA dose of 80mg/kg.   
 
Arterial hypertension is commonly associated with uncontrolled production of reactive oxygen species 
(ROS) leading to oxidative stress (20). This study, therefore, evaluated the free radical activities of 
superoxide dismutase (SOD), catalase (CAT), GSH and NO concentrations in kidney tissues and 
erythrocytes of hypertensive rats. The decreased activities of SOD, CAT and GSH in the L-NAME rats, 
in both  erythrocytes and the kidney tissues, as observed in this study, may be due to their over utilization 
in ROS scavenging, as a result of increased blood pressure (21). However, their increased levels in the 
Ramipril and TA treated groups, demonstrates their role in promoting the bioavailability of these 
antioxidants, to aid the body to reduce oxidative stress (22).    
 
Furthermore, lipid peroxidation, as a measure of oxidative damage in tissues, is measured using 
thiobarbituric acid reactive substances (TBARS) (23). Our study showed a significant increase in TBARS 
in the L-NAME group, indicating possible cellular damage in the kidneys and the erythrocytes. However, 
the decreased levels of TBARS in the Ramipril and TA treated groups, further supports their possible 
protective role in the maintenance of cellular integrity in the kidney, and the prevention of possible 
haemolysis in the erythrocytes due to oxidative stress (23). 
 
We further examined the role of heamatological parameters in the development and progression of 
hypertension. It is worth noting that our study is amongst the few, recent studies that have focused on the 
investigations of haematological parameters, as indicators of the progression of hypertension, especially 
in the L-NAME hypertensive model. The tendency towards increased levels of haemoglobin (Hb), red 
blood cell (RBC) and haematocrit (HCT) in the L-NAME group, is in keeping with others (24, 25). This 
may be partially attributed to increased oxygen requirements, as a result of increased metabolic activity, 
during hypertension (25). Moreover, the significant increase in red cell distribution width (RDW) 
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observed in the L-NAME group in this study corroborates with other findings (26, 27). RDW is a measure 
of the variation of the size and volume of the circulating erythrocyte (27). The mechanism by which 
hypertension leads to an increased RDW is still under investigation (28). It may be attributed to increased 
arterial pressure which leads to the activation of RAS, causing angiotensin II  induced erythropoietin 
activity, leading to the early proliferation of erythroid progenitors, therefore accounting for the variation 
in sizes of circulating erythrocytes (29). Therefore, the decreased RDW in the TA and Ramipril treated 
groups, may be probably due to the RAS blockade by TA and Ramipril in L-NAME induced rats.  We 
also postulate that the compromised perfusion during hypertension, leading to hypoxia, may also cause 
erythropoietin secretion. 
 
Furthermore, in our study, the platelet and mean platelet volume (MPV) increased significantly in the L-
NAME group, as compared to the other experimental groups. This could  be due to increased platelet 
activation, associated with endothelial damage, during high blood pressure (30). Other studies that are in 
keeping with our study, suggest that the consumption of platelets increases at the site of blood vessel 
injury, and this occurrence enhances the release of larger platelets which are known to be more 
physiologically active, and hence accounting for the increased MPV in hypertension (31). TA and 
Ramipril treatment are shown in our study to reduce blood cell and vessel injury, thereby preventing the 
over production of platelets and increased MPV, as reflected in the reduction of platelets and MPV values 
in these groups. 
 
Additionally, white blood cell (WBC) indices are also known as prognostic markers of hypertension (32). 
The findings in our study showed a significantly increased WBC in the L-NAME hypertensive rats when 
compared to the control group. Treatment with TA and Ramipril significantly reduced the WBC, in 
agreement with recent findings of increased WBC among hypertensive patients (32, 33). This occurrence 
could be explained mostly due to the chronic inflammatory conditions associated with hypertension (34). 
WBC is a well-known inflammatory marker and tends to increase in hypertension (34). However, TA and 
Ramipril treatment, as shown in this study, attenuates the complications that arise from inflammation 
associated with hypertension, hence decreasing WBC. 
 
To critically examine the role of white blood cell indices in hypertension, the neutrophil-lymphocyte ratio 
(NLR) and the lymphocyte-monocyte ratio (LMR), are recognized as emerging prognostic indicators for 
hypertension (35). Interestingly, our study shows a significant increase in NLR and LMR in L-NAME 
hypertensive rats, which was significantly attenuated with the administration of TA and Ramipril. This 
finding is in corroboration with other findings that indicate that increased NLR and LMR are predictive 
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markers of mortality in hypertension (36, 37). A combination of neutrophil and lymphocyte, as well as 
lymphocyte and monocyte, are known to be better indicators as compared to the individual parameters 
(36). Our study further supports the findings from other studies, that support the protective role of 
antihypertensives such as TA and Ramipril in decreasing NLR and LMR, hence, ultimately impacting on 
the complications and mortalities associated with hypertension (38). 
 
It is established that hypertension causes biochemical and electrolyte changes in renal function, which 
also predicts the severity of the disease (39). Renal dysfunction is usually typified by a decreased 
glomerular filtration rate (GFR), increased serum creatinine, and progressive increase in proteinuria (40). 
In this study, we found improved renal function under TA treatment as evidenced by the decrease in 
serum creatinine and proteinuria. Additionally, we found increased creatinine clearance as well as a slight 
increase in the urine and serum electrolytes. Although most of these biomarkers were not significant, it 
indicates a tendency for TA to improve renal function, especially at a dose of 80mg/kg.  
 
Surprisingly, TA and Ramipril treatment produced a non-significant decrease in fractional excretion of 
sodium (FeNa) and potassium (FeK+) as compared to the L-NAME hypertensive rats, suggesting that 
chronic inhibition of NO may increase FeNa and FeK+. Variable effects of NO inhibition, on sodium and 
potassium excretion, have been reported.  Several authors have reported that L-NAME enhances sodium 
and potassium reabsorbtion, resulting in decreased FeNa and FeK+ whereas, others postulate that chronic 
inhibition of NO with L-NAME, may override the anti-natriuretic effect initially stimulated, and lead to 
increased FeNa and FeK+ (40, 41). In view of this discrepancy, we postulate that NO may play a crucial 
role in renal function, independent of changes in sodium and potassium excretion. Additionally, chronic 
inhibition of NO, has been demonstrated to decrease GFR in some studies, and not in others (42, 43). 
Previous studies also suggest that NO inhibition may decrease the blood flow in the renal system without 
affecting the GFR(44). This may explain in part the reason for the non significant decrease in GFR, as 
measured by the creatinine clearance, in the L-NAME rats, as compared to the other experimental groups 
in our study. 
  
Furthermore, our assessment of mRNA expression of renal inflammatory markers such as renal HO-1, 
NF-κB, and eNOS revealed a significant upregulation of renal HO-1 and e-NOS in the TA treated group.  
We also found a significant downregulation of NF-κB in the TA and Ramipril treated groups, compared 
to the untreated L-NAME group. This observation is in support of improved renal function in an L-
NAME induced hypertensive rat model. The significant up-regulation of  HO-1 in TA and Ramipril 
treated groups, when compared to the control,  is in keeping with other studies, that suggest that increased 
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expression of HO-1 in renal tissue confers a protective role on renal integrity (45). HO-1 is known to be 
the rate limiting enzyme responsible for the degradation of heme (46). It must be noted that free heme 
could be a highly toxic compound, and could lead to oxidative stress (47). Although free heme was not 
measured in the current study, its presence could lead to increased influx of leukocytes (WBC) into 
organs during inflammation (48), which was evident in our study. Finally, heme forms part of several pro-
inflammatory enzymes such as cytochrome p450 mono-oxygenases, cyclooxygenase, and inducible nitric 
oxide synthase. Therefore, when HO-1 eliminates excessive free heme, it compromises the optimal 
activity of those enzymes, leading to an attenuation of inflammation (49). In view of this, we can 
postulate that TA and Ramipril may prevent inflammation associated with hypertension, through the 
expression of HO-1 and eNOS in kidney tissues. 
 
Furthermore, NF-κB, as an inflammatory marker, plays a crucial role in the progression of hypertension 
(50). NF-κB is known to promote WBC infiltration in renal tissues during hypertension (51). Therefore, 
the increased white blood cells observed in our study, together with the increased expression of NF-κB in 
the L-NAME treated rats, confirms the inflammatory basis of hypertension. Additionally, a decreased 
expression of NF-κB, as well as decreased WBC in the TA and Ramipril treated groups, also confirms the 
anti-inflammatory effects.  
 
Conclusion 
In the current study, it has been demonstrated for the first time, that Tulbaghia acutiloba has a beneficial 
effect on renal function in an L-NAME induced hypertensive rat model, based on the haematological and 
biochemical parameters, which may be a good prognostic indicator of its antihypertensive efficacy. The 
dose of 80mg/kg of TA possessed a strong antihypertensive effect which is most likely related to the 
reduction in oxidative stress, increased bioavailability of NO, decreased heamatological parameters such 
as NLR, LMR, MPV, RDW, WBC, as well as, upregulation of HO-1 and downregulation of NF-κB. We 
can infer that TA (80mg/kg) may have a crucial role in maintaining renal function as well as maintaining 
the cellular integrity of circulating blood cells.  Our study confirms the direct and indirect relationship 
between haematological and renal function in the disease progression and treatment of arterial 
hypertension. However, further studies are needed to ascertain the role of each bioactive compound 
responsible for the antihypertensive, renoprotection and haematological function of Tulbaghia acutiloba. 
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CHAPTER 6 
SYNTHESIS AND CONCLUSION 
 
This study aimed to investigate the chemical composition, and in vitro and in vivo antihypertensive 
activities of the extracts of Tulbaghia acutiloba Harv. in an hypertensive experimental model to 
understand the biological activity and therapeutic benefits of the plant extracts.   
 
The objectives to address the studies were: 
1. To identify the phytochemical constituents, in vitro antioxidant potential and analyse heavy metal 
toxicity of the crude extracts of Tulbaghia acutiloba  
2. To evaluate the in vitro Angiotensin-converting enzyme (ACE) Inhibition potential of the crude 
extracts of Tulbaghia acutiloba  
3. To evaluate the antihypertensive and cardioprotective effect of Tulbaghia acutiloba extracts in an 
L-NAME hypertensive rats 
4. To examine the effects of Tulbaghia acutiloba  extract on renal function in an L-NAME  
hypertensive rats 
5. To determine the effects of Tulbaghia acutiloba extract on heamatological indices in an L-NAME  
hypertensive rats 
 
A comprehensive review and analysis of Tulbaghia acutiloba was conducted on its use to manage blood 
pressure. This formed the theoretical framework to evaluate Tulbaghia acutiloba phytochemicals using in 
vitro tests of antioxidant activity, and its inhibition of the angiotensin converting enzyme (ACE). 
Moreover, the heavy metal toxicological properties of the plant were evaluated to ascertain the acceptable 
limits for safe traditional use. Based on the promising in vitro findings obtained, the long term 
antihypertensive effects of Tulbaghia acutiloba was evaluated in an L-NAME induced hypertensive 
model. 
 
A review of reports pertaining to alternative antihypertensive therapies, specifically phytotherapy, 
revealed a number of potential antihypertensive phytochemicals, many having been identified in South 
Africa, with its rich traditional knowledge systems and botanical diversity (Chapter 2). While many 
medicinal plants have been screened for in vitro biological activity, the studies lacked mechanistic insight 
into their in vivo effects.  Furthermore, a holistic approach was applied to address the involvement of the 
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kallikrein-kinin system in combination with the renin-angiotensin system in the pathogenesis and 
treatment of hypertension.  
 
Our findings showed that Tulbaghia acutiloba contains phytohemicals with strong antioxidant activity in 
vitro and in vivo, that it inhibits ACE activities under both conditions, and has antihypertensive and 
cardioprotective effects in vivo. The plant was also observed to improve renal function and 
haematological parameters associated with hypertension. This study provides evidence of the efficacy of 
Tulbaghia acutiloba and a basis for its further evaluation as a candidate for novel drug discovery. The key 
findings of the study and the relevant conclusions are summarized below. 
 
In vitro preliminary investigations 
Objectives 1 and 2 entailed identifying the phytochemical constituents to establish the in vitro antioxidant 
potential and heavy metal toxicity analysis as well as the ACE inhibition activities of the crude extracts of 
Tulbaghia acutiloba. The preliminary screening of Tulbaghia acutiloba phytochemicals from the roots, 
rhizomes, flowers and leaves showed promising biological activity (Chapter 3). The in vitro antioxidant 
analysis was conducted to evaluate the scavenging activity of the plant on DPPH, hydrogen peroxide and 
nitric oxide. Moreover, as a culinary herb, there was a need for a heavy metal toxicity analysis to shed 
more light on its safety profile. Additionally, its antihypertensive potential was evaluated in vitro using 
the ACE inhibition activity assay, with all extracts being evaluated against the conventionally used ACEI 
drug, Ramipril.  
 
The findings indicated the presence of α-linolenic acid (ALA), an omega-3- fatty acid, in the plant’s 
leaves. This is notable, as ALA, an essential fatty acid, is not produced by the body, but is obtained from 
dietary sources, and has several beneficial effects, including lowering blood pressure (1), and  is unique in 
the genus, Tulbaghia. While this was identified only in the leaves as a major compound, and not in other 
parts of the plants; palmitic acid, oleic acid and other bioactive compounds were observed in the other 
parts of the plant. Other compounds identified included phenols, saponins, alkaloids and amino acids in 
all parts of the plant, which also showed significant antioxidant activities and a strong ACE inhibitory 
activity, with the maximum effect being observed in the leaves that was comparable to the conventional 
ACEI, Ramipril, used in the study. Additionally, heavy metals were not detected in all parts of the plants, 
confirming their safety for consumption, when harvested from KwaZulu-Natal Province. It is of interest 
to note that the leaves, which contained ALA, coupled with the highest phenolic content, showed 
significant ACE inhibition, indicating that this effect may be related to the presence of these compounds. 
These findings led to further investigations of its potential therapeutic effect, in vivo. 
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Antihypertensive and cardioprotective effects of Tulbaghia actuliloba leaves 
Objective 3 entailed evaluating the in vivo antihypertensive and cardioprotective efficacy of the crude leaf 
extracts of Tulbaghia acutiloba. It is well documented that untreated hypertension can lead to end-organ 
damage, including  major organs  in the cardiovascular system, especially the heart (2). This study 
therefore evaluated the antihypertensive efficacy and cardioprotective role of Tulbaghia acutiloba leaf 
extracts at different concentrations (40, 60 and 80mg/kg b.w.) in an L-NAME induced hypertensive rat 
model (Chapter 4). Tulbaghia acutiloba decreased the systolic and diastolic blood pressure levels, with 
maximal effect observed at the dose of 80mg/kg, which was comparable to the activity of Ramipril. 
Moreover, cardiac hypertrophy was not observed in the L-NAME hypertensive rats treated with 
Tulbaghia acutiloba. The plant’s effect on the renin-angiotensin system and the kallikrein-kinin system in 
hypertension was observed, and a decrease in serum and cardiac tissue ACE activity identified in the 
hypertensive rat model. This was coupled with an increase in bradykinin receptor levels (B1 and B2) and 
a subsequent decrease in the AT1 and AT2 levels. The cardioprotective role of Tulbaghia acutiloba was 
also supported by a significant decrease in serum cardiac troponin I, CK and CKMB levels in the treated 
hypertensive model. This was further confirmed by histological analysis by attenuating cardiac 
hypertrophy and inflammation after administering Tulbaghia acutiloba. Generally, these findings indicate 
the beneficial therapeutic effects of the plant, as it decreased hypertensive vasoconstrictors, such ACE and 
ATI, whiles increasing vasodilatory effects via B1 and B2. These effects lower blood pressure with an 
impact on cardiac remodeling, and may account for the near normal histomorphology observed in the 
Tulbaghia acutiloba treated hypertensive model. 
 
The role of oxidative stress in the progression of hypertension cannot be over emphasised, making its 
evaluation necessary. The findings indicated a significant increase in antioxidant activity in superoxide 
dismutase (SOD), catalase and GSH levels, as well as increased cardiac tissue NO bioavailability when 
treated with Tulbaghia acutiloba, and that lipid peroxidation was significantly reduced.  Even at a high 
concentration of 80mg/kg b.w, the plant had no toxic effect on the liver, as indicated in the pattern of liver 
enzymes comparable to the control groups, with the lipid profiles indicating a non-significant difference 
in all treatment groups. Generally, the trends observed corroborate other studies conducted in potentially 
therapeutic medicinal plants (3-5).  It is also important to note, based on biological activity, that the dose 
of 80mg/kg b.w. of Tulbaghia acutiloba leaf extract showed an optimal therapeutic effect, comparable 
with the activity of Ramipril.  
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Effects of Tulbaghia acutiloba (TA) on renal function 
Objective 4 entailed evaluating the effect of Tulbaghia acutiloba on renal function. Untreated 
hypertension may also alter the physiologic functioning of the kidney, and the markers of kidney function 
were therefore evaluated (Chapter 5). The plant extract was found to improve renal function, at different 
concentrations, as evidenced in the increased urine volume and creatinine clearance, coupled with 
decreased Urine protein-creatinine ratio (UPr/UCr) and proteinuria. Other studies on garlic extracts have 
exhibited a similar pattern in hypertensive rat models (6, 7). 
 
As the role of oxidative stress in the body during hypertension may be localised, the antioxidant effect of 
Tulbaghia acutiloba in the kidney was also examined, with a similar antioxidant trend being observed in 
both the kidney and heart tissues. There was a significant increase in the activities of SOD, catalase and 
GSH, coupled with the increased bioavailability of NO and reduced lipid peroxidation in the renal tissues 
after treatment, with pronounced effect at 80mg/kg b.w. These parameters work synergistically in an 
organism to improve the physiological function by impacting positively on various biochemical 
pathways, which could otherwise lead to pathology. Other reports also suggest that plants in the Alliaceae 
family inhibit Ang II-induced ROS generation, decrease lipid peroxidation in rat kidneys, improve 
antioxidative status, increase NO production and prevent vascular inflammation (8, 9).  
 
Furthermore, a significant decrease in renal NF-kβ expression in the Tulbaghia acutiloba and Ramipril 
treated groups was found. A number of studies have suggested that activation of NF-kB is mediated 
through Ang II (9-11), with the decreased expression of this gene alluding to the effects related to RAS. 
Additionally, Heme oxygenase-1 (HO-1), an emerging gene of interest in the pathogenesis of 
hypertension, was investigated. HO-1 has become a recent gene of focus in hypertension due to its 
protective role in the kidney when highly expressed (12, 13). Our study found a significant increase of 
HO-1 expression in renal tissues in the Tulbaghia acutiloba treated L-NAME induced hypertensive 
group, which is a significant finding, as  the role of HO-1 gene in hypertension is an emerging tool for 
assessing the therapeutic potentials of medicinal plants (14, 15).  
 
Effects of Tulbaghia acutiloba (TA) on haematological function 
Objective 5 entailed evaluating the effect of the plant on haematological function. Current accumulating 
evidence has underscored the importance of haematological parameters in the treatment and prognosis of 
hypertension (16, 17). The haemoglobin and haematocrit levels, red cell distribution width (RDW), 
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platelet, white blood cells and differential ratios, such as neutrophil-lymphocyte ratio (NLR) and 
lymphocyte-monocyte ratio (LMR), have become a major focus area, as a novel yet inexpensive marker 
to determine the progress and treatment efficiency in hypertension. Haematocrit levels are related to 
blood viscosity, and therefore affects haemodynamics (17). Additionally, white blood cells, and their 
relative differential ratios, mark the progress of the inflammatory processes associated with hypertension,  
with an elevation leading to possible end-organ damage (17). This study therefore evaluated the effect of 
Tulbaghia acutiloba on haematological parameters to better understand the mechanism of its 
antihypertensive efficacy (Chapter 5). Administering Tulbaghia acutiloba significantly reduced the RDW 
and haematocrit levels, while the white blood cells, NLR, LMR, platelet and mean platelet levels were 
significantly reduced in the plant and Ramipril-treated groups. Generally, the haematological findings in 
this study indicate that Tulbaghia acutiloba has a beneficial effect on circulation, as represented by 
reduced inflammatory markers, as well as platelet levels. These findings may be integrated with increased 
expression of HO-1 and NO levels, which are known to positively impact the vasculature and 
haematological parameters (Chapter 5). This study is among the few emerging reports that highlight the 
effect of medicinal plants on haematological function as a marker of its antihypertensive efficacy, and 
therefore serves to contribute immensely to investigations of this nature. 
 
Conclusion  
The study findings constitute multiple mechanisms in assessing the antihypertensive potential of 
Tulbaghia acutiloba. Our evaluation of its phytochemical constituents and biological activities has 
supported the therapeutic efficacy of this plant in lowering blood pressure, and therefore has the potential 
to be used to treat hypertension. Our results show that chronic administration of T.acutiloba leaf extracts 
produce cardioprotective, antihypertensive, improved renal and haematological function with no 
toxicological effect in an L-NAME induced hypertensive model.  We may therefore conclude that the 
evidence produced in this study provides a strong basis and lays the groundwork for further scientific 
validation of the traditional use of T.acutiloba in primary health care to treat and manage hypertension 
and its associated complications. 
 
Recommendations and future studies 
The following recommendations are made to further understand the use of T.acutiloba to treat and 
manage hypertension.  
1. To perform in vivo studies on the antihypertensive effect of T.acutiloba in other in vitro and in vivo 
hypertensive models to fully understand the integrative pathways in the pathogenesis and treatment 
of hypertension.  
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2. To isolate and test individual phytochemical bioactive compounds, both in vitro and in vivo, in 
order to identify novel therapeutic agents.  
3. To determine the effect of T.acutiloba and Ramipril in the novel RAS pathway, such as the Ang 1-
7/ACE2/Mas axis. 
4. To evaluate the safety and efficacy of T.acutiloba on pregnancy-induced hypertension, as 
traditional healers may administer this herbal plant under these circumstances. 
5. To evaluate the effect of T.acutiloba on gut microbiota, a relatively novel target, in the progression 
and treatment of hypertension.  
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